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Urinary tract infection (UTI) is one of the oldest and most common infections seen in out- 
patient department, second to respiratory tract infection and acute gastroenteritis. It is commonly 
seen in women of reproductive age group.  While majority of the patients with UTI is being 
treated on outpatient basis however, in select population, this infection still remains a threat to 
life. 
Worldwide, about 150 million people are diagnosed with UTI each year. The spectrum of disease ranges 
from asymptomatic bacteriuria to cystitis to pyelonephritis and life threatening complications of 
emphysematous pyelonephritis in patients with diabetes, pregnancy etc. 
UTI are commonly community acquired and also form an important proportion of hospital acquired 
infections. Community acquired UTIs are commonly seen in women more than men. 
 Symptomatic UTI is common among sexually active women and it is estimated that atleast 1 out of 3 
women would have had an episode of UTI requiring physician visit and antimicrobial therapy before the 
age of 24.(1)  
It is important to differentiate the type of urinary tract infection in terms of it being restricted to the lower 
urinary tract versus upper urinary tract, if it is complicated or uncomplicated and the antibiogram of the 
common local pathogens that cause the urinary tract infection. Prompt initiation of appropriate 
antibiotics and the preventive measures would save the patient and the institution, of the unnecessary 
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economic burden, given the fact that, in poor countries like India, one hospital admission can push the 
family below poverty line and into irrecoverable debts. 
Enterobacteriaceae, commonly found as gut flora are the ones that colonize the urinary tract and cause 
infection commonly.  
Escherichia coli by far, has been the commonest pathogen implicated in causing urinary tract infection. 
In patients with long indwelling catheters, and prolonged hospitalization, one would expect to see other 
organisms like pseudomonas, proteus etc causing fulminant urinary tract infections. 
Hence describing the local antibiogram becomes very important if we were to avoid unnecessary hospital 
admissions and fulminant /life threatening infections that would develop from untreated or improperly 
treated early infections. 
Also, identifying the susceptible population that is at risk for developing fulminant infections  and the 
risk factors that might predispose to development of life threatening infection become equally important. 
Multiple risk factors have been described earlier for example, structural abnormalities in urinary tract, 
instrumentation of the urinary tract, biological and genetic factors of the host and the pathogen , 
metabolic conditions that cause increase susceptibility to infections like poorly controlled diabetes 
mellitus , pregnancy etc. 
Hence we took up this study to describe the clinical profiles and outcomes in patients who are admitted 
and treated for urinary tract infection of varying degrees of severity and the risk factors and the incidence 
of recurrence among them, the risk factors for developing recurrent UTIs and the preventive measures 
taken to prevent recurrence of infection. 
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We also considered prior catherization as a risk factor to develop urinary tract infection and hence went 
on to evaluate the incidence of catheter associated urinary tract infections in our hospital. 
 
 
PROPOSED STUDY:  
Concurrent cohort study looking at the clinical profile and outcome of patients with urinary tract 
infection requiring admission into a medical ward and those at risk of catheter associated urinary 
tract infection in a tertiary care centre in south India. 
We have described two cohorts- 
A. Descriptive study of patients admitted with urinary tract infections into our hospital and the risk 
of recurrence among them. 
B. Of the risk factors for recurrence, as has been said earlier of our interest, we decided to look at 













1. To describe the clinical profile and outcome of patients 
with urinary tract infection requiring admission into a 
medical ward in a tertiary care centre in south India, and 
  











A. To evaluate the clinical profile, risk factors, treatment and outcomes of 
patients admitted with urinary tract infection and the risk of recurrence 
among them as studied in the past 3 years and prospectively over next 1 
year. 
 
1. To describe the demographic profile of patients admitted with urinary 
tract infection during the study period. 
2. To identify the following risk factors for developing urinary tract 
infection  
a. Co-morbid / predisposing illnesses  
b. Structural illnesses or prior interventions 
3. To study the common organisms and their antibiogram 
4. To evaluate the outcomes of patients treated for the Urinary tract 
infection in terms of clinical cure, microbiological cure, 
instrumentation/procedures and mortality. 
5. Incidence of recurrent urinary tract infections, any risk factors 









B. To assess the following outcome during 6 months follow-up period post-
catheterization in a medical ward:  
1. To study the incidence of urinary tract infection in those catheterized for reasons 
other than current urinary tract infection. 
2. To study the risk factors that might predispose to developing CAUTI. 
3. To study the rate of colonization and the common colonizing organisms. 
4. To describe the outcomes in those who developed CAUTI, and the mortality 
risk. 









REVIEW OF LITERATURE 
 
Urinary tract comprises of kidneys on either side with renal pelvis,with ureters draining the urine to the 
bladder and the bladder empties out via the urethra. And infection of the urinary tract refers to the 
presence of pathogens in the urinary tract in numbers enough to cause symptoms. (1)  
Hence the infection of Urinary tract might range from a simple urethral syndrome to a life threatening 
pyelonephritis and in view of the long length of the tract involved and the course of the ureters through 
the abdomen and pelvis, there could be multiple developmental anomalies/ structural problems/ back 
flow problems, all of which can complicate the UTI. 
Epidemiology: 
 Burden of UTI: With an estimated overall incidence rate of 18 per 1000 person per year, UTIs are a 
major cause of hospital admissions and are associated with significant morbidity and mortality as well as 
a high economic burden. The majority of UTIs are community acquired (57.4%), whereas 35.6% are 
health care associated and 7% are nosocomial(3); In India, it was noticed that the incidence of UTI was 
36,3 % in hospitalized patients and 16.5% in a non-hospitalized outpatient population group(4). As 
mentioned already, catheterization /instrumentation is one of the major risk factors and #CA-UTI 
account for up to 40% of all nosocomial infections and more than 1 million cases in US hospitals and 
nursing homes each year(5) while the incidence of CA-UTI differed in different settings (eg.,ICU vs Non 





Economic burden: India being the diabetic capital of the world with the economic burden of diabetes 
close to 1230 billion INR, the incidence of UTI in such population was found to be 59.5/1000 person-
years for all patients(6) only worsening the already existing economical burden .Community acquired 
UTI per say costs the global economy in excess of 6 billion US dollars every year. 
Natural history of UTI: 
The urinary tract infection is sterile except for the distal one third of it which contains mixed commensal 
flora.(7) This commensal flora are supposed to be protective to prevent ascension of infection to the 
bladder and kidneys. 
When the urinary tract gets infected , the infection may be restricted to lower urinary tract when the 
patients , characteristically , develop dysuria and increased frequency with severe discomfort(urethral 
syndrome) suggestive of the lower urinary tract infection. Associated with these they may also have 
lower abdominal discomfort and occasional hematuria (cystitis). 
They may go on to involve the upper urinary tract – where there is infection of the kidneys , the 
perinephric space and the Gerota’s fascia and formation of abscesses in the system ,when, the patients 
will report fever with shaking chills and flank pain and severe pain radiating to the hip or the leg(if there 
is tracking of pus along the gerota’s fascia). 
Asymptomatic bacteriuria: This is a where there is isolation of bacteria from the urine in 
significant quantities consistent with infection, but marked by the absence of local or systemic 
genitourinary signs or symptoms .Among general population the prevalence of asymptomatic bacteriuria 
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Cystitis: This is defined as the infection of the bladder epithelium with uropathogens. Almost 
exclusively seen in women between 15-45 yrs of age .Usually it is uncomplicated in the sense that, it can 
be treated with short courseo f antibiotics therapy but, the relapse rates are high with cystitis. 
Here, of worth mentioning is the term ‘interstitial cystitis’ which was being used earlier for 
patients with long history of frequency  and dysuria, many courses of antibacterial treatment and 
a repeated finding of apparently ‘sterile’ pyuria(10). Earlier study done showed presence of 
inflammatory changes and tissue biopsies growing fastidious organisms and hence was 
recommended that patients who present with intersititial cystitis /painful bladder syndrome 
should be recognized early and initiated on appropriate multimodal therapy that includes 
pharmacologic and behavioural therapy.(11)(12). 
 
Pyelonephritis: This is defined as the Inflammation of the of upper urinary tract (Kidneys, the 
ureters, tissue surrounding the retroperitoneal or perinephric space) associated with clinical 
features of high grade fever with flank pain and laboratory evidence of pyuria with urine and/or 
blood culture growing the same uropathogenic organism.(2) 
Prompt clinical suspicion and initiation of antibiotics has been life saving and at the same time, 
the converse of it, delay in diagnosis and intiiation of therapy in the presence of risk factors like 
diabetes mellitus,nephro/urolithiasis and structural problems might lead to life threatening sepsis 
with the same infection. 
Pyelonephritis is important to understand because of the high chances of complications that arise 
from this infection. 
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Earlier, in the pre-antibiotic era, infection of kidneys was almost always hematogenous and the 
organisms commonly isolated were from the blood stream infections like Staph aureus etc. 
However now, >75% of the time the infection is by ascending infection from the bladder to the 
kidney. The bacteria may directly invade the renal parenchyma from medulla to the cortex and . 
The local vascular channels in the kidney facilitate this spread /transport of infection. This leads 
to development of abscesses within the kidney parenchyma that may rupture into perinephric 
space. This perinephric space contains peri renal fat and adrenal glands which are in turn 
surrounded by gerota’s fascia that extends up to the diaphragm-above and down to the pelvic fat 
inferiorly, so when the abscesses rupture into the gerotas fascia they may even track down into 
the psoas /transversalis fascia anteriorly , into the subdiaphragmatic space superiorly and 
inferiorly into the pelvis causing pain at the typical referred sites of leg/groin etc . 
Presence of nephrolithiasis producing obstruction is an important risk factor for development of 
perinephric abscesses. 
All this ascending infection was to be kept in check by the commensal flora which act by 
different methods to prevent infection of the uroepithelial cells by the pathogenic 
microorganisms. It is when this balance  is disrupted or overwhelmed that the UTI occurs. 
 
Commensals in the urinary tract:  
As has been mentioned before, the distal third of the urinary tract harbours mixed commensal 
flora the purpose of which is to prevent ascension of infection.(13) and as said earlier, the 
asymptomatic bacteriuria increases with age as does the colonization of oropharynx with 
gramnegative aerobes suggesting that there is a dynamic change is the composition of normal 
flora and that it is dependent on different variables. 
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A study was done in 1980 by Marrie et al from Canada who looked at the composition of 
urethral flora in normal women of different age groups comparing with women who had urinary 
tract infection. 
Age groups were defined as premenarchal/reproductive and post menopausal. 
They have found that there is significant increase in the quantity of microbes with increase in age 
and that there is colonization with aerobic bacteria in premenarchal and reproductive age gropu 
as compared to those in post menopausal age group with predominantly anaerobic flora and also 
sometime aerobic gram negative rods. Though these Gram Negative aerobic bacilli were isolated 
from the Post menopausal women who were carrying th organism, it accounted only to 1% of the 
urethral flora as compared to those who had urinary tract infection where these organism 
accounted upto 95% of the flora.(13) 
Further studies done showed that there was predominance of lactobacillus in the urethral flora  in 
the reproductive age group women  and in girls just at the time of menarche bringing in the 
possibility of effect of estrogen on the commensal flora in the urogenital tract.(14) 
It is with the example of lactobacillus colonization in the gut and the urinary tract that , a study 
was done to review the effectiveness of lactobacillus the predominant commensal in preventing 
the infection of the epithelial cells. 
At this point, few pathogenetic mechanisms were described  
a. Phenomenon of Bacterial interference 
b. Production of enzymes by the pathogenic organisms 




Phenomenon of bacterial interference:  This was first proposed when there was an observation 
made by Elie Methcnikoff in 1894 who observed that cholera could be prevented by the presence 
of the antagonistic organisms in the intestine. He implied that normal flora help by the by-
products to in someway to affect the health status at points other than just intestinal 
colonization.(here is where the use of oral lactobacillus came about for use for minor illness like 
diarrhea) 
Later in 1956, Sears et al used a gelatin capsule containing an avirulent strain of E.Coli and 
implanted in a dog’s intestine and which later repelled a challenge with virulent strain of E coli 
suggesting the role of bacterial interference in pathogenesis of infection. 
Wells et al showed that bacterial translocation of E coli from the gut can be interfered with, by 
the anaerobic bacteria and enterococci in the gut. 
In the Urogenital tract, the leading organism, lactobacillus co aggregates and colonises the 
epithelial cells and in vitro is shown to neutralize the uropathogens in the process. 
However, the same phenomenon as is described may also be a pathway for uropathogens to gain 
adhesion to urothelial surface by this so called ‘co aggregation’. 
Interestingly, it has also been shown that the E coli (uropathogenic) which have type 1 Fimbriae , 
commonly associated with infection of the urinary tract tend to adhere to Lactobacillus and 
B.fragilis suggesting the possibility of co aggregation in the pathogenesis of infection. 
Production of substances to facilitate pathogenesis and adherence mechanisms: 
Uropathogens express many virulence factors such as adhesions, hemolysin , siderophores, O 
antigens etc .It is the production of these substances that help the pathogens adhere to the 
uroepithelium as well as to co aggregate forming the biofilms on the surface of the 
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epithelium.(15) Other well known susbstance is the urease produced by Proteus, that makes the 
pH alkaline facilitating the frowht of the organism. 
 
Escherichia coli, the commonest organism in the last few decades to cause urinary tract infection 
, has been shown to have specific organelles that help in adherence of the bacteria to the uro 
epithelium- P fimbriae.  
For any bacterium to infect and induce any inflammation, adherence to cell surface and 
establishment of bacteriuria is of utmost importance.P fimbriae are the organelles that are coded 
by the pap gene cluster that help in achieving this goal in E.coli. 
 
A study was done from Lund university,Sweden, that demonstrated the pathogenic ability of p-
fimbriation in E coli. In this study a non fimbriated strain of E coli was used to  deliberately 
colonise the patients with recurrent UTIs with which there was no significant bacteriuria and 
there were only transient host responses and it was of significance only in those with detrusor 
instability and structural abnormality of the urinary tract. 
While on the other hand, fimbriated version of the E coli significantly increased the possibility of 
Pyuria and levels of IL-6,IL-8 that induce host inflammation and also less bacterial numbers 
were required to induce host inflammatory response.(16)the role of these P fimbriae in 
decreasing the motility of the ureters and inducing inflammation has also been shown in another 
study.(17). 
 




Not to forget, the post antibiotic era where the organisms have been evolving themselves to 
develop resistance through plasmid mediated and other mechanisms .Classic example is the 
acquired resistance to trimethoprim through plasmid mediated mechanism (18)rendering it 
useless in the treatment of UTI of the new age. The acquiring of Antibiotic resistance in the 
community acquired strains of E.coli , the alarmingly increasing number of isolates from 
community acquired infections with ESBL producing E coli is of concern.(19) 
 
Etiology of UTI:  
The etiology of UTI has not changed much in the last few decades with Escherichia coli being 
the most common isolate from patients with urinary tract infection from all over the world. 
Approximately 80% of UTIs, have the causative organism as E.coli. Next commonest being 
Klebsiella, Proteus, and in hospital acquired UTIs, Pseudomonas. 
A review of etiology of UTI from USA is tabulated below:  
Uncomplicated UTI Pathogens Complicated UTI Pathogens 
Escherichia coli Escherichia coli 
Staphylococcus saprophyticus Klebsiella spp 
Klebsiella spp Enterobacter Cloacae 
Enterococcus Faecalis Serratia marcescens 
 Proteus mirabilis 
 Pseudomonas aeuruginosa 
 Enterococcus feacalis 




Extended Spectrum Beta Lactamase (ESBL) producing E.coli: 
ESBL production was first identified in 1960s in the bloodcutlure isolate of E.coli of a woman in 
Greece and hence the enzyme was named after her- TEM(20). ESBL hydrolyses the oximino-
beta-lactams such as extended –spectrum cephalosporin and are highly susceptible to 
Clavulanate and Tazobactam. These cannot hydrolyse the carbapenem group. 
This enzyme production is mediated by plasmid and transposon and hence has facilitated its 
spread to other species of bacteria. 
Within few years,this spread worldwide and later another enzyme SHV-1 was identified which is 
chromosomally mediated in klebsiella and Plasmid mediated in E.coli. 
Over the last few years, many new B-lactam antibiotics were developed but with each new 
development, the organisms emerged with novel resistance patterns. 
TEM-1 is the commonest ESBL encountered in GNB and it is responsible for ampicillin 
resistance upto 90% in E.coli. This is also responsible for increasing number of resistance 
towards ampicillin and penicillin in H.influenzae and N.gonorrhoea. 
The emergence of newer ESBLs happens with just a single aminoacid substitution rendering it 
vulnerable to the selection pressure that happens with the use of a particular group of antibiotics 
in a given institution(21).This observation came from the fact that the mutations that happen in 
TEM in laboratory other than those naturally described are constructed.Hence the fluctuating 
selective pressure with different B lactams in the same institution rather than a single agent 
might be responsible for further emergence of resistance. 
Newer enzyme CTX-M and OXA are the new families added to this class of enzymes. 
CTX-M type is plasmid mediated and confers resistance to Cefotaxime while OXA confers 




The resistance patterns described by Kang et al have been similar to the ones that we have 
observed in our institution and our study.The table of comparison is found in the annexure(19). 
 
Various risk factors have been described for emergence of ESBL in community acquired 
infections. 
Study from Spain identified that the prevalence of ESBL infection in the community in the 
period between 2000 and 2003 has increased from 0.47% to 1.7% and that the riskfactors that 
showed trend towards significant association were previous hospital admission in the last 12 
months, use of 2nd gen Cephalosporins prior , intravenous antibiotic use, previous bacterial 
infection, presence of a genitourinary pathology. However on multivariate analysis,only use of 
2nd gen cephalosporins was shown to be significant in prediciting the development of ESBL in 
community.(22) . At the same time kang et al found that prior use of cephalosporins and 




History dates back to 1956/57 when Edward Kass proposed the term – ‘significant bacteriuria’ to 
differentiate between women with infection and without infection and to aid in the diagnosis and 
treatment of these women who are symptomatic. 
With the advent of antibiotics in the mid 1950s, this distinction became necessary to avoid 
unnecessary prescription of antibiotics and also to identify those at risk of developing UTI. 
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Method of collection of Urine: The earlier studies done had shown the correlation of 
culture growth of the initial 10ml of urine with the peri-urethral swab cultures, both growing the 
same organism. Those studies were used to identify the normal resident flora of the urinary tract. 
That extrapolated to collection of midstream clean catch of urine to be a better indicator of 
pathogen causing the urosepsis. 
Methods of diagnosis:  
Microscopic examination of urine: In a patient with significant bacteriuria, a centrifuged 
sample will almost always show bacteria. In patients with Colony forming units <10*5 
approximately 10% of them show bacteria. The presence of bacteria is more specific and less 
sensitive(23) 
 Pyuria is present in patient with UTI. About 60-75% will have WBC >10 in urine .This has high 
sensitivity (95%) but may not always be diagnostic of the UTI(low specificity)(24) since it may 
be falsely present in patients with Genital tract infections/WDPV or Genital 
Tuberculosis(described as sterile pyuria)(25). Pyuria can be detected by direct microscopy of 
centrifuged urine or by dipstick for leucocyte esterase.  
A dipstick rule--based on having nitrite or both leucocytes and blood--was moderately sensitive 
(77%) and specific (70%) [positive predictive value (PPV) 81%, negative predictive value 
(NPV) 65%].(26) 
 
Urine culture:  As discussed earlier, Midstream clean catch urine has been the best method of 
collection of urine for culture of organism from patients with UTI. However, the technical 
difficulties in collecting the sample in the elderly/obese/children and the likelihood of 
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contamination of urine while collecting, made the other methods of collection – catheterized 
sample/suprapubic sample as important alternatives. 
The growth of organism in the culture – the number of colony forming units ,as first mentioned, 
was said to be significant if the number was >10*8 according to Kass(27). 
However, Maskell et al questioned this number, noting that, many women with significant 
symptoms were left untreated or treated with short course of antibiotic with risk of recurrence. 
She also pointed out that some of those women would have had lots of water to drink and 
passing urine and diluted the urine due to the lower urinary symptoms at which time such high 
cut off was not feasible.  
Hence the IDSA –FDA has given the guidelines for pretreatment significant growth of pathogens 
is defined as = 104 colony forming units/mL in women (midstream urine) or = 103 colony-
forming units/mL in men (midstream urine) or = 103 colony-forming units/mL (catheter urine) or 
= 102 colony-forming units/mL of midstream urine collected during antibiotic treatment of UTI 
(28). 
Individual symptoms have modest ability in accurately predicting the diagnosis of UTI 
however,when combined with other signs and laboratory techniques like dipstick, the diagnostic 
accuracy increases steeply.(29) 
 
Treatment strategies: 
Medical management of UTI:  
With emerging resistance to newer antibiotics and newer resistance patterns, it is important to 
know the antibiotic profile- the local antibiogram of common organisms to be able to choose the 
right drug . 
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Urine culture and blood cultures must be done prior to initiation of antibiotics. 
Important principle is to downgrade to a lower antibiotic once the culture sensitivity reports are 
available , in keeping with the patient’s clinical condition ,to prevent collateral damage in terms 
of emergence of resistance among the innocent bystander organisms(commensals) which might 
later get transmitted and also wiping off of commensals which, as discussed earlier, might 
remove the advantage of bacterial interference leading to superadded invasive infection with 
more more resistant pathogens. 
 
American Urology society and European society along with IDSA have provided guidelines 
towards management of Urinary tract infection and prevention of indence of catheter associated 
urinary tract infection along with economical analysis of the cost of treatment and prevention.  
Principle of management: 
1.Prompt diagnosis and intiation of treatment after appropriate cultures and prompt 
upgradation/downgradation of antibiotics based on culture reports and clinical judgement. 
2.Evaluation of risk factors for development of UTI  
3.Identifying the riskfactors for development of recurrence of UTI. 
4.Identifying the vulnerable population – pregnant women, diabetics,children,patients on 
prolonged immunosuppression etc for careful follow up. 
5. As and when needed source control in terms of surgical intervention if there are any 
collections/abscesses. 
 
For complicated urinary tract infections first drug of choice is a carbapenem as compared those 
with uncomplicated, less severe UTI can be managed with oral Trimethoprim - sulfamethoxazole 
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in resource limited setting and tailor based on the local anitbiogram. There are areas where 
bacteria are still sensitive to fluoroquonolones and in such places Oral Fluoroquinolones can be 
used.(30) 
 
Everybody is equally at risk of developing a UTI but certain vulnerable populations exist like 
pregnant women, children, patients with diabetes(6) disorders of spinal cord, those on long 
indwelling catheter ,other debilitating neurological conditions, immunocompromised state like 
cushings,HIV/AIDS, and those with structural urological problems. 
So far the risk factors identified for increased susceptibility towards development of urinary tract 
infection  have been (8) : 





Sexual intercourse Urogyneacological surgeries 
ABO blood group 
antigens 
Urinary obstruction Diaphragm use Estrogen deficicency 
 Prior history of UTI Condom use  
 Diabetes Spermicide use  










Recurrence of UTI has been the major health issue in patients who are admitted with Urinary 
tract infection. It has been shown that approximately 25% of women have another episode of 
UTI following the first episode within 6 months.(31). 
Those who are at risk of recurrence  are mostly women and the list includes post menopausal 
women (32)(33),men and women with uncontrolled/poorly controlled diabetes, those who 
underwent urological surgeries(34) ,those with improperly treated ,unfinished treatment course 
for any preceeding UTI. 
The characterisitics of bacteria have also been widely studied in view of recurrence of UTI and it 
has been shown that the presence of infection with the p-fimbriated E.coli is associated with 
recurrent urinary tract infection because of their ability to adhere to the urothelium and to form 
biofilms. 
Various forms of therapy have been tried to prevent recurrences especially among women. 
Cranberry juice(35), Probiotics(32), Estrogen therapy for postmenopausal women ahevall been 
tried but nothing has been proven of significant benefit. 
Prophylaxis with anitbiotics has been extensively studied – one dose versus daily low dose of 
anitbiotics has been debated. (37) Cochrane review suggested that 6-12months of antibiotic 
prohylaxis in women will help in preventing recurrent UTIs in non-pregnant women. (36). 
 






Catheter associated urinary tract infection (CAUTI):  
Catheter associated urinary tract infection is the commonest device associated nosocomial 
infection worldwide. 
 Device associated infection rate, in general has been increasing worldwide and most hospital-acquired 
UTIs are associated with catheterization, and most occur in patients without signs or symptoms referable 
to the urinary tract , CA-bacteriuria being the most frequent health care–associated infection worldwide, 
accounting for up to 40% of hospital-acquired infections in US hospitals each year(38) . Vonberg et al 
from Germany had reported an incidence of 6.8 CAUTI per 1000 device days while an Indian Study by 
Singh .S from Gujarat reported the same as being 0.6CAUTI per 1000 catheter days. The incidence of 
CAUTI changes again in patients admitted into ICU – 4.3 cases per 1000 device days from Columbian 
data (39)(40) Vs 1.41 per 1000 catheter days form Indian ICUs (41) 
It is noteworthy that Fewer than 5% of bacteriuric cases actually go on to develop bacteremia, and 
CAUTI is the leading cause of secondary nosocomial bloodstream infections; about 17% of hospital-
acquired bacteremias are from a urinary source, with an associated mortality of approximately 10%. The 
risk of bacteriuria with catheterization is 3% to 10%, every day ,approaching 100% after 30 days(42).In a 
study done in Thailand in 2005, the risk of CAUTI was maximum within 2 weeks of indwelling 
catheterization  and half of the study group developed UTI within one month. One other study from 
Michigan evaluating Condom catheter Vs Indwelling cathter found that those who had an indwelling 
catheter were approximately five times as likely to develop bacteriuria or symptomatic UTI or to die 
(hazard ratio=4.84, 95% confidence interval=1.46-16.02) as those with a condom catheter (P=.01).Hence 
we wanted to study the burden of CAUTI in our hospital and the risk factors and outcomes related to the 
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same by evaluating the patients who are catheterized and by following them up till 6 months to look for 
any development of urinary tract infection. 
CA-UTI is defined as the development of symptoms and signs with significant bacteriuria in a patient 
with indwelling catheter currently or who had it in the last 48 hrs. 
CA- Asymptomatic bacteriuria – is described as bacteriuria but without symptoms in patients who have 
long standing indwelling catheter. 
Pathogenesis:  
The presence of a foreign body in the form of an indwelling catheter introduces an inoculum of bacteria. 
This can be the native flora from the patient or transitory flora that gets introduced during the 
catheterization procedure. 
The presence of a foreign body helps the microbes to form colonization further leading to the formation 
of so called ‘biofilm’ .Biofilms are usually formed by one species but once the bacteria start growing on 
the biofilm, they produce polysaccharides that adhere and trap other bacteria and the biofilm supports the 
growth thus becoming polymicrobial. 
The catheter also helps in ascension of organisms easily now that there is a conduit to help the process. 
This happens especially if the bag is contaminated/if there’s contamination of the tubing by the frequent 
handling of the personnel/ if there is delayed bladder emptying etc. 
Also it has been shown that the uro-epithelial cells after catheterization are more prone for adherence f 
bacterium than the normal cells due to breach in the mucosal barrier during cathterisation and by the 
sheer presence of the catheter.(43). 
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The common organism isolated is E.coli. Other Enterobacteriaceae like klebsiella, citrobacter, 
enterobacter and others like proteus, pseudomonas aeruginosa are the other commonly encountered 
bacteria in CA-UTI. 
Clinical features: CA-UTI are seldom symptomatic. The presence of a new fever, hypotension, frank 
hematuria, flank pain etc. In patients whom, it has been removed, features like increased frequency, 
dysuria etc should alarm the physician of a possibility of a CA UTI. Significant growth on urine culture 
may be present. The significant growth in patient suspected to have CA UTI has been debated .The 
presence of low Colony count does not rule out infection (in patients with symptoms), the converse, 
presence of significant bacteriuria without symptoms does not warrant treatment always . 
Hence the decision to treat the urine culture and suspect CA UTI is dependent on the treating physicians. 
Guidelines have been laid for the same by the IDSA.(38) 
Prevention strategies : 
-Avoiding unnecessary catheterizations 
-Prompt removal of catheter in situation where patient has recovered and the indication ceases to exist. 
-Changing over to condom cathter (in men ) whenever required. 
-Avoiding unnecessary handling of the catheter bythe health care personnel. 
-Using closed catheter drainage system. 
It has been shown that addition of antibiotics to the urosac, regular cleaning of the meatus by povidoen 
iodine etc, cranberry method, low dose antibiotic prophylaxis have all been unsuccessful in preventing 




MATERIALS and METHODOLOGY: 
Setting:   
a. The Christian Medical College is a 2400 bed teaching College in Vellore, South India. 
Though it caters to approximately 1 million citizens of the town it also serves patients 
from all over India and South-East India. The C-ward is among the three main general 
medical wards of the hospital. It is a 40-bed ward with average bed occupancy of 80—
90% and has patients from lower to middle socio-economic adult patients. 
b. Duration: March 2008 till March 2011 as retrospective analysis and from August 2011 
till July 2012 as a prospective study. 
 
Participants:  
Cohort A:  




 All these patients will be followed up till discharge and up to July 2012 with a maximum 







Urinary tract infection:  
Significant bacteriuria (>10^5 CFU/ml) in a patient with symptoms or signs attributable to 
the urinary tract and no alternate source. 
Pyelonephritis:  
It is defined as inflammation of the upper urinary tract (Kidneys, ureters, tissue surrounding 
the retroperitoneal or perinephric space). Criteria for diagnosis of pyelonephritis include:  
1. The isolation of the same pathogen from urine and blood cultures.  
or  
2. The simultaneous presence of : 
a. Fever, defined as an axillary temperature of 38°C or greater; 
b. Pyuria, defined as the presence of 10 or more leukocytes per high-power field 
in the centrifuged specimen; and  
c. Positive urine culture (>105 colony-forming units [cfu]/mL) or signs and 
symptoms with probably significant bacteriuria.(2) 
Urosepsis:  






Definitions (IDSA-FDA): Urinary tract infections can be classified  
- According to the setting of onset, such as nosocomial infection, health care-associated 
infection, and community-acquired infection. 
- According to the anatomic site of infection, such as cystitis or pyelonephritis. 
- Complicated or uncomplicated, irrespective of the site and severity of the infection: 
Complicated urinary tract infections (cUTIs) being defined as those occurring in patients  
with anatomic or functional abnormalities of the urinary tract or in those with significant 
medical or surgical comorbidities. 
- Clinical cure is defined as being alive with the absence of fever (temperature < 38.0°C) 
and the resolution of UTI symptoms 
- Clinical treatment failure is the opposite of clinical cure and defined as deterioration, 
persistent fever and/or symptoms of UTI or relapse of UTI with the same uropathogen for 
which additional antimicrobial treatment is prescribed. 
- Pre-treatment significant growth of uropathogens is defined as = 104 colony forming 
units/mL in women (midstream urine) or = 103 colony-forming units/mL in men 
(midstream urine) or = 103 colony-forming units/mL (catheter urine) or = 102 colony-
forming units/mL of midstream urine collected during antibiotic treatment of UTI at 
study entry(22) 
- Bacteriologic cure or eradication is defined as the elimination of the uropathogen or as 
pathogen growth of less than 104 colony forming units/mL in women or less than 103 
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colony-forming units/mL in men, of a midstream urine sample collected combined with 
the disappearance of leucocyturia(22) 
- Co-morbidity is defined as the presence of any urinary tract disorder, post menopausal 
status or prolapse or gynaecological malignancy (in women), heart failure, 
cerebrovascular disease, renal insufficiency, diabetes mellitus, malignancy or chronic 
obstructive pulmonary disease for which the patient is prescribed medication and/or 
consults a hospital-based medical specialist. 
- Recurrent UTI: defined as =3 microbiologically documented episodes of symptomatic 
UTI managed in the clinic during the last year or 2 episodes during the last 6 
months.(80% of Recurrent UTI are Re-infection) 
- Re infection : Recurrent infection with the same or a different organism. 
- Relapse: Infection with the same strain of organism within 2 weeks of treatment – 










 Inclusion:  
1. All adult patients catheterised (indwelling urinary catheter) in the Emergency 
department and admitted into medical ward. 
2. All patients catheterised for any reason while admitted in the medical ward/ Medical 
ICU/HDU.  
For a period of approximately 6 months (from Nov 2011 - May 2012) and following them upto 
discharge and for 6 months thereafter. 
Definition:  
Catheter associated Urinary tract infection is defined as the new appearance of bacteriuria or 
funguria with a count of more than 103 CFUs/mL occurring in person whose urinary tract is 
currently catheterized or has been catheterized within the past 48 hrs.(2). If intercurrent 
antimicrobial therapy is not given to the patient, the level of bacteriuria or candiduria 
uniformly rises to more than 105 CFUs/mL within 24 to 48 hours.(5) 
However, in our hospital, since we do not always have the clinical details available, we have 
been using 105 CFUs/mL as a criterion for significant bacterial growth in the cultured urine 
specimen based on our hospital data about the commonest uropathogens and their anti-
bacterial resistance pattern. 





1. Patients with history of urinary tract infection in the last 1 month or patients catheterised 
while admitted for treatment of UTI. 
2. Paraplegic/Bed bound patients who have been on catheter for more than 3months. 
3. Patients with External catheterisation (Uro-condom), intermittent catheterisation, 
suprapubic catheterisation are not included. 
Cohort A: We used the clinical research form and collect the required data from the inpatient 
record of the patients admitted with UTI during the study period with informed consent from the 
patients being recruited prospectively and followed up till discharge and thereafter for 1 year to 
look for recurrence. 
 
Cohort B: We estimated approximately 20% of our hospitalized patients requires 
catheterisation annually. We included all the patients meeting the inclusion criteria consecutively 
from November 2011 – August 2012. We did culture and sensitivity on catheter cleaned, 
clamped and collected urine specimen along with urine routine analysis.  The cultures were done 
on the third day of catheterisation in keeping with the CA-UTI guidelines from CDC (48hrs as 








Since it is a descriptive study we looked at the previous admission statistics and our question to be 
addressed which is , the risk of recurrent UTI . 
We looked at the admission statistics over the last 4 years and calculated the approximate number of 
patients that are admitted with the diagnosis of urinary tract infection (as given in table below) 
 
Year 2007 2008 2009 2010 
Total number of patients admitted to C-ward 1984 1936 1884 1993 
Number of patients admitted with UTI 134 143 136 143 











Sample size Calculation:  
Our  literature review showed that the approximate incidence of recurrent UTI in diabetics is 
40%. However, as given below, for Cohort A, we would like to analyse as much of available 
data in the 3 yr study period as possible, keeping the minimum number as 162 and the maximum 
number as 586. 
Table 1: Sample Size for Objective A 
Two Proportion - Hypothesis Testing - Large Proportion - Equal Allocation 
Incidence of Recurrent UTI is nearly 20%   
Proportion of recurrent UTI in MII 0.2 0.2 
Proportion of recurrent UTI in Diabetes or Catheterization is around 1.5 to 2 
times more 0.4 0.3 
Estimated risk difference -0.2 -0.1 
Power (1- beta) % 80 80 
Alpha error (%) 5 5 
1 or 2 sided 2 2 
Required sample size for each arm 81 293 
 
The incidence of UTI in MII patients have been nearly 20% per 6 month. However, this is 
expected to be 1.5 times for patients with history of catheterization and 2 times more for patients 
with Diabetes. In order to test this difference, with α and β errors at 5% and 20% respectively 
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and a drop out of 10%, we need to study nearly 300 subjects with primary UTI 
with Catheterization and 300 subjects without  Catheterization. 
 
Table 2:  Sample Size for Objective B 
Proportion of catheterized patients with Colonization in Med II 
who could develop UTI  0.25 0.25 
Proportion of patients without Colonization in Med II who could 
develop UTI 0.06 0.06 
Estimated risk difference  0.19 0.19 
Power (1- beta) % 80 90 
Alpha error (%) 5 5 
1 or 2 sided  2 2 
Required sample size for each arm  56 74 
 
The proportion of patients with colonization in Med II who could develop UTI has been 
expected to be around 25%, while this is 6% in the no colonization group. In order to show that 
this difference is statistically significant with α and β errors at 5% and 20% respectively, we 
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During the period of study, total of 185 patients were recruited (N=185).  The baseline clinical 
characteristics at presentation are depicted in Table 1. 
85.4 % patients had fever and about 59% of the patients had dysuria at presentation. However 
only 25.4% and 45% patients had LUTS and rnal angle tenderness, respectively. Alteration of 
the mental status was the most common associated complaint (25.4%). 
Diabetes mellitus was the most common comorbidity (60.5%) associated with the diagnosis of 
UTI. 
 Despite being the tertiary care referral centre, only 17.8 % of the patients had confirmed history 
of prior use of antibiotic before presentation to CMC. Less than one-fourth of the patients had 
history of urinary catheterization in the past. 












Table 1. Clinical characteristics at presentation: 
Presenting symptoms N=185 (percentages) 
Fever with chills 158(85.4) 
Dysuria 109(58.9) 
LUTS 47(25.4) 
Renal Angle / Supra-pubic tenderness 83(44.9) 



















Other comorbidities  142(76.8) 
Structural Condition.
Metabolic Predisposition






History of previous admissions 81(43.8) 
Past history of catheterisation 43(23.2) 
Past history of instrumentation  11(5.9) 





Table 2 - Clinical signs at presentation: 
Clinical signs at the time of presentation  Number (%) 
Pulse (>100) 110(59.5) 
Resp.Rate (>20) 133(71.9) 
Hypotension 37(20.0) 











































Out of 185 patients, urine culture was performed on 178 (96.2%) patients. 140 urine culture 
showed uropathogenic organism.  E. coli was the most frequent organism (58.4%). 68 out of the 
108 (63%) E. coli isolate were ESBL producers (table 4). 
Table 4: Organism grown in urine culture 
Organism Number(Percentage) 
E Coli- non-ESBL 40(21.6) 





No growth 35(18.9) 
Not done 7(3.8) 
 
Among the 140 urine cultures, mid-stream clean catch urine collection was the most frequently 
performed (77.1%) method of urine specimen collection. The rate of isolation of significant 
colony forming units among the three methods of urine collection has been tabulated below in 
table 5. When all the 3 methods are compared, there was no statistical difference among the 3 
different methods of isolation of the organism with respect to the rate of significant colony count 





Table 5:  Rate of isolation of significant colony forming unit organism from 3 
methods of urine collection. 
 
Out of 185 patients with urinary tract infection, 63 patients (34%) had blood culture positive for 
the causative organism (table 6). 59 (93%) of the blood culture isolates were E. coli and 44 
isolates (74.5%) were ESBL producers.  
 
Table 6 -Organism grown in blood culture (N=63) 
Organism  Number(percentage) 
ESBL E. coli 44(69.9) 
E. coli (non-ESBL) 15(23.8) 
Klebsiella species 3(4.8)                        
S. aureus 1(1.6)                          
 
 
  CFU per ml Total 












Mid-stream Clean Catch  38 (35.2%) 70 (64.8%) 108 
Directly from urinary catheter 8 (30.8%) 18 (69.2%) 26 
Supra-Pubic Aspiration 0 (0%) 
. 
6 (100.0%) 6 




Table 7. Initial choice of antibiotic 
 Initial choice of antibiotic for UTI 
 Frequency Percent 
Amikacin 8 4.3 
Cephalosporins 8 4.3 
Cefoperazone 4 2.2 
Pipercillin-tazobactam 83 44.9 
Co-trimoxazole 2 1.1 
Fluoroquinolone 6 3.2 
Ertapenem 40 21.6 
Imipenem 1 0.5 
Meropenem 29 15.7 
Others  4 2.2 
Total 185 100.0 
The most common antibiotic of choice was Pipercillin-tazobactam (45%)  followed by 
carbapenem (38%). Among the carbapenems, Ertapenem was the preferred agent due to its 






Total  enrolled for follow up = 185
89 followed up
Had UTI = 40 
No UTI = 49
Lost to follow up = 96
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Table 8. Follow up for recurrence: 
Follow up Number Percentage 
No. UTI episodes 49 55.1 
UTI episode 36  
E Coli 9 10.1 
Enterococci 2 2.2 
ESBL E coli 19 21.3 
Klebsiella 2 2.2 
NFGNB > 1000000 1 1.1 
Pseudomonas significant 1 1.1 
Culture Negative Pyelonephritis 2 2.2 
Details not available 4  
 
Total of 89 patients were followed up for a period of 3 years. The data for 4 
patients was unavailable, therefore excluded from the analysis. 49 (57.6%) had no 
further UTI episodes while. Total of 36 (42.3%) patients had confirmed UTI (table 
8, figure1). 28 out of 36 (93.3%) of the cases of the recurrent UTI was caused by 


























Risk factors associated with recurrent UTI: 
The most consistently associated risk factor for recurrent urinary tract infections was diabetes 
mellitus (Table 9a). Our study was in agreement with this well known fact and indeed of all the 
risk factors that were studied, despite the numbers being low, diabetes mellitus was the only risk 
factor that was found to be significantly associated with the development of recurrent UTI (p 
value – 0.067).  
Table 9a.  Diabete as risk factor associated with recurrent UTI 
 
Other risk factors for recurrent UTI considered were the history of prior hospitalization, history 
of prior instrumentation of urinary tract or catheterization. On multivariate analysis, none of the 
risk factors was statistically significant. However, the odds ratio for developing recurrent UTI 
was 10 times higher among the patients who had prior history of catheterization, with a trend 
towards association but not statistically significant.  
Table 9 b.  Other risk factors associated with recurrent UTI 
 
S. No Risk Factors OR (95% CI) P-value 
1. Prior hospitalization 1.034 [0.44-2.42] 0.938 
2. History of instrumentation 4.5 [0.4-49.1] 0.207 
3. Prior history of Catheterization 10.8 [ 1.028-114.15] 0.26 
4. Procedures/interventions done during this admission  0.924 
 Recurrent UTI  
Absent Present Total (row) 
Diabetic 29 (48.3%) 31 (51.7%) 60 (100.0%) 
Non-diabetic 20 (69.0%) 9 (31.0%) 29  (100.0%) 

































Table 10. Demographic Profile: 























Occupation   
House wife  
Unemployed/student  
Unskilled labourer 





Place of catheterization  
Emergency 
Ward  













Aseptic precautions followed  82(96.5) 













Mean duration of catheterization(days) 6.73 
Removal of catheter   
Patient recovered  
Changed to condom 
Catheter  in situ 








This Cohort of patients included more men than women and with most of the patients in the age 
group <49 yrs. This is the set of patients who are admitted for reasons other than urinary tract 
infection needing a catheter to be placed. 
The majority of the patients were from urban Vellore presenting with a short duration serious 
illness requiring tertiary care. 
Of the women, they were mostly housewives. The most common diagnosis at presentation was 
altered sensorium due to various causes like seizures/cerebrovascular accident and other 
conditions that lead to debilitation such as meningitis/ventriculitis and SLE with nephritis. 
Deliberate self harm is the other commonest single diagnosis for which patients required 
catheterisation and monitoring. 
The fact that the patients were mostly catheterized in the emergency indicates that these are 
unplanned admissions and the patients were probably very sick at presentation. 
Most of them were catheterised by the nurses and the interns and few of them by the technicians. 
According to the details available, aseptic precautions were followed in 97% of patients. As 
mentioned earlier, the indication for catheterisation was mostly the low sensorium of the patient.   
Mean duration of catheterization was 6.7 days. However patients were quickly changed over to 
condom and the CBDs were removed except in those who died or those who got discharge 







                                            







¾ 85 patients were included over the  period of 11 months. 
¾ 9 patients were lost to follow up. 
¾ 76 patients were followed up with a median follow up period of  71.5 days. 
¾ Of them, 4 had Catheter associated urinary tract infection while they were still admitted. 
 
 
Duration of follow up: Patients were followed up for a minimum of 31 days to a maximum 
of 315 days with a median follow up period of 71.5 days.  They were contacted over the phone to 




Total  enrolled 
=85
76 followed up
Had UTI = 4 
No UTI = 72




Table 11. Organism grown in culture: 
 
Organism isolated Number 
(percentage) 
Colony count Interpretation  
B-hemolytic 
Streptococci 
1(1.2)  Insignificant 
ESBL E.coli  7(8.2) >10*3 Significant 












Pseudomonas 1(1.2) <10*5 Probably Significant  
Non Fermenting GNB 1(1.2) >10*5 Significant 















The urine cultures were sent on the third day to document colonizers and to study the incidence  
of significant bacteriuria and the association of the colonizing organisms with the development 
of UTI. The common organism isolated in the 3rd day culture was colonization by candida and 
contaminants. A few isolates had ‘probably significant’ growth of gram negative organisms 
(ESBL E.coli,Pseudomonas,E.coli, Klebsiella). 
Enterococcus as discussed in the literature review was one of the other predominant organisms 
isolated in these cultures.Though not usually associated with CAUTI, in our cohort,25% of the 






































COHORT A : 
Urinary tract infection has been one of the rewarding infections to treat for physicians, provided the right 
diagnosis is made and management of the disease is started right away. If treated appropriately the 
chances of complete recovery are extremely good.. On the other hand, if there’s a delay in presentation 
and initiation of therapy, there is a significant risk of morbidity and mortality associated with the gram 
negative bacillary sepsis that ensues. 
This study was done to describe the clinical profile of the patients who were admitted in a medical ward 
of a tertiary care centre with a diagnosis of urinary tract infection. We also followed up the patients 
prospectively after discharge for 6 months who had been catheterized for the development of catheter 
related UTI and those who discharged after treatment of UTI for the development of recurrence of 
infection. 
Urinary tract infection, pyelonephritis and urosepsis are defined for this study as per the pre-defined and 
standard laid down criteria. We recruited 185 patients with a diagnosis of UTI, pyelonephritis and 
urosepsis admitted during the study period that is, 2008-2011 under a single medical unit.  
Demographic profile:  
Gender and Occupation: Our patient cohort had almost equal number of men and women (47.6% vs 
52.4%). Most of the women were housewives (94%) whereas unskilled and un-employed retired elderly 
male formed the majority of the male cohort (37.5% each). Most of the patients were from the local 
places of Tamil Nadu.  
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Age-wise distribution: While 33.4% of the patients belonged to the age group of less than 49 years; 
66.6% of the patient belonged to age group more than 49 years comprising the majority.  
Clinical characteristics: 
Symptoms and signs: The commonest presenting complaint was fever (88%) and dysuria (51%). 
However, only one third of the patients had renal angle tenderness. It was interesting to note that in the 
elderly age group who did not have significant dysuria or renal angle tenderness, altered sensorium was 
the most common complaint at the time of presentation (25%). Other non-specific symptoms included 
vomiting and dyspnoea. 
Co-morbidities: In this study, the single most common comorbidity associated with UTI, 
pyelonephritis or urosepsis was diabetes mellitus (60.5%). The next most frequent comorbidity was post-
menopausal state (40.5%). From the above discussion, we conclude that urinary tract infection is seen 
more frequently among the elderly due to higher prevalence of comorbidities i.e. Diabetes mellitus and 
post menopausal status, in this age-group. 
However other comorbidities like, structural urogenital anomalies and debilitating conditions were less 
frequently found in our cohort of patients (17% and 5.4%, respectively).  
Risk factors for recurrent urinary tract infection: 
History of prior catheterization was the strongest risk factor associated with the development of urinary 





With a suspected urinary tract infection, the most important cheaper and readily available initial 
investigation i.e. urine dip-stick test was done in 179 (~97%) patients. When individual components of 
Urinary dip-stick test e.g. Pyuria / leucocyte esterase / nitrites were compared with the confirmatory 
diagnosis, there was no significant association of either variable. Thus a combined interpretation of all 
the components of the urinary dip-stick is recommended for initial screening of suspected urinary tract 
infection.  
Urine culture was done in 178 (96.2%) patients and there was significant growth in ~ 72%. The observed 
culture negativity in the remainder patient could be due to the history of being treated with antibiotics 
prior to admission as observed in 17.8% of patients in our study (the commonest used antibiotic group 
was the fluoroquinolones). E. coli was the most frequent organism among the urine culture isolates 
(58.4%). 63% of the E. coli isolates were ESBL producers. This corroborates the fact that there is 
increasing number of ESBL E.coli being isolated in patients with community acquired urinary tract 
infection. 
Blood cultures showed growth in 34% of the patients. Again the commonest organism isolated was 
Escherichia coli with 74% of them being ESBL producers. We noticed high level of fluoroquinolone 
resistance in our cohort of patients with only 8% of them being sensitive to ciprofloxacin. We have also 
noted a significant resistance to piperacillin – tazobactam (~ 32%) which is of concern as many tertiary 
centers start on a broad spectrumantibiotic, the first choice being piperacillin tazobactam. The ‘inoculum 
effect’ of piperacillin tazobactam, is of concern with such high levels of resistance as this might lead to 
incomplete microbiological clearance and recurrence of UTI and.  
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Hence we recommend Carbapenem, preferably Ertapenem as an empirical choice of antibiotic for 
seriously ill patients admitted with suspected urinary tract infection in our hospital considering the 
antibiogram where E coli is the commonest organism with high rates of ESBL producers. 
Our center has published data in the last decade(2005) regarding the resistance patterns of E.coli.(44) 
 
Comparing the then data and now:- 
Resistance rates of E. Coli 
Antibiotic 2005 2012(our study) 
Cotrimoxazole 36% 29% 
Nitrofurantoin 73% 89% 
Amikacin 78% 85% 
Gentamicin 60% 43% 
Ciprofloxacin 38% 14% 
Cefuroxime/cefotaxime  
(comparable to cefpodoxime) 
62% 26% 
 
This comparison clearly warns us about the emerging resistance pattern among the community acquired 
E. coli urinary tract infection. 
Excepting for nitrofurantoin and amikacin, all other antibiotics compared here, have shown emerging 
patterns of resistance. Resistance is more pronounced to fluoroquinolones rendering them of little benefit 
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in the community and resource limited settings where these antibiotics are used for first line of therapy of 
UTI.  
Outcomes:   
The outcomes of all these patients who have been admitted with urinary tract infection were looked at. 
a) Cure / Death / DAMA 
b) Factors that favor /associate with mortality-  
a. Presence of Bacteremia,  
b. Critically ill requiring ICU care at presentation,  
c) First choice of antibiotic. 
d) Follow up- recurrence  
- Incidence, at first episode- common organism, and time to first episode. 
- Additional risk factors; 
o Duration of catheterization,  
o Blood organism,  
o Severity of infection at index admission: Ultrasound kidney appearance at admission as 
surrogate marker of severity. 
Outcome (N=185)  Number (%age)
Cured  
Clinical 155 (83.8) 
Bacteriological 80 out of 96 culture done (83.3) 
Death 15 (8.1) 




Out of the 185 patients enrolled and followed up during the hospitalization, more than 83% of the 
patients had clinical as well documented microbiological cure. However 15 patients (8%) patients 
expired during the hospital stay.  
We analyzed the 15 patients who expired and compared the following variables to further ascertain the 
risk of death in urinary tract infection. 
 
A). Comparison of outcome based on blood culture isolate: 
 Blood culture isolate 
  Sterile E coli Klebsiella S. aureus Total 
Outcome 
Expired 10 (66.7%) 3 (20.1%) 1 (6.7%) 1 (6.7%) 15 
Alive 112(65.9%) 56 (32.9%) 2 (1.2%) 0 170 
Total 
(column) 
122 (65.9%) 59 (31.9%) 3 (6.1%) 1 (0.5%) 185 
 
The above table shows that 33.3% of the patients in the expired group and 34.1% of the patients those 
who were alive at discharge were bacteremic. This difference was not statistically significant.  
B). Comparison of outcome based on severity of illness at admission: 
The severity of illness at admission did not correlate significantly with the mortality. However, 
admission into ICU/HDU at admission was significantly associated with less mortality probably because 




Initial choice of antibiotic for empirical treatment: 
Majority of the patients (~45%) were initiated on Pipercillin-tazobactam and 38% patients were initiated 
on carbapenem empirically. This is in keeping with the hospital antimicrobial policy based on local 




Follow up for recurrence:  
Out of 89 patients on follow up, after excluding the 4 patients whose data was 
incomplete, 42.3% patients had recurrent UTI after a mean period of 77 days. Even 
in the cases of culture proven UTI, E.coli remains the most important causative 
agent (93.3%).  
As discussed earlier, Diabetes mellitus was the risk factor consistently associated 




















This cohort included patients who have been catheterized for reasons other than Urinary tract 
infection and the The urine cultures were sent on the third day to document colonizers and to 
study the incidence of significant bacteriuria and the association of the colonizing organisms 
with the development of UTI. The common organism isolated in the 3rd day culture was 
colonization by candida and contaminants. A few isolates had probably significant growth of 
gram negative organisms (ESBL E.coli,Pseudomonas,E.coli, Klebsiella). However, patients were 
treated based on the clinical suspicion rather than just based on the interpretation of the culture 
report. There was no significant association between the organism isolated to the risk of 
development of UTI or death due to CAUTI on follow up.  
CAUTI incidence was 4.7% (4/85) in our cohort of patients. 
All the above patients were housewives. Three of them were from in and around Vellore. 
It is interesting to note that all of them developed CAUTI during this hospital  admission . 
Average duration of catheterization was found to be 5.25 days (maximum of 7 days and a 









Analysis of the patients who had CAUTI : 
¾ Clinical feature ¾ Finding 
¾ Gender ¾ Female 4/4 
¾ Age  ¾ 56-66 
¾ Occupation  ¾ Housewives(4/4) 
¾ Place ¾ 3/4 urban tamilnadu 
¾ Primary diagnosis  ¾ chronic disease(3/4) 
¾ scrub typhus(1/4) 
¾ Culture on day 3 ¾ ESBL E coli (1/4) 
¾ Enterococci(2/4) 
¾ No growth (1/4) 
Average duration of cathterisation ¾ 5.25 days 
¾ Time to first urinary symptom ¾ 8.25 days 
¾ Symptom ¾ Fever(2/4) 
¾ No symptoms(2/4) 
¾ Organism isolated during CAUTI ¾ Enterococci(1/4) 
¾ Enterococci/E.coli(1/4) 
¾ ESBL E.coli(2/4) 
¾ Antibiotic used ¾ Linezolid(1/4) 
¾ Piperacillin Tazobactam (1/4) 
¾ Ertapenem(1/4) 
¾ Colistin/rifampicin(1/4) 
¾ Outcome ¾ Death (1/4) 
¾ Recovered (3/4) 




Only one of the patients had diabetes mellitus while the other two had hypertension   and 
cerebrovascular accident. One of the patients had scrub typhus. 
As described in the literature patients were mostly asymptomatic, with new onset fever in two 
out of four patients. 
Culture done on  day 3 of catheterization showed significant  growth in 3 patients, Enterococci 
isolated in two patients and ESBL E Coli in one. The organism isolated during the episode of 
urinary tract infection , was the same as the colonizing organism that was grown on culture done 
on day 3. This shows that urinary tract was colonized by uropathogenic organism as early as day 
3 .  However, the time taken to manifest the first systemic symptom was an average of 8.2 days. 
All four patients were treated with appropriate antibiotics. 
Mean duration of total hospital stay was 17 days, and  mortality was 25%. 
Though the numbers were small, the risk of mortality was 25% in patients with Catheter 
associated Urinary tract infection which is significant and is preventable by avoiding 
























This cohort study showed that community acquired urinary tract infection occurs in increased 
frequency among those who are older than 49 years. At age over and above 49 years, the 
incidence of UTI is almost as frequent among males as in females. Diabetes and post-
menopausal state are the most frequent associated comorbidity among the patients with UTI. 
A vast majority of the community acquired UTI are caused by Escherichia coli. In our hospital 
the prevalence of extended spectrum beta lactamase producers rate are quite high, hence the 
initial therapy of choice is beta-lactam/beta-lactamase inhibitor combination (e.g. Pipercillin-
tazobactam) or carbapenem (especially in patients who are critically ill at presentation).  
Cohort B: 
The incidence of catheter associated UTI was 4.7% (comparable to the international data) . 
The colonization of the urinary tract with uropathogenic organism can occur as early as 3 days 
following the catheterization and the common ,organisms isolated was E Coli.. Though the 
numbers were small. the morality risk was 25%.  
Hence it is prudent to avoid unnecessary catheterizations and when ever possible to remove the 
catheter to prevent development of catheter associated UTI. 








1. The sample size of this cohort does not give adequate power to derive the risk factors for 
UTI or recurrent UTI and mortality rate. 
2. Inadequate follow up of the patients after discharge makes the correct diagnosis of 
recurrent UTI difficult. 
3.  Significant number of Deaths and Lost to follow up in Cohort B, would have affected the 
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SNo HospitalNumbName NAge GenderMaritalStatuNoccupat Place gnosisPrimverWithCh Dysuria RenalAneucocytosrinecultu organism  umberofCFoodcultuOrganism SecondarDm htn Como
1 441049d RAJAM 59 2 2 1 1 1 1 1 1 1 2 No growth 1 ESBL E.COL 1 1 1 1
2 460164D SHAMEEN BASHA 55 1 2 4 1 1 1 1 1 2 2 No growth 2 No growth 1 1 1 1
57 901116D Jothilingam 58 1 2 4 1 2 1 1 1 1 2 No growth 1 ESBL E.COL 1 1 2 2
4 460127D MALLIGA 44 2 2 1 1 1 1 2 2 1 2 No growth 2 No growth 1 1 1 1
5 326014D JAYAPALAN 62 1 2 4 1 2 1 1 1 1 1 ESBL E.CO 2 1 ESBL E.COL 1 1 2 2
6 452371D PAMRVATHI DEVI 49 2 2 1 4 2 1 1 1 1 1 ESBL E.CO 2 1 ESBL E.COL 1 1 1 1
13 633592D KALA DEVI 55 2 2 1 1 2 1 1 2 1 2 No growth 1 ESBL E.COL 1 1 2 2
14 225887C RAJATHI 64 2 2 1 1 1 1 2 2 2 1 KLEBSIELLA 2 2 No growth 1 1 1 2
15 528706D LIANSWAMI 63 1 1 4 4 2 1 1 1 1 1 E Coli 2 No growth 1 1 1 1
16 211511B REV.THOMAS 75 1 1 2 1 1 1 1 1 1 1 PSEUDOM 1 2 No growth 1 2 1 1
17 625148D VALLIYAMMAL 69 2 2 1 1 1 1 1 2 1 2 No growth 2 No growth 1 1 2 1
18 651454d KARUNANIDHI 40 1 2 2 1 1 1 1 2 1 2 No growth 2 No growth 2 2 2 1
7 470303D PARUL MAJI 46 2 2 1 3 1 2 2 2 2 1 ESBL E.CO 1 2 No growth 2 2 2 1
8 173601D BALA CHANDRAN 62 1 2 4 1 2 1 1 2 1 2 No growth 2 No growth 1 1 2 1
9 089935C THAVAMANI 63 2 2 1 1 3 1 1 2 1 1 ESBL E.CO 1 1 ESBL E.COL 1 1 1 1
10 419862D CHENGALRAYALU 54 1 2 2 2 1 1 1 1 1 1 ESBL E.CO 1 1 ESBL E.COL 1 1 2 1
12 538047A PRABASKAR 37 1 2 4 1 2 1 1 1 1 2 No growth 2 No growth 1 1 2 1
119 872801B JAYALAKSHMI 60 2 2 1 2 3 1 2 2 1 1 E Coli 2 1 E Coli 1 1 2 1
120 423329D INIYAVAN JOSEPH 28 1 2 3 1 1 1 2 1 1 1 E Coli 2 2 No growth 2 2 2 1
121 365675D MOHAN 56 1 2 2 1 3 1 1 1 1 1 E Coli 2 2 No growth 1 1 2 2
122 497242C VENKATARATHINAM 81 1 2 3 2 1 1 2 2 2 1 ESBL E.CO 2 2 No growth 1 1 1 1
123 534965B MESHAK 64 1 2 4 2 2 1 1 1 1 1 ESBL E.CO 2 1 ESBL E.COL 1 1 2 1
124 564957C TULASI 52 2 2 1 1 1 1 1 1 1 1 ESBL E.CO 2 2 No growth 2 2 2 1
125 587326B JAYANTHI 35 2 2 1 1 1 2 2 2 1 1 ESBL E.CO 1 2 No growth 1 2 1 1
126 630017D GOWRI 51 2 2 1 1 3 1 1 2 1 No growth E Coli 1 1 2 2
127 686562D EMILYA RANI 61 2 2 1 2 1 2 2 2 1 2 No growth 2 No growth 2 2 2 1
128 793694c SHAKUNTALA AGGA 63 2 2 1 4 1 2 1 2 2 1 ESBL E.CO 1 2 No growth 1 1 1 1
129 843055B JESSIE BAI 61 2 2 1 1 2 1 2 1 1 1 ESBL E.CO 1 1 ESBL E.COL 1 1 1 1
130 882437D MAGALINGAM 67 1 2 4 1 2 1 1 1 1 1 ESBL E.CO 1 2 No growth 1 1 1 1
131 003252F RAMYA RAJAN 19 2 1 3 4 2 1 1 1 1 1 E Coli 1 2 No growth 2 2 2 2
132 036022 JESSIE 62 2 2 1 1 2 1 2 2 1 1 ESBL E.CO 1 2 No growth 2 2 2 1
133 159577F SHAIK JHULEKHA 63 2 2 1 2 2 1 1 1 1 1 Candida 1 2 No growth 1 1 1 1
134 168297F KUPPUSWAMY 80 1 2 3 1 1 1 2 1 1 1 E Coli 1 2 No growth 1 1 2 1
19 182267A PADMAVATHY 65 2 2 1 1 1 2 1 1 1 1 E Coli 2 2 No growth 1 1 1 1
20 564879A SAMUEL S 82 1 2 3 1 3 1 1 2 1 2 No growth 1 E Coli 1 1 1 2
21 494054D SAROJA 55 2 2 1 1 1 1 1 2 1 1 MIXTURE OF ORGAN 2 No growth 1 2 1 1
22 882437D MAGALINGAM 66 1 2 4 1 2 1 1 1 1 1 ESBL E.CO 1 1 ESBL E.COL 1 1 2 1
23 895709D PEDDDAREDDAPPA 55 1 2 4 2 2 1 1 2 2 2 No growth 2 No growth 1 1 2 2
24 885913D ASTO MONDAL 42 2 2 1 3 2 1 1 2 1 1 ESBL E.CO 1 2 No growth 1 1 2 2
25 875062D MOORTHY R M 61 1 2 2 1 1 2 2 2 1 1 PSEUDOM 1 2 No growth 2 2 2 2
26 911567D MARY STELLA 53 2 2 1 1 2 1 2 1 1 1 ESBL E.CO 2 2 No growth 1 1 2 1
27 355612b KANNAN 59 1 2 4 1 2 1 1 1 1 1 ESBL E.CO 2 2 No growth 1 1 1 2
28 613347D CHANDRAMMAL 75 2 2 1 1 3 1 2 2 1 1 E Coli 2 1 E Coli 1 1 1 1
29 166024D CHANDRAVANI 66 2 2 1 1 3 1 1 2 1 2 No growth 1 ESBL E.COL 1 1 2 1
30 549399D MAHESWARI 60 2 2 1 1 2 1 2 2 1 2 No growth 2 No growth 1 1 1 1
31 885042D KALI KUMAR SARKA 54 1 2 2 4 1 1 1 1 1 1 ESBL E.CO 1 1 ESBL E.COL 1 1 2 1
32 839935C KROSPARI 39 2 2 1 4 3 1 1 2 1 1 E Coli 1 1 E Coli 1 1 1 1
33 484123D CHAKKUBAI 55 2 2 1 1 3 2 2 2 1 1 ESBL E.CO 1 1 ESBL E.COL 2 2 2 2
34 569715B DEVA 74 2 2 1 1 1 2 2 2 1 1 E Coli 1 2 No growth 2 2 2 1
35 185226F LATHA 38 2 2 1 1 2 2 2 2 1 1 E Coli 1 2 No growth 2 2 2 1
36 191303F YELLAMMAL 48 2 2 1 1 1 1 1 1 1 2 No growth 2 No growth 2 2 2 1
37 569880D MERCY 28 2 2 1 1 2 1 1 1 2 2 No growth 2 No growth 2 2 2 1
38 179245F GRACE AMMAL 73 2 2 1 1 2 1 1 1 1 2 No growth 2 No growth 2 2 2 1
39 049653F FATIMA BI 78 2 2 1 1 1 2 1 1 1 1 ENTEROCO 2 2 No growth 1 1 2 1
40 048765f SANJEEVI 42 1 2 2 1 1 1 1 2 1 1 ESBL E.CO 1 2 No growth 1 1 2 2
41 151993F VIJAYAN 74 1 2 2 1 2 1 1 2 1 1 ESBL E.CO 1 2 No growth 2 2 2 1
42 025567D NARESH 27 1 1 2 1 2 1 1 1 1 1 ESBL E.CO 2 2 No growth 2 2 2 2
43 098548F ARUMUGAM 62 1 2 4 1 2 1 2 2 1 1 E Coli 1 1 ESBL E.COL 1 1 1 1
44 098515F BALAKRISHNAN 77 1 2 3 1 1 1 1 2 1 1 ESBL E.CO 1 2 No growth 1 1 1 1
45 093269F ALOKA JANA 47 2 2 1 3 1 1 1 2 1 1 ESBL E.CO 1 2 No growth 2 2 2 1
46 554347D MANI 55 1 2 4 1 2 1 1 2 1 1 E Coli 2 2 No growth 2 2 2 2
47 572148D ANIL 40 1 2 4 1 3 1 1 1 1 1 E Coli 1 1 E Coli 1 1 2 2
48 271349D ATHISAYARAJ 31 1 1 3 1 1 1 1 2 1 2 No growth 2 No growth 2 2 2 2
49 513743D SRINIVASAN 40 1 2 2 1 2 1 1 2 1 1 ESBL E.CO 1 2 No growth 1 1 1 1
50 670630B GOVINDAN 68 1 2 4 1 1 1 1 2 1 1 ENTEROCO 1 2 No growth 1 1 2 1
51 183175b ROSELINE VIOLET RA 45 2 2 2 1 1 1 1 1 1 1 ESBL E.CO 2 1 ESBL E.COL 1 1 2 1
52 770913B ANDAL 61 2 2 1 1 3 1 1 1 1 1 Candida 1 2 No growth 1 2 1 1
53 382845C SUNDARESAN 73 1 2 3 1 2 1 2 2 1 2 No growth 2 No growth 1 2 1 1
54 606805D SHANMUGAM 81 1 2 3 1 1 2 2 2 1 1 Pseudomo 1 2 No growth 1 1 2 1
55 507074A VIJAYALAKSHMI 54 2 2 1 2 3 1 1 1 1 1 ESBL E.CO 2 1 ESBL E.COL 1 1 1 2
56 481013D SHYAMKUMAR PRA 57 1 2 2 4 2 2 1 2 1 1 ESBL E.CO 1 2 No growth 1 1 2 2
57 481756D SHALINI BENGANI 28 1 1 2 4 2 2 1 1 1 2 No growth 2 No growth 2 2 2 1
58 484195d SUBRAMANI 55 1 2 4 1 1 2 2 1 1 1 E Coli 2 2 No growth 1 1 1 1
59 882254D PADMINI 45 2 2 1 1 1 1 2 2 1 1 GNB 1 2 No growth 2 2 2 1
60 616393D SUNITHA 33 2 2 1 2 1 1 2 2 1 1 ESBL E.CO 2 2 No growth 2 2 2 2
61 989641C GIRIJA 38 2 2 2 1 2 2 1 1 1 2 No growth 2 No growth 1 1 1 2
62 651314D NARAYANA 46 1 2 4 2 2 1 1 1 2 2 No growth 2 No growth 1 1 2 1
63 664114D SAROJA 63 2 2 1 1 3 1 2 1 1 1 ESBL E.CO 1 2 No growth 1 1 1 1
64 673061B MUNISWAMY 70 1 2 3 1 1 1 2 1 1 2 No growth 2 No growth 1 1 1 1
65 385383d VEERASWAMY 68 1 2 1 1 1 1 1 2 2 1 Candida 2 2 No growth 1 1 1 1
66 615888B PADMANABHAN 66 1 2 3 1 2 1 1 1 1 1 ESBL E.CO 1 1 ESBL E.COL 1 2 1 1
67 975022A MINOTI HAZRA 62 2 2 1 3 3 1 1 2 1 1 ESBL E.CO 2 1 ESBL E.COL 1 2 1 1
68 505597D KUPPAMMAL 70 2 2 1 1 1 1 1 2 1 1 KLEBSIELLA 1 2 No growth 1 1 1 1
69 504052D SUDHAKAR 51 1 2 2 1 2 2 2 1 1 1 E Coli 2 2 No growth 2 2 2 1
70 475664D ASIYA 65 2 2 1 1 1 1 2 2 2 1 KLEBSIELLA 1 2 No growth 2 2 2 1
71 685344C DEVI 25 2 2 1 1 2 1 1 1 1 1 ENTEROCO 2 2 No growth 1 1 2 1
72 500517D SAROJAMMA 72 2 2 1 1 1 2 2 2 2 1 E Coli 1 2 No growth 1 1 1 1
73 427083D GOVINDARAJ 78 1 2 3 1 3 1 2 2 1 1 Candida 1 1 KLEBSIELLA 1 1 1 1
74 504091D RADHA 45 2 2 1 1 3 1 2 2 1 1 ESBL E.CO 1 2 No growth 2 2 2 2
75 102179F SHEKAR 49 1 1 2 1 2 1 1 1 1 1 ESBL E.CO 2 2 No growth 2 2 2 2
76 107034F SHANMUGAM 62 1 1 3 1 2 1 2 1 1 1 Candida 1 1 ESBL E.COL 1 1 2 1
77 107048F ADHAR ADHIKARY 35 1 1 4 3 1 1 2 1 2 1 ENTEROCO 2 1 ESBL E.COL 2 2 2 1
78 107465F LALITHA 21 2 2 1 2 1 1 2 2 1 1 E Coli 1 2 No growth 2 2 2 1
79 110033F SARASWATI 56 2 2 1 1 1 1 2 2 1 1 E Coli 1 2 No growth 1 1 2 1
80 110147F VIJAY 19 1 1 3 1 1 1 2 2 1 1 ESBL E.CO 1 2 No growth 2 2 2 2
81 117315F IBRAHIM 26 1 1 4 1 2 1 1 1 1 1 ESBL E.CO 1 1 ESBL E.COL 2 2 2 2
82 119206F SUDHA 26 2 2 1 1 2 1 1 1 1 1 ESBL E.CO 1 1 ESBL E.COL 2 2 2 2
83 589899C SULOCHANA` 69 2 2 1 1 3 1 1 2 1 2 No growth 2 No growth 1 1 2 1
84 951222C NAGAMMAL 69 2 2 1 1 1 1 2 2 1 1 E Coli 2 2 No growth 1 1 1 1
85 562286D EK BAHADUR GURU 50 1 2 4 4 2 1 1 1 1 1 ESBL E.CO 1 2 No growth 2 2 2 1
86 429068d MEENAKSHI SUNDA 63 1 2 3 1 3 1 1 2 1 1 ENTEROCO 2 1 ESBL E.COL 1 1 2 1
87 577141D RAMAKRISHNAN 75 1 2 3 1 1 1 1 2 1 2 No growth 2 No growth 1 1 1 1
88 540153D KISHORE SINHA 35 1 2 4 3 1 1 1 2 1 1 Pseudomo 1 2 No growth 1 1 2 1
89 106586D SAROJA 62 2 2 1 1 1 2 1 2 1 2 No growth 2 No growth 1 1 1 1
90 229547D PRABHU 23 1 1 4 1 1 1 1 2 1 2 No growth 2 No growth 2 2 2 1
91 233114D SURYA BEGUM 50 2 2 1 1 2 1 1 2 1 2 No growth 2 No growth 1 1 2 1
92 106287D VIMALA 51 2 2 1 1 3 1 1 2 1 1 E Coli 1 1 E Coli 2 2 2 1
93 567200D VARADHAN 70 1 2 4 1 1 1 2 2 1 1 E Coli 2 2 No growth 1 2 1 1
94 450476D TUSLIMA BEGUM 60 2 2 1 1 3 1 2 2 1 1 Candida 1 1 STAPH AUR 1 1 1 1
95 361267B BASHA 60 1 2 4 1 1 1 2 2 2 1 ENTEROCO 1 2 No growth 1 2 1 1
96 147891f KUMUDAM 51 2 2 1 1 2 1 1 1 1 1 E Coli 2 1 E Coli 1 1 2 1
97 140383F SAMPATH 59 1 2 2 2 2 1 1 2 1 1 ESBL E.Col 1 1 ESBL E.COL 1 1 2 2
98 133474F ALAMELU 44 2 2 1 1 2 1 1 1 1 1 ESBL E.Col 2 2 No growth 2 2 2 1
99 126466F PADMASINI 47 2 2 1 1 1 1 1 2 1 2 No growth 2 No growth 1 1 2 2
100 152084F LAKSHMI NARAYAN 75 1 2 3 2 3 1 1 2 1 2 No growth 1 ESBL E.COL 1 1 2 2
101 152086F RAJAMOHAN 20 1 1 3 1 3 1 2 2 1 2 No growth 1 E Coli 2 2 2 2
102 282500B MUZIBUR RAHMAN 29 1 1 3 3 2 1 2 1 1 2 No growth 2 No growth 2 2 2 1
103 363366D MAHALAKSHMI 31 2 2 1 1 3 2 2 2 1 2 No growth 1 ESBL E.COL 2 2 2 1
104 520662D CHINNAPIE 50 2 2 1 1 1 1 2 2 1 1 ESBL E.Col 1 2 No growth 2 2 2 1
105 094569f MOULA 27 1 2 4 2 2 1 1 2 1 2 No growth 1 ESBL E.COL 2 2 2 2
106 115744F PERAMMA 64 2 2 1 2 1 1 2 2 2 1 Candida 1 2 No growth 1 1 1 1
107 590443D KIRUBANANDAM 55 1 2 2 1 2 1 1 2 1 1 ESBL E.Col 1 2 No growth 2 2 2 2
108 953581C MANIKAMMA 53 2 2 1 1 1 2 2 1 1 1 ESBL E.Col 1 2 No growth 2 2 2 2
109 985754C GNANAMANI 40 2 2 1 1 2 1 2 1 1 1 E Coli 1 1 E Coli 2 2 2 1
110 999428c RAVI 46 1 2 2 1 2 1 2 1 1 1 E Coli 2 1 ESBL E.Coli 1 1 2 2
111 MANI 995098C 55 1 2 4 2 2 1 1 2 1 1 E Coli 1 2 No growth 1 1 2 1
112 035535C NIRMALA 33 2 2 1 1 2 1 1 1 2 1 E Coli 1 2 No growth 1 1 2 1
113 407380D KRISHNAMURTHY 58 1 2 2 1 3 1 2 2 1 1 ESBL E.Col 2 1 ESBL E.Coli 1 1 1 2
114 423973D SHELLA MUTHU 62 1 2 4 1 2 1 1 2 1 1 ESBL E.Col 1 2 No growth 1 2 1 2
115 465699D DORASWAMY REDD 82 1 2 3 2 3 1 2 2 1 1 E Coli 2 1 E Coli 1 1 2 1
116 420554D BECHURAM MANNA 48 1 2 4 3 1 1 2 2 1 1 E Coli 1 2 No growth 1 1 2 1
117 469119C SHAKUNTALA SINHA 58 2 2 1 4 3 1 2 2 1 1 ESBL E.Col 1 1 ESBL E.Coli 1 1 2 1
118 444055D MEHARAJ 33 2 2 1 1 1 1 1 2 2 1 ENTEROCO 1 2 No growth 2 2 2 1
135 169405F SANTHOSH KUMAR 47 1 2 4 4 1 1 2 2 2 1 ESBL E.Col 1 2 No growth 1 1 1 1
136 170094F MUNIAMMAL 47 2 2 1 1 2 1 1 1 1 1 ESBL E.Col 2 1 ESBL E.Coli 1 1 2 1
137 170100F THANGAMANI 75 2 2 1 1 2 1 1 1 1 2 No growth 1 ESBL E.Coli 2 2 2 1
138 171904d ANAND KUMAR 40 1 2 4 1 1 1 1 2 1 1 ESBL E.Col 1 2 No growth 2 2 2 1
139 174323F AMMAKANNU 77 2 2 1 1 2 1 2 1 1 1 E Coli 1 1 E Coli 1 1 2 1
140 180230F RAMANUJAN 61 1 2 3 1 1 1 2 2 2 1 E Coli 1 2 No growth 1 2 1 1
141 180693F SELVAA VINAYAGA 18 1 1 3 1 2 1 1 1 1 1 E Coli 1 1 ESBL E.Coli 2 2 2 2
142 173213C RADHA BHAI 69 2 2 1 1 2 1 2 2 1 1 E Coli 1 1 ESBL E.Coli 1 1 2 1
143 170078F PARIMALA 39 2 2 1 1 2 1 1 1 1 2 No growth 1 E Coli 2 2 2 2
144 194056F BHASKAR 40 1 2 3 1 2 1 1 1 2 1 E Coli 1 2 No growth 1 1 2 1
145 194417F ERUSAMMAL 87 2 3 3 1 2 1 2 1 2 1 Klebsiella 2 1 KLEBSIELLA 1 1 1 1
146 194613F JYOTHI 40 2 2 1 1 2 1 2 1 1 1 Klebsiella 2 2 No growth 1 1 2 1
147 199733F PONNUSAMY 85 1 2 3 1 3 1 2 1 1 2 No growth 2 No growth 2 2 2 1
148 888913c HENA BEGUM 57 2 2 4 3 2 2 2 2 2 1 ESBL E.Col 1 2 No growth 1 1 1 1
149 449022D PADMAVATHI 46 2 2 1 1 1 1 1 2 1 1 ESBL E.Col 1 2 No growth 1 1 2 1
150 451312D SWAPNA LAHA 50 2 2 1 3 1 1 2 2 2 1 E Coli 1 1 E Coli 2 2 2 1
151 452590D VISALAKSHI 55 2 2 1 1 2 2 2 2 2 1 ESBL E.Col 1 1 ESBL E.Coli 1 1 2 1
152 461665D ANNAPURNAM 73 2 2 1 2 1 2 2 1 1 1 Klebsiella 1 2 No growth 1 2 1 1
153 211898F ELUMALAI 67 1 2 3 1 1 1 2 1 1 2 No growth 2 No growth 1 1 2 1
154 215139D KRISHNAMURTHY 86 1 2 3 1 3 1 1 2 1 1 E Coli 1 1 E Coli 2 2 2 1
155 222394F KASTHURI 45 2 2 1 2 2 1 1 2 1 2 No growth 2 No growth 1 1 1 1
156 533643A MOHAN RAJ 61 1 2 3 1 2 2 1 2 1 1 ESBL E.Col 1 1 ESBL E.Coli 1 1 1 1
157 231824f YASODHA 53 2 2 1 1 2 1 1 2 1 1 Candida 2 1 ESBL E.Coli 1 1 1 1
158 234808F PALANI 61 1 2 4 1 1 1 2 2 1 1 ESBL E.Col 1 2 No growth 2 2 2 2
159 235831F KALIDAS ROY 72 1 2 3 4 1 1 1 2 1 1 ESBL E.Col 1 2 No growth 2 2 2 1
160 240558F VENKATASWAMY 86 1 2 3 2 3 2 2 2 1 1 E Coli 1 2 No growth 1 1 2 1
161 240746F MANIKAM 70 1 2 3 1 2 1 1 2 1 2 No growth 1 ESBL E.Coli 1 1 1 1
162 240997F KARUNAKARAN 40 1 2 2 1 1 1 2 1 1 1 Klebsiella 1 2 No growth 2 2 2 2
163 252477F RAMANUJAM 70 2 2 1 1 2 1 2 1 1 2 No growth 1 ESBL E.Coli 1 1 1 1
164 252920F MARIAMMA 48 2 2 1 1 1 1 2 2 1 1 ESBL E.Col 1 1 ESBL E.Coli 1 1 2 1
165 257969F SARASWATHI 43 2 2 1 1 1 1 1 1 2 1 ESBL E.Col 1 2 No growth 1 1 2 1
166 526296D FATIMA 62 2 2 1 1 1 1 1 1 1 1 ESBL E.Col 1 2 No growth 1 1 1 1
167 557491C MUJIR 54 1 2 2 1 2 1 2 1 1 1 ESBL E.Col 1 2 No growth 1 1 1 1
168 787707B RAJAMMAL 65 2 2 1 1 1 1 2 1 1 2 No growth 2 No growth 1 1 2 1
169 963424A SAROJAMMA 75 2 2 1 1 2 1 1 1 1 2 No growth 1 E Coli 1 1 1 1
170 034480C ADILAKSHMI 72 2 2 1 1 2 1 2 2 2 2 No growth 2 No growth 1 1 2 1
171 079791B KALAVATHI 57 2 2 1 1 2 2 2 2 2 1 E Coli 1 1 E Coli 1 1 2 1
172 130884F RAJENDRA PRASAD 60 1 2 3 3 2 1 2 1 1 1 Klebsiella 2 2 No growth 2 2 2 1
173 218613C UMA MAHESHWAR 50 2 2 1 2 1 1 1 1 1 1 ESBL E.Col 1 2 No growth 1 1 1 1
174 246787F SAJIDA 20 2 2 1 2 1 1 1 1 1 1 ESBL E.Col 1 1 ESBL E.Coli 2 2 2 1
175 269207F THASIL NAIDU 88 1 2 3 1 3 1 2 1 1 2 No growth 2 No growth 2 2 2 2
176 591237D KOTHAMMAL 53 2 2 1 1 1 1 1 1 1 2 No growth 2 No growth 2 2 2 1
177 082402F NASIM BIBI 33 2 2 1 3 2 1 1 1 1 2 No growth 2 No growth 2 2 2 1
178 130231F PREMA DEBI 49 2 2 1 4 1 2 1 1 2 1 ESBL E.Col 1 2 No growth 1 1 2 1
179 169615F SALAMAN 57 1 2 4 2 1 1 1 1 1 1 E Coli 1 2 No growth 1 1 2 1
180 221820D ANWAR 66 1 2 3 1 2 1 1 1 1 1 ESBL E.Col 2 2 No growth 1 1 1 1
181 222304F CHANDRA BABU 45 1 2 4 1 1 1 1 1 2 1 E Coli 1 2 No growth 2 2 2 1
182 222643F SUNDARAMURTHY 60 1 2 2 1 1 1 1 2 1 1 E Coli 1 2 No growth 1 1 1 1
183 222888F NAGARATNAM 63 2 2 1 4 1 1 2 1 1 2 No growth 2 No growth 2 2 2 1
184 22905F PAPAMMA 71 2 2 1 2 1 1 1 2 2 1 E Coli 2 1 ESBL E.Coli 1 1 1 1
185 227982F BALAKRISHNA NAID 50 1 2 2 2 1 1 1 2 1 1 ESBL E.Col 1 2 No growth 1 1 1 2
186 231494F CHAYA BHATTACHA 50 2 2 1 3 3 1 1 2 1 1 ESBL E.Col 1 1 ESBL E.Coli 1 1 2 1
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4 2 None 1 10 1 10 1 10 1 10 2
4 2 None 1 4 1 7 2 0 1 4 1 4
0 2 None 1 2 1 7 1 7 2 1 3
2 2 None 2 0 1 3 1 3 2 0 2 0
0 1 01‐09‐2008 CMC 1 1 Cephalo 14 2 1 1 1 1 1 1 1 1 2 0
2 2 None 1 3 1 3 1 3 1 3 1 3
0 2 None 2 1 3 1 3 2 2
0 2 None 2 0 2 0 2 0 2 0 2 0
4 2 None 1 5 1 5 1 5 1 5 2
1 2 None 1 2 1 2 2 0 2 0 1 2
2 1 01‐01‐2010 Elsewher 1 2 2 1 60 1 60 1 60 2 0 1 60
1 2 None 1 10 1 10 1 10 2 0 2 0
2 2 None 2 1 450 2 0 2 0 2 0
3 1 01‐06‐2008 CMC 1 2 2 1 1 5 1 5 1 5 2 0 1 5
3 2 None 1 2 1 2 1 2 2 0 1 2
2 2 None 1 5 1 5 1 5 1 5 2 0
1 1 01‐01‐2010 CMC 1 2 1 1 1 1 2 1 3 1 7 1 7 1 7 1 6
2 2 None 2 1 4 1 4 2 2
2 2 None 1 20 1 20 2 1 20 1 20
0 1 01‐12‐2008 Elsewher 2 2 2 1 1 5 1 3 1 3 1 5 2
3 1 31‐01‐2008 CMC 2 1 2 2 1 4 1 4 2 2
2 2 None 1 7 1 7 1 7 1 7 1 7
2 2 None 1 5 1 5 1 5 1 5 1 5
2 1 08‐02‐2012 CMC 2 1 2 2 2 2 2 2
0 1 01‐09‐2010 CMC 1 1 AUGME 5 ORZID 4 1 1 1 1 1 1 4 1 4 1 4 2 2
2 1 01‐01‐1991 Elsewher 1 2 2 1 2 2 2 2 1 5
2 2 None 1 7 2 2 2 2
2 1 05‐08‐2010 CMC 1 1 CP/Clox 7 2 1 4 1 4 1 4 1 4 2
3 1 06‐06‐2011 CMC 1 1 MEROP 14 1 1 2 1 1 1 2 1 2 1 2 1 2 2
0 2 None 1 2 1 2 1 2 1 2 2
2 2 None 2 1 60 1 60 2 2
2 2 None 1 30 1 2 1 2 1 30 2
3 2 None 2 1 5 1 5 1 5 2
2 1 01‐01‐2006 CMC 1 2 1 2 2 2 2 1 7 1 7 2 0 2 0 2 0
0 2 None 2 0 1 2 1 2 2 0 2 0
2 2 None 2 0 1 7 1 7 2 0 2 0
4 2 None 2 0 1 3 1 3 1 3 1 90
0 1 Elsewher 1 1 PIPTAZ 2 DOXY 2 1 1 2 2 1 1 5 1 5 1 5 1 5 2 0
0 2 None 1 2 1 2 2 0 2 0 2 0
0 2 None 2 0 2 0 2 0 2 0 2 0
2 1 01‐01‐2010 Elsewher 1 2 1 1 2 2 1 2 0 1 60 1 60 1 60 2 0
0 2 None 1 20 1 20 1 20 1 20 1 20
2 2 None 1 2 1 2 1 2 2 0 2 0
2 1 01‐02‐2010 CMC 1 1 PIPTAZ 2 CEBANE 14 1 1 2 2 1 1 2 1 2 1 2 1 2
2 1 01‐02‐2010 CMC 1 1 CP/Clox 42 PIPTAZ 3 1 1 2 1 1 2 0 1 2 2 0 2 0 2 0
2 2 None 1 2 1 2 1 2 2 0 2 0
2 1 01‐03‐2008 CMC 2 1 2 2 0 1 10 1 10 2 0
0 2 None 2 2 2 2 2
2 1 24‐04‐2012 CMC 2 1 2 2 2 2 2 2
2 1 14‐04‐2012 Elsewher 1 1 Cephalo 7 2 1 2 1 2 2 2 2
2 2 None 1 5 1 5 1 5 1 5 2 0
2 1 02‐03‐2012 Elsewher 1 1 AMIKAC 7 CEFTRIA 7 LEVO 10 1 1 1 1 1 1 8 1 8 2 2 2
2 2 None 1 3 1 3 1 3 1 3 2
2 1 02‐04‐2012 CMC 1 1 ERTAPE 7 1 1 2 1 1 1 15 1 15 2 2 2
0 1 01‐09‐2011 CMC 1 2 1 2 2 2 2 1 5 1 5 1 5 1 5 2
1 1 01‐01‐1998 Elsewher 1 2 1 1 1 1 1 1 7 1 7 1 7 2 0 2
0 2 None 1 7 1 14 1 14 1 7 2
4 2 None 2 1 3 1 3 2 1 180
1 1 11‐12‐2011 Elsewher 1 2 2 2 1 10 1 10 2 1 180
2 1 01‐12‐2010 Elsewher 2 2 2 2 1 90 1 90 2 2
0 2 None 1 5 1 5 1 5 1 5 2
0 2 None 1 10 1 10 1 10 1 8 2
0 2 None 1 5 1 5 1 5 2 2
2 1 01‐07‐2009 Elsewher 1 1 Cephalo 5 1 1 2 2 1 1 5 1 5 1 5 2 2
1 1 01‐10‐2009 Elsewher 2 2 2 2 1 2 1 2 2 2
3 2 None 1 5 1 5 1 5 1 5 2
2 1 01‐03‐2010 Elsewher 2 2 2 1 7 1 7 1 7 1 7 1 7
3 2 None 2 1 2 1 2 2 2
3 1 01‐02‐2010 CMC 2 1 2 2 2 2 2 2
0 2 None 2 1 5 1 5 1 5 2
0 2 None 1 2 1 1 2 2 1 60
2 1 01‐05‐2009 Elsewher 1 2 1 1 2 2 1 2 2 2 1 7 2
1 2 None 2 2 2 1 2 1 2
1 2 None 1 2 1 2 1 2 2 2
0 1 01‐01‐2010 Elsewher 1 1 Cephalo 3 LEON 50 3 ORNI 3 1 2 2 2 2 2 1 15 1 15 2 0 2
0 1 07‐03‐2007 CMC 2 1 2 1 15 1 15 2 1 15 1 15
3 1 01‐01‐2010 Elsewher 1 2 1 1 2 1 1 1 5 1 5 1 5 1 3 2
2 1 15‐02‐2010 Elsewher 1 2 2 2 1 10 1 10 2 2
1 1 01‐01‐2004 CMC 1 1 Cephalo 1 2 1 2 1 7 1 7 2 2
3 1 01‐01‐2009 Elsewher 1 2 1 1 2 1 1 1 3 1 3 1 3 2 0 2 0
2 2 None 1 3 1 3 1 3 1 3 1 3
3 1 18‐05‐2009 CMC 2 1 2 1 7 1 7 1 7 2 2
2 1 01‐06‐2009 Elsewher 1 2 1 1 2 0 1 14 1 14 2 0 2 0
2 2 None 2 0 1 2 2 0 1 2 2
3 2 None 2 2 2 2 2
1 2 None 2 1 5 1 5 1 5 1 5 2
3 2 None 2 2 2 2 2
4 1 20‐03‐2009 CMC 1 1 Fluoroq 120 AMIKAC 120 ATT 2 2 1 1 2 2 2
0 2 None 1 2 1 2 1 2 2 2
0 2 None 1 7 1 7 1 7 1 7 2
1 1 01‐12‐2011 Elsewher 1 2 1 1 1 1 1 2 1 4 1 4 1 4 2 0
3 1 01‐11‐2011 Elsewher 1 2 2 1 2 1 30 1 30 2 2
2 1 01‐12‐2011 Elsewher 1 2 2 1 2 1 5 2 2 2
4 1 09‐01‐2012 CMC 1 1 CP/Clox 3 AZITHRO 3 2 2 2 1 5 1 5 2 2
0 2 None 1 1 1 8 1 8 2 0 2 0
0 2 None 1 4 1 4 1 4 1 4 2
0 2 None 1 7 1 2 1 2 1 7 2
1 2 None 1 3 1 3 1 3 2 0 1 2
2 2 None 2 1 2 1 2 2 2
1 1 01‐07‐2009 Elsewher 1 2 1 1 1 1 1 1 3 1 3 1 3 1 2 1 2
2 1 01‐04‐2009 CMC 1 1 Fluoroq 7 CEPHAL 7 2 1 1 3 1 3 1 3 2 2
1 2 None 1 3 1 7 1 7 2 0 1 7
4 2 None 1 3 1 3 1 3 2 1 3
2 2 None 1 2 2 0 2 0 2 0 2
4 2 None 1 3 1 3 1 3 2 0 2
2 2 None 1 8 1 8 1 8 2 0 2
2 1 01‐04‐2009 CMC 2 2 2 2 0 1 2 1 2 2 2
1 2 None 2 1 1 1 1 2 1 180
2 2 None 2 1 14 2 2 1 60
1 1 01‐01‐2007 Elsewher 1 2 2 1 1 2 1 2 2 2 2
2 2 None 1 2 1 2 1 2 2 2
0 2 None 2 1 20 1 20 2 2
1 1 01‐01‐2012 Elsewher 1 2 1 1 2 2 1 1 20 1 20 1 20 1 20 2
0 1 15‐01‐2012 Elsewher 1 2 1 1 2 1 2 1 15 1 15 1 15 2 2
0 2 None 1 8 1 2 1 2 2 1 365
0 2 None 2 1 2 1 2 2 2
1 2 None 2 1 2 1 2 1 2 2
2 1 25‐01‐2012 CMC 1 1 MAGNE 7 METROG 7 FLUC 7 1 2 2 1 2 2 2 2 2 2
2 2 None 2 1 60 1 60 2 2
0 2 None 1 7 1 7 1 7 1 5 2
1 1 08‐01‐2012 Elsewher 2 2 2 1 30 2 2 1 30
0 1 15‐10‐2009 Elsewher 2 2 2 2 1 15 2 2 1 15
0 1 01‐02‐2007 CMC 1 1 MAGNE 14 1 1 2 1 1 2 2 2 1 8 2
3 2 None 2 1 3 1 3 1 2 2
0 2 None 2 1 7 2 1 35 2
1 1 Elsewher 1 2 1 1 1 1 1 1 10 1 10 1 10 2 1 180
2 2 None 1 20 1 20 2 1 4 1 30
0 2 None 2 1 3 1 3 2 2
0 1 01‐02‐2009 Elsewher 1 1 Fluoroq 7 MAGNE 7 IMIP 2 1 1 2 1 1 1 30 1 30 1 30
3 2 None 1 4 1 4 1 4 2 1 20
1 2 None 2 1 10 2 2 1 20
2 1 12‐02‐2009 Elsewher 1 2 2 2 1 210 1 210 2 2
2 1 15‐04‐2009 CMC 2 1 2 2 2 1 1 1 1 2 2
2 2 None 2 1 45 1 45 2 2
1 1 Elsewher 1 2 2 1 1 5 1 5 1 5 1 5 2
2 2 None 1 4 1 1 1 1 1 4 2
2 2 None 1 4 1 4 1 4 2 2
2 2 None 2 1 4 1 4 1 4 1 4
3 2 None 2 1 4 1 4 2 2
0 2 None 1 5 1 5 1 5 1 5 2
2 1 18‐11‐2011 CMC 2 2 2 1 2 1 3 1 3 2 2
0 2 None 1 10 1 10 1 10 1 10 2
1 1 01‐05‐2008 Elsewher 1 2 2 2 1 10 1 10 1 10 2
2 2 None 2 1 7 1 7 1 7 2
2 1 05‐05‐2012 CHAD 1 1 AMIKAC 7 1 1 2 2 1 2 1 7 1 7 2 2
4 2 None 2 1 4 2 2 2
3 1 23‐04‐2009 CMC 2 1 ATT 2 1 2 2 2 2 1 3
2 1 01‐10‐2008 Elsewher 1 2 2 2 1 2 1 2 2 2
3 2 None 2 1 180 1 180 1 180 2
2 1 01‐04‐2009 Elsewher 1 2 2 2 2 2 2 1 14
2 1 19‐05‐2009 CMC 2 1 2 1 2 2 2 2 1 3
1 2 None 1 5 1 5 1 5 2 2
1 1 Elsewher 1 2 1 1 1 1 1 1 3 1 3 1 3 2 0 1 180
2 1 Elsewher 1 1 AZITHR 3 IMIPENE 5 1 1 2 2 1 1 7 1 14 1 14 2 2
3 1 21‐09‐2010 CMC 2 1 2 1 1 2 1 2 1 2 2 2
2 2 None 2 1 5 1 5 1 5 2
0 2 None 2 1 15 1 15 2 1 15
3 1 01‐05‐2012 Elsewher 2 2 2 2 1 3 1 3 1 3 2
1 1 01‐05‐2012 Elsewher 1 2 2 1 2 2 2 2 2
1 1 01‐06‐2012 Elsewher 1 2 2 1 2 1 14 1 14 2 1 180
0 2 None 2 1 2 1 2 1 2 2
2 2 None 2 1 2 1 2 1 2 2
2 2 None 2 1 4 1 4 2 2
2 2 None 1 4 1 7 1 7 1 7 2
2 1 02‐08‐2010 CMC 1 1 PIPTAZ 5 SEPMAX 60 1 1 2 1 1 1 2 1 2 1 2 1 2 2
3 2 None 1 8 1 8 1 8 1 8 2
2 2 None 2 1 3 1 3 1 3 2
1 2 None 1 3 1 3 1 3 1 3 2
2 1 26‐04‐2005 CMC 1 1 Fluoroq 14 1 1 2 1 1 2 1 2 1 2 1 2 1 2
2 2 None 2 2 2 1 3 1 2
1 1 14‐07‐2012 CMC 2 1 2 1 1 2 2 1 14 1 14 1 14 2
3 1 15‐12‐2011 CMC 2 1 2 1 1 1 1 1 1 1 1 1 2
2 2 None 2 1 20 1 20 1 20 2
0 2 None 2 1 3 1 3 1 3 2
2 1 29‐11‐2009 CMC 1 1 MAGNE 14 AMIKAC 14 1 1 1 1 1 1 15 1 7 1 7 1 4 2
1 1 01‐10‐2011 Elsewher 1 2 NITROF 270 1 1 2 1 1 1 2 1 2 1 2 1 2 2
2 1 27‐02‐2012 CMC 2 1 2 2 2 2 1 7 1 7
2 2 None 1 4 1 4 1 4 1 4 2
1 1 14‐04‐2011 CMC 2 1 2 1 1 7 1 7 1 7 1 7 1 7
1 2 None 1 9 1 4 1 4 1 9 2
1 2 None 1 2 1 2 1 2 1 2 1 2
2 1 01‐05‐2011 Elsewher 1 2 1 1 2 1 1 2 1 2 1 2 2 2
3 1 20‐05‐2012 Elsewher 2 2 2 1 2 1 7 1 7 2 2
0 2 None 1 10 1 15 1 15 2 2
2 2 None 1 2 1 2 1 2 2 2
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None 2 1 CIPROFLOX 1 500 130 80 2 104 20 1 LEFT 2 Not don 2 Not done
Change 4 2 2 60 0 1 104 44 1 Bilateral 2 Not don 2 Not done
Altered 1 2 2 90 70 1 116 34 1 RIGHT 2 Not don 2 Not done
Altered 3 2 2 120 70 2 114 28 2 No Tend 2 Not don 2 Not done
VOMIT 1 2 1 CIPROFLOX 1 500 110 70 2 112 22 1 RIGHT 2 Not don 2 Not done
VOMIT 1 2 2 110 60 2 90 22 1 RIGHT 2 Not don 2 Not done
VOMIT 1 2 2 100 70 1 112 26 1 RIGHT 2 Not don 2 Not done
VOMIT 1 2 2 110 70 2 80 24 2 No Tend 2 Not don 2 Not done
None 2 2 120 70 2 112 30 1 LEFT 2 Not don 2 Not done
Change 2 2 2 160 90 2 102 22 2 No Tend 2 Not don 2 Not done
None 2 2 140 90 2 110 24 2 No Tend 2 Not don 1 Normal
others 30 2 2 130 80 2 102 20 2 No Tend 2 Not don 2 Not done
None 2 2 120 80 2 76 16 2 No Tend 2 Not don 2 Not done
Altered 2 2 2 90 70 1 112 26 1 Bilateral 2 Not don 2 Not done
Altered 1 2 2 80 0 1 114 34 2 No Tend 2 Not don 2 Not done
None 2 2 94 70 1 101 22 1 RIGHT 2 Not don 2 Not done
None 1 3 1 2 1 2 1 CIPROFLOX 1 500 100 70 2 106 28 1 Bilateral 1 Normal 2 Not done
VOMIT 4 2 2 120 90 2 110 24 2 No Tend 2 Not don 1 Normal
None 2 1 NORFLOXACIN 120 80 2 100 20 2 No Tend 2 Not don 2 Not done
None 2 2 100 60 2 70 17 1 LEFT 2 Not don 2 Not done
Altered 1 2 2 130 80 2 100 24 2 No Tend 1 Normal 2 Not done
VOMIT 7 2 2 140 70 2 108 18 1 Bilateral 1 Normal 2 Not done
None 2 2 130 70 2 84 20 2 No Tend 2 Not don 1 Normal
None 2 2 124 80 2 88 24 2 No Tend 2 Not don 2 Not done
Altered 1 1 2 1 2 1 540 2 70 0 1 134 30 2 No Tend 2 Not don 2 Not done
Altered 5 2 2 140 90 2 80 24 2 No Tend 2 Not don 2 Not done
others 7 2 2 130 80 2 99 24 2 No Tend 2 Not don 2 Not done
None 2 2 130 80 2 90 24 1 LEFT 2 Not don 1 CYSTOCE
None 1 2 1 2 1 180 2 120 80 2 110 24 1 Bilateral 2 Not don 2 Not done
VOMIT 2 2 2 118 70 2 84 20 1 RIGHT 2 Not don 2 Not done
None 1 1 2 2 2 60 1 CIPROFLOX 30 500 NITROFU 7 100 120 80 2 92 24 2 No Tend 2 Not don 1 Normal
VOMIT 2 2 2 100 60 2 90 21 1 LEFT 2 Not don 2 Not done
Altered 5 2 2 90 0 1 112 30 1 Bilateral 1 Normal 2 Not done
VOMIT 5 1 2 2 2 2 1 1 CIPROFLOX 1 500 130 70 2 102 24 2 No Tend 2 Not don 1 Normal
Change 1 2 2 100 70 1 102 20 1 Bilateral 2 Not don 2 Not done
others 7 2 2 110 70 2 98 18 2 No Tend 2 Not don 2 Not done
VOMIT 3 2 2 100 70 1 94 40 1 LEFT 1 Enlarged 2 Not done
Altered 1 2 1 PIPTAZ 3 4500 DOXY 3 100 112 70 2 104 22 1 LEFT 2 Not don 2 Not done
None 0 2 2 130 70 2 104 22 1 Bilateral 2 Not don 2 Not done
Altered 1 2 2 110 70 1 100 22 2 No Tend 1 Normal 2 Not done
None 2 2 110 70 2 118 24 1 Bilateral 2 Not don 1 Normal
Change in urine 2 2 170 100 2 101 21 1 LEFT 2 Not don 2 Not done
Dyspno 1 2 2 140 70 2 60 30 2 No Tend 2 Not don 2 Not done
VOMIT 2 1 1 1 2 1 2 2 80 60 1 98 26 2 No Tend 2 Not don 2 Not done
Altered 1 1 1 1 2 2 2 2 150 100 2 128 28 2 No Tend 2 Not don 2 Not done
None 0 2 2 110 70 2 104 24 2 No Tend 2 Not done Not done
others 14 2 2 80 60 1 104 24 2 No Tend 2 Not don 2 Not done
Altered 1 2 2 80 50 1 62 30 2 No Tend 2 Not don 2 Not done
Altered 3 2 2 140 80 2 102 32 2 No Tend 2 Not don 2 Not done
None 2 1 CEFTRIAXON 7 100 120 60 2 102 16 2 No Tend 2 Not don 2 Not done
None 2 1 AMOXICLAV 1 625 120 80 2 99 24 1 Bilateral 2 Not don 2 Not done
None 1 1 1 1 1 2 1 CIPROFLOX I 3 200 METROG 3 500 120 80 2 96 24 2 No Tend 2 Not don 2 Not done
None 2 2 130 60 2 108 26 1 RIGHT 2 Not don 2 Not done
None 1 2 1 2 1 1 2 100 70 2 112 18 1 LEFT 2 Not don 1 Normal
None 1 1 2 2 2 1 1 NORFLOX 1 400 110 80 2 92 26 1 RIGHT 2 Not don 2 Not done
None 1 1 1 2 1 2 90 50 1 99 24 2 No Tend 2 Not don 2 Not done
None 1 1 2 2 2 2 1 CIPROFLOX 7 500 100 70 2 104 24 2 No Tend 2 Not don 2 Not done
Altered 1 2 1 140 70 2 112 34 2 No Tend 2 Not don 2 Not done
Altered 2 2 2 140 80 2 104 30 2 No Tend 1 Enlarged 2 Not done
None 2 2 130 70 2 120 16 2 No Tend 2 Not don 2 Not done
others 2 1 1 2 2 2 2 2 86 50 1 106 24 1 LEFT 2 Not don 2 Not done
others 2 2 2 130 80 2 130 42 1 Bilateral 2 Not don 2 Not done
others 5 2 2 100 70 2 102 20 2 No Tend 2 Not don 2 Not done
None 2 1 CEPHALOSPO 5 130 80 2 92 30 1 RIGHT 2 Not don 2 Not done
Dyspno 1 2 2 130 90 2 100 20 2 No Tend 2 Not don 2 Not done
Dyspno 2 2 2 100 70 2 116 38 2 No Tend 2 Not don 2 Not done
Altered 1 2 2 80 60 1 100 24 2 No Tend 2 Not don 2 Not done
Altered 1 2 2 100 60 2 123 45 2 No Tend 2 Not don 2 Not done
others 1 2 2 130 70 2 88 26 2 No Tend 2 Not don 2 Not done
Altered 1 2 2 130 80 2 102 21 1 LEFT 2 Not don 2 Not done
None 2 2 130 80 2 92 16 2 No Tend 2 Not don 2 Not done
None 2 2 120 80 2 92 24 1 RIGHT 2 Not don 2 Not done
None 2 2 120 80 2 94 24 2 No Tend 2 Not don 2 Not done
None 2 2 150 10 2 98 28 2 No Tend 2 Not don 2 Not done
others 15 2 2 100 70 2 98 22 2 No Tend 2 Not don 2 Not done
None 2 2 130 60 2 114 26 2 No Tend 2 Not don 2 Not done
None 1 3 1 2 1 7 1 CEPHALOSPO 4 1500 OFLOX 7 400 130 80 2 102 16 1 RIGHT 2 Not don 2 Not done
Altered 1 2 1 130 60 2 90 26 2 No Tend 2 Not don 2 Not done
others 1 2 2 80 0 1 124 32 2 No Tend 2 Not don 2 Not done
others 1 2 1 94 0 1 108 24 2 No Tend 2 Not don 2 Not done
Altered 1 1 2 70 0 1 102 20 1 Bilateral 2 Not don 2 Not done
None 2 2 130 80 2 98 20 2 No Tend 1 Not don 2 Not done
None 2 1 130 90 2 102 28 2 No Tend 2 Not don 2 Not done
VOMIT 1 2 2 130 90 2 104 26 1 RIGHT 2 Normal 2 Not done
Altered 1 2 2 140 90 2 98 28 2 No Tend 2 Not don 2 Not done
others 1 9 2 2 2 30 1 130 90 2 102 26 1 RIGHT 2 Not don 2 Not done
others 60 2 2 160 100 2 60 16 2 No Tend 2 Not don 2 Not done
Altered 1 2 2 110 70 2 104 22 2 No Tend 2 Not don 2 Not done
VOMIT 1 2 2 80 40 1 150 30 2 No Tend 2 Not don 2 Not done
others 7 2 2 110 80 2 110 23 1 Bilateral 1 LOADED 2 Not done
Altered 2 2 2 100 70 2 94 26 2 No Tend 2 Not don 2 Not done
None 2 2 100 70 2 116 28 2 No Tend 2 Not don 2 Not done
VOMIT 2 2 2 100 70 2 110 20 2 No Tend 2 Not don 2 Not done
Dyspno 2 2 2 130 70 2 100 24 2 No Tend 2 Not don 2 Not done
Altered 1 2 2 100 70 2 90 22 2 No Tend 2 Not don 2 Not done
None 2 2 110 70 2 104 20 1 Bilateral 2 Not don 2 Not done
None 2 1 CIPROFLOX 4 1000 110 70 2 100 22 1 Bilateral 2 Not don 2 Not done
VOMIT 2 2 2 50 0 1 106 32 2 No Tend 2 Not don 2 Not done
Altered 1 2 2 180 70 2 90 24 2 No Tend 2 Not don 2 Not done
None 1 4 1 2 1 90 2 110 80 2 86 22 1 Bilateral 1 Normal 2 Not done
others 3 2 2 110 70 2 132 40 2 No Tend 2 Not don 2 Not done
others 3 2 2 110 80 2 96 24 2 No Tend 1 Normal 2 Not done
Altered 2 2 2 120 70 2 102 24 2 No Tend 1 Normal 2 Not done
Altered 2 2 2 130 80 2 102 24 2 No Tend 2 Not don 2 Not done
others 1 2 2 110 70 2 86 16 2 No Tend 2 Not don 2 Not done
Altered 1 2 2 50 0 1 150 30 2 No Tend 2 Not don 2 Not done
others 1 2 2 170 90 2 104 30 2 No Tend 2 Not don 2 Not done
Altered 2 2 2 110 70 2 102 34 2 No Tend 2 Not don 2 Not done
Altered 1 2 2 90 60 1 104 32 2 No Tend 2 Not don 2 Not done
vomitin 5 2 2 200 100 2 108 26 2 No Tend 2 Not don 2 Not done
Dyspno 1 2 2 110 60 1 88 20 1 RIGHT 2 Not don 2 Not done
Altered 6 2 1 150 100 2 120 34 2 No Tend 2 Not don 2 Not done
Altered 2 2 1 120 80 2 99 24 2 No Tend 2 Not don 2 Not done
vomitin 2 2 1 130 80 2 92 18 2 No Tend 2 Not don 2 Not done
Dyspno 1 2 2 120 80 2 102 24 2 No Tend 1 Normal 2 Not done
vomitin 1 2 2 80 50 1 140 35 2 No Tend 2 Not don 2 Not done
vomitin 2 2 2 90 60 1 128 32 1 Bilateral 2 Not don 2 Not done
Dyspno 1 1 1 2 1 2 30 2 140 90 2 100 40 2 No Tend 2 Not don 1 Normal
vomitin 60 2 2 110 70 2 112 30 2 No Tend 2 Not don 1 Normal
None 2 1 100 50 1 102 25 1 Bilateral 2 Not don 2 Not done
Change 1 1 9 2 2 2 1 130 80 2 60 22 2 No Tend 2 Not don 2 Not done
None 2 2 100 80 2 110 24 2 No Tend 2 Not don 2 Not done
None 1 1 1 2 1 90 2 120 80 2 94 22 1 RIGHT 2 Not don 2 Not done
Altered 1 2 2 130 80 2 96 22 1 Bilateral 2 Not don 2 Not done
vomitin 7 2 2 130 70 2 120 30 1 Bilateral 1 Normal 2 Not done
None 1 9 1 2 1 1 160 90 2 120 30 2 No Tend 2 Not don 2 Not done
None 2 2 110 70 2 120 28 1 LEFT 2 Not don 2 Not done
Altered 1 2 2 140 60 2 88 31 2 No Tend 1 Normal 2 Not done
None 2 1 120 80 2 88 20 2 No Tend 1 Normal 2 Not done
Altered 1 2 2 70 0 1 100 28 2 No Tend 1 Not don 2 Not done
Altered 4 2 2 130 60 2 66 20 2 No Tend 1 Normal 2 Not done
Dyspno 1 2 2 130 80 2 102 22 2 No Tend 2 Not don 2 Not done
Altered 1 2 2 100 60 2 90 22 2 No Tend 2 Not don 2 Not done
others 45 2 1 150 80 2 80 25 2 No Tend 1 Normal 2 Not done
None 2 2 120 80 2 99 24 2 No Tend 2 Not don 2 Not done
None 2 2 110 60 2 124 24 1 Bilateral 2 Not don 1 Normal
others 4 2 2 120 80 2 99 24 2 No Tend 2 Not don 2 Not done
vomitin 1 2 2 100 80 2 78 24 2 No Tend 2 Not don 1 Normal
Altered 4 2 2 120 80 2 99 24 2 No Tend 1 Normal 2 Not done
Change 2 2 2 120 80 2 100 20 1 Bilateral 2 Not don 2 Not done
Change 3 2 2 100 70 2 110 24 2 No Tend 2 Not don 1 Normal
None 2 2 120 70 2 102 24 1 RIGHT 2 Not don 2 Not done
None 2 2 110 80 2 88 20 2 No Tend 2 Not don 2 Not done
Altered 1 2 2 140 70 2 11 28 1 Bilateral 2 Not don 2 Not done
vomitin 7 2 1 AMIKAICN 7 750 110 60 2 110 20 1 RIGHT 2 Not don 2 Not done
Altered 1 2 2 120 80 2 80 24 2 No Tend 2 Not don 2 Not done
Altered 1 2 2 90 50 1 90 26 2 No Tend 2 Not don 2 Not done
None 2 2 160 110 2 110 24 2 No Tend 2 Not don 2 Not done
others 180 2 2 130 70 2 72 20 2 No Tend 2 Not don 2 Not done
Altered 14 2 2 140 90 2 110 22 2 No Tend 2 Not don 2 Not done
vomitin 3 2 2 90 60 1 62 30 2 No Tend 2 Not don 2 Not done
None 2 2 150 100 2 90 20 2 No Tend 1 Enlarged 2 Not done
Dyspno 2 2 2 80 0 1 121 36 2 No Tend 1 Enlarged 2 Not done
None 2 1 160 80 2 100 20 2 No Tend 2 Not don 1 Normal
Dyspno 10 2 2 130 80 2 80 20 2 No Tend 2 Not don 2 Not done
Change 1 2 2 100 50 1 110 20 1 Bilateral 1 Normal 1 Normal
None 2 2 120 90 2 100 20 2 No Tend 1 Normal 2 Not done
others 1 2 2 90 0 1 111 30 2 No Tend 2 Not don 2 Not done
Altered 1 2 2 90 0 1 111 25 2 No Tend 2 Not don 2 Not done
Change 14 2 1 140 80 2 102 24 2 No Tend 1 Enlarged 2 Not done
None 2 2 90 0 1 113 20 2 No Tend 1 Normal 2 Not done
Change 2 2 2 130 90 2 92 18 1 Bilateral 2 Not don 1 Normal
Altered 1 2 2 130 80 2 112 20 2 No Tend 2 Not don 1 Normal
None 2 1 NORFLOX 5 400 110 80 2 100 20 1 Bilateral 2 Not don 1 Normal
others 2 1 3 1 2 1 730 2 100 70 2 86 18 2 No Tend 2 Not don 1 Normal
vomitin 2 2 2 120 70 2 92 24 2 No Tend 2 Not don 2 Not done
Altered 3 2 2 80 0 1 120 26 1 Bilateral 2 Not don 1 Normal
None 2 2 140 90 2 109 22 1 RIGHT 2 Not don 1 Normal
None 1 1 1 2 1 999 2 130 80 2 82 14 1 RIGHT 2 Not don 2 Not done
vomitin 1 2 2 110 70 2 120 22 1 LEFT 2 Not don 1 Normal
None 2 2 110 80 2 88 18 1 LEFT 1 Normal 2 Not done
vomitin 1 1 1 2 2 2 270 2 110 80 2 96 24 1 LEFT 2 Not don 2 Not done
vomitin 4 2 2 120 80 2 100 24 2 No Tend 2 Not don 2 Not done
vomitin 1 2 2 110 60 2 98 28 1 LEFT 2 Not don 2 Not done
None 1 2 1 2 1 450 2 110 70 2 99 20 1 RIGHT 2 Not don 1 Normal
Change 1 1 1 1 2 1 270 1 NITROFURAN 270 100 130 80 2 112 20 1 Bilateral 2 Not don 2 Not done
vomitin 1 2 2 110 70 2 88 19 1 Bilateral 2 Not don 1 Normal
None 2 2 110 80 2 88 24 1 RIGHT 2 Not don 2 Not done
Altered 2 2 2 110 80 2 108 24 2 No Tend 1 Normal 2 Not done
Change 9 2 2 110 80 2 90 20 2 No Tend 1 Normal 2 Not done
Change 1 2 2 140 80 2 92 20 2 No Tend 1 Enlarged 2 Not done
others 1 1 2 1 2 1 365 2 130 80 2 99 20 2 No Tend 1 Normal 1 Normal
Altered 5 2 2 110 70 2 102 20 2 No Tend 1 Normal 1 Normal
vomitin 1 2 2 140 90 2 18 16 2 No Tend 1 Normal 2 Not done
None 1 2 2 110 70 2 112 20 2 No Tend 2 Not don 2 Not done
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2 Not catheterised 12900 8 0 84 1 99.99 2.03 0 0 1 1
1 1 OLIGURIA 2 2 10000 4 0 90 1 99.99 1.02 2 2 6 1
2 Not catheterised 6400 7 2 88 1 15.2 8.1 1 1 2 1 2
1 1 ALTERED SENSO 2 2 9900 4 0 92 1 99.99 10.12 0 0 1 2
2 Not catheterised 13000 4 0 80 1 99.99 1.02 3 1 2 1 ESBL E.COLI 13000 2
1 2 SHOCK 3 2 17400 2 0 91 1 99.99 2.03 0 0 1 1 ESBL E.COLI 16000 2
2 Not catheterised 15000 4 0 89 1 99.99 8.1 2 0 4 1
1 2 OLIGURIA 2 2 15900 16 3 73 1 99.99 6.08 1 0 1 1 KLEBSIELLA 400 2
2 Not catheterised 7200 23 0 66 1 10.15 8.1 1 1 3 1 E coli 1000000 1 AMOXICLAV 1
2 Not catheterised 8400 11 0 80 1 8.1 4.06 2 0 1 1 PSEUDOMONAS 1000000 1 AZTREONAM 2
1 1 RENAL FAILURE 4 2 1800 30 3 15 1 1.02 99.99 0 0 1 2 2
2 Not catheterised 16200 13 2 82 1 8.1 6.08 1 0 2 1 2
2 Not catheterised 4400 21 0 59 2 1 1 ESBL ECOLI 1000000 1 AMOXICLAV 2
1 1 ALTERED SENSO 3 2 6000 8 1 88 1 99.99 30.35 3 0 1 1
1 1 SHOCK 7 2 11500 1 16 72 1 20.25 2.04 1 0 0 2 ESBL E.COLI 1000000 2
2 Not catheterised 13300 1 0 99 1 20.25 8.1 1 0 2 1 ESBL E.COLI 100000 2
1 2 ACUTE RETENT 8 2 12400 14 0 79 1 99.99 10.12 1 0 1 1
2 Not catheterised 23400 8 2 86 1 99.99 15.2 1 0 0 1 ESBL E.COLI 48000 1 AMOXICLAV 2
2 Not catheterised 10200 27 5 59 1 99.99 6.08 1 0 1 1 E coli 55000 1 AMOXICLAV 1
2 Not catheterised 11500 10 76 1 25.3 4.06 1 0 2 1 E coli 2000 1 AMIKACIN 1
2 Not catheterised 9600 13 0 72 1 2.03 6.08 0 0 0 1 ESBL E.COLI 1400 2
2 Not catheterised 21000 4 0 87 1 99.99 10.15 3 1 2 1 ESBL E.COLI 40000 1 AMOXICLAV 2
2 Not catheterised 16000 7 0 84 1 25.3 4.07 2 0 1 1 ESBL E.COLI 85000 1 AMOXICLAV 2
2 Not catheterised 19200 8 0 86 1 99.99 10.15 0 0 1 1 ESBL E.COLI 100000 1 AMOXICLAV 2
1 1 SHOCK 4 2 15300 8 0 89 1 99.99 4.06 3 0 3 NOT DONE
1 1 UNRESPONSIVE 3 2 17200 12 0 80 1 20.25 4.06 3 0 0 NOT DONE
2 Not catheterised 12800 22 0 69 1 20.25 1.02 3 0 1 1 ESBL E.COLI 100000 1 AMOXICLAV 2
2 Not catheterised 13900 7 0 83 1 20.25 6.08 3 0 2 1 ESBL E.COLI 100000 1 AMOXICLAV 2
2 Not catheterised 19300 6 0 89 1 99.99 30.35 0 0 1 1 ESBL E.COLI 100000 1 AMOXICLAV 1
2 Not catheterised 16900 7 0 83 1 6.08 2.04 1 1 1 1 ESBL E.COLI 100000 1 AMOXICLAV 2
2 Not catheterised 8500 22 0 68 1 20.25 2.04 1 0 1 1 ESBL E.COLI 100000 1 AMOXICLAV 1
2 Not catheterised 21400 8 0 86 1 8.1 6.08 2 0 5 1 YEAST 100000 2
1 1 SHOCK 17 2 14100 24 0 69 1 99.99 1.01 3 1 3 1 E coli 100000 1 AMOXICLAV 2
2 Not catheterised 11000 19 0 74 1 12.15 2.04 0 0 1 1 E coli 5000 1 AMOXICLAV 2
1 2 SHOCK 2 2 9300 3 8 89 1 1.01 1.01 0 0 1 1 2
1 1 OLIGURIA 3 2 7900 25 1 59 1 20.25 3.05 1 0 1 1 MIXTURE OF ORGANISM 2
2 Not catheterised 12400 2 3 88 1 99.99 15.2 2 0 3 1 ESBL E.COLI 100000 1 AMOXICLAV 1
2 Not catheterised 12700 3 0 94 1 20.25 4.06 0 0 3 1 2
2 Not catheterised 17000 5 0 90 1 20.25 8.1 3 0 2 1 ESBL E.COLI 100000 1 AMOXICLAV 2
1 1 ALTERED SENSO 2 2 11400 7 0 87 1 99.99 4.06 0 0 1 1 PSEUDOMONAS 100000 1 AZTREONAM 2
1 1 OUTPUT MONIT 3 2 12600 18 0 76 1 20.22 2.04 0 0 6 2 ESBL E.COLI 100000 1 AMOXICLAV 2
2 Not catheterised 25600 4 0 90 1 25.3 6.08 2 0 1 1 ESBL E.COLI 13500 1 AMOXICLAV 2
2 Not catheterised 14200 4 0 95 1 4.05 6.08 0 0 1 2 E coli 500 1 AMOXICLAV 2
1 1 SHOCK 4 2 19100 17 0 82 1 99.99 99.99 4 0 1 1 ESBL E COLI 0 2
1 2 ALTERED SENSO 1 2 12000 30 0 63 1 10.12 2.04 1 0 5 1 2
2 Not catheterised 17000 12 83 1 99.99 1.02 3 0 1 1 ESBL E.COLI 100000 1 AMOXICLAV 2
2 Not catheterised 16300 6 0 87 1 25.3 3.05 1 1 3 1 E coli 100000 1 AMOXICLAV 2
1 1 SHOCK 1 2 6700 18 4 77 1 20.25 4.06 1 0 1 2 ESBL E.COLI 100000 1 AMOXICLAV 2
1 2 ALTERED SENSO 7 2 9800 21 0 70 1 10.12 2.04 0 0 2 1 ESBL E.COLI 100000 1 AMOXICLAV 2
2 Not catheterised 15300 27 0 65 1 99.99 1.02 2 0 1 1 ECOLI1/ESBL 2 100000 1 AMOXICLAV 2
2 Not catheterised 9600 10 0 84 1 20.4 14.4 2 0 2 1
2 Not catheterised 10700 12 0 74 1 6.08 30.35 0 0 1 1
1 1 ALTERED SENSO 1 2 17900 6 0 88 1 99.99 10.15 3 0 3 1
1 1 OLIGURIA 4 2 30400 3 0 93 1 99.99 6.08 3 0 4 1 ENTEROCOCCI 34000 1 AMPICILLIN 2
2 Not catheterised 17000 7 0 88 1 10.12 2.04 1 0 1 1 ESBL E.COLI 100000 1 AMOXICLAV 2
1 1 OLIGURIA 5 2 19900 4 0 95 1 99.99 6.08 2 0 2 1 ESBL E.COLI 100000 1 AMOXICLAV 1
2 Not catheterised 10900 8 0 86 1 99.99 99.99 2 0 1 1 ESBL E.COLI 3000 1 AMOXICLAV 2
1 1 OLIGURIA 2 1 12500 5 0 90 1 45.5 12.15 3 1 3 2 E coli 100000 1 AMOXICLAV 2
2 Not catheterised 13000 6 0 80 1 8.1 4.06 0 0 1 1 E coli 100000 1 AMOXICLAV 2
2 Not catheterised 3700 29 0 52 1 2.04 2.04 1 0 1 1 E coli 100000 1 AMOXICLAV 1
2 Not catheterised 16400 12 0 78 1 20.25 10.12 2 0 2 1 E coli 48000 1 AMOXICLAV 2
1 1 ALTERED SENSO 1 2 25900 7 6 85 1 20.22 10.12 1 1 2 1 E coli 100000 1 AMOCICLAV 2
2 Not catheterised 14800 12 0 84 1 30.35 1.02 0 0 1 1 E coli
2 Not catheterised 8800 29 0 60 1 99.99 15.2 2 1 2 1 E coli 0.01 1 AMOXICLAV 1
2 Not catheterised 1890 6 0 91 1 2.04 1.02 0 0 1 1 ENTEROCOCCI 100000 1 AMPICILLIN 1
1 2 OUTPUT MONIT 2 2 15200 7 0 92 1 20.25 8.1 2 0 2 1 ESBL E.COLI 6000 1 AMOXICLAV 2
1 1 SHOCK 21 2 27600 10 4 80 1 99.99 99.99 1 0 1 2 CANDIDA 100000 2
1 1 ALTERED SENSO 2 2 9500 10 0 89 1 15.2 5.06 2 0 0 2 NO GROWTH
1 2 UTI 6 2 21600 9 0 87 2 1 2 PSEUDOMONAS 100000 1 AZTREONAM 1
1 1 NO RESAON 3 1 6400 11 0 85 1 99.99 4.06 3 1 2 2 ESBL E.COLI 17000 1 AMOXICLAV 2
2 Not catheterised 17400 9 0 84 1 45.5 12.15 3 1 1 1 ESBL E.COLI 100000 1 AMOXICLAV 2
2 Not catheterised 5000 24 0 62 1 10.15 1.02 0 0 2 1 NO GROWTH
2 Not catheterised 9400 5 0 94 1 20.25 99.99 0 0 1 1 E coli 2000 1 AMOXICLAV 1
1 2 IMMOBILISATIO 7 2 15000 17 0 75 2 0 2 GNB/CITROBAC 100000 1 AMOXICLAV 2
2 Not catheterised 11400 21 0 74 1 40.45 20.25 0 0 1 1 ESBL E.COLI 16200 1 AMOXICLAV 2
2 Not catheterised 16300 14 0 81 1 1.02 10.12 0 1 2 1 YEAST 3500 2
2 Not catheterised 9200 9 0 80 1 10.12 1.02 0 0 2 1 2
1 2 ALTERED SENSO 7 2 13600 23 0 59 1 99.99 15.2 0 0 1 2 ESBL E.COLI 0 1 AMOXCICLAV 2
1 1 SHOCK 7 2 9600 6 19 72 1 1.02 2.04 0 0 1 2
1 3 OLIGURIA,SHOC 3 2 6500 3 0 95 1 1.01 18.2 0 0 0 2 YEAST 11600 2
1 1 SHOCK 10 2 2300 7 1 80 1 99.99 8.1 2 0 3 1 ESBL E.COLI 100000 1 AMOXICLAV 2
2 Not catheterised 18900 3 0 97 1 20.25 8.1 2 1 2 1 ESBL E.COLI 400 2
1 1 IMMOBILISATIO 14 2 11300 9 0 88 1 3.05 8.1 3 0 1 2 KLEBSIELLA 100000 1 AMOXICLAV 2
1 1 UTI 3 1 25500 4 3 90 1 2.03 99.99 2 0 1 2 E coli 800 2
1 1 IMMOBILISATIO 60 2 9900 21 0 70 1 15.2 20.25 1 1 0 2 KLEBSIELLA 100000 1 AMOXCICLAV 2
2 Not catheterised 12800 25 0 63 1 2.04 1.02 0 1 1 1 ENTEROCOCCI 30000 1 AMPICILLIN 1
2 Not catheterised 13600 1 81 14 1 99.99 15.18 1 1 0 1 ESBL E.COLI 100000 1 AMOXICLAV 2
1 2 NOT KNOWN 5 2 6100 6 0 84 1 99.99 0 0 0 0 1 CANDIDA 100000 2
2 Not catheterised 13600 5 8 86 1 99.99 4.06 2 1 0 1 ESBL E.COLII 100000 1 AMOXICLAV 2
2 Not catheterised 14400 7 0 87 1 25.3 2.03 2 0 2 1 ESBL E.COLI 2400 1 AMOXICLAV 2
1 2 SPC 999 2 18400 2 0 97 1 99.99 99.99 2 0 4 3 YEAST 100000 2
1 3 IMMOBILISATIO 30 2 7700 11 0 79 1 20.25 15.2 2 0 1 2 ENTEROCOCCI 4000 1 AMPICILLIN 2
2 Not catheterised 10400 4 0 91 1 6.08 1.02 0 0 1 1 E coli 100000 1 AMOXICLAV 1
1 1 IMMOBILISATIO 4 2 27600 5 0 92 1 99.99 1.02 3 0 0 1 E coli 100000 2
2 Not catheterised 11500 6 0 89 1 50.55 6.08 0 0 2 1 ESBL E.COLI 100000 1 AMOXICLAV 2
2 Not catheterised 8700 7 0 87 1 99.99 10.2 3 0 2 1 ESBL E.COLI 100000 1 AMOXICLAV 1
2 Not catheterised 11400 9 0 82 1 20.25 2.04 2 1 2 1 ESBL E.COLI 100000 2
1 1 SHOCK 3 2 22300 8 11 74 1 35.4 2.04 2 0 1 1
1 1 ALTERED SENSO 2 2 17300 8 0 81 1 99.99 2.03 2 0 0 2 E coli 21000 1 AMOXICLAV 2
2 Not catheterised 15500 12 0 84 1 25.3 4.06 0 0 1 1 ESBL E.COLI 100000 1 AMOXICLAV 1
2 Not catheterised 16300 6 0 89 1 99.99 1.02 0 0 3 1 ENTEROCOCCI 6500 1 AMPICILLIN 1
2 Not catheterised 11600 4 0 84 1 20.25 8.1 2 0 1 1 YEAST 28000 2
1 2 SHOCK 2 2 18900 6 0 88 1 35.4 10.15 0 0 1 1 PSEUDOMONAS 11000 1 AMOXICLAV 2
2 Not catheterised 16100 24 0 70 1 10.12 1.02 3 0 0 1 2
1 2 ALTERED SENSO 3 2 12600 27 0 50 1 10.12 2.04 0 1 1 2 2
1 3 SHOCK 1 2 6000 24 1 71 2 0 2 2
1 2 SHOCK 3 2 400 2 0 3 1 2.04 6.08 0 0 1 2 E coli 100000 1 AMOXICLAV 2
1 2 ACUTE RETENT 3 2 13800 4 0 88 1 99.99 99.99 0 0 1 1 E coli 1000 1 AMOXICLAV 2
1 1 ACUTE RENAL F 14 2 18600 4 2 88 1 1.02 99.99 0 0 2 2 CANDIDA TROP 100000 2
1 1 CHANGE OF CA 999 2 10700 11 0 73 1 99.99 99.99 3 1 1 2 KLEBSIELLA 100000 1 AMOXICLAV 2
1 1 SHOCK 5 2 1400 20 0 80 1 99.99 10.12 3 1 5 1 E coli 1200 1 AMOXICLAV 2
1 1 ALTERED SENSO 2 2 14500 7 0 87 1 99.99 18.2 1 0 0 1 ESBL E.COLI 100000 1 AMOXICLAV 2
1 2 SHOCK 7 2 12700 9 0 86 1 99.99 18.2 3 0 3 1 ESBL E.COLI 4200 1 AMOXICLAV 2
2 Not catheterised 11400 6 0 92 1 99.99 5.06 1 0 1 1 YEAST 2800 2
2 Not catheterised 22600 16 0 81 1 99.99 99.99 0 0 3
1 1 SHOCK , SEIZUR 3 2 3000 12 0 87 1 1.02 0 0 0 1
1 1 SHOCK 1 2 18900 8 0 86 2 4
1 1 IMMOBILISATIO 7 2 24700 13 0 79 1 99.99 1.02 0 0 0 1
2 Not catheterised 11300 19 0 68 1 3.05 1.02 0 0 1 1 ESBL E.COLI 100000 1 AMOXICLAV 1
1 1 SHOCK 4 2 11700 10 0 82 1 25.3 18.2 2 0 2 3
1 1 RETENTION 5 2 10100 19 0 76 1 99.99 2.03 3 0 4 1 CANDIDA TROP 100000 2
2 Not catheterised 15400 9 0 81 1 99.99 8.1 1 0 2 1 ESBL E.COLI 100000 1 AMOXICLAV 2
2 Not catheterised 28000 4 7 88 1 99.99 99.99 1 1 3 1 ESBL E.COLI 100000 1 AMOXICLAV 2
2 Not catheterised 23800 9 3 88 1 99.99 99.99 2 1 2 1 ESBL E.COLI 100000 1 AMOXICLAV 2
2 Not catheterised 8900 7 0 88 1 20.25 99.99 1 1 5 1 E coli 1500 2
1 1 ACUTE RETENT 14 2 17000 17 0 76 1 99.99 4.06 3 1 1 2 ESBL E.COLI 100000 1 AMOXICLAV 2
2 Not catheterised 4000 14 0 76 1 14.16 8.1 1 1 1 1 E coli 100000 1 MAGNEX 1
2 Not catheterised 13600 2 0 86 1 30.35 1.02 1 1 2 1 E coli 600 2
2 Not catheterised 13300 16 0 70 1 99.99 2.04 0 0 5 3 ESBL E.COLI 100000 1 AMOXICLAV 2
1 1 SHOCK, ALTERE 17 2 25800 2 0 93 1 30.35 99.99 3 0 1 1 E coli 2800 1 AMIKACIN 1
1 1 ALTERED SENSO 1 2 13800 10 0 78 1 1.02 4.06 0 0 1 1 E coli 100000 1 AMOXICLAV 2
1 2 PULMONARY ED 18 2 18300 20 0 72 1 99.99 20.25 3 0 1 1 ESBL E.COLI 100000 1 AMOXICLAV 2
1 1 ALTERED SENSO 7 2 7900 37 17 44 1 1.02 1.02 0 0 0 1 ENTEROCOCCI 100000 1 NITROFURANTO 1
2 Not catheterised 8900 9 0 83 1 30.35 10.12 3 0 2 1 ESBL E.COLI 100000 1 AMOXICLAV 2
2 Not catheterised 19700 10 0 82 1 25.3 6.08 3 1 1 1 ESBL ECOLI 600 1 AMOXICLAV 2
2 Not catheterised 21300 6 0 86 1 99.99 99.99 3 1 1 1 CONTAMINANTS
2 Not catheterised 13300 13 0 81 1 99.99 6.08 2 0 1 1 ESBL E.COLI 100000 1 AMOXICLAV 2
2 Not catheterised 18000 10 0 79 1 99.99 12.14 3 0 1 1 E coli 100000 1 AMOXICLAV 2
2 Not catheterised 9100 26 0 61 2 0 1 E coli 100000 2
2 Not catheterised 19600 7 0 87 1 35.4 3.05 3 1 2 1 E coli 100000 2
1 1 OLIGURIA 4 2 17900 5 0 84 1 99.99 6.08 2 0 1 1 E coli 100000 1 AMOXICLAV 1
2 Not catheterised 15700 13 0 74 1 25.3 12.14 1 1 2 NOT DONE
1 1 CHANGE OF CA 12 2 7000 34 0 46 1 99.99 2.04 2 1 1 2 E coli 100000 1 AMOXICLAV 2
2 Not catheterised 10800 11 0 79 1 99.99 1.02 3 0 2 1 KLEBSIELLA 800 2
2 Not catheterised 16800 10 0 84 1 25.3 0 2 0 5 1 KLEBSIELLA 3000 1 AMOXICLAV 1
2 Not catheterised 22100 4 0 91 1 14 0 1 0 4 1 CONTAMINANTS
1 1 ANURIC, SHOCK 4 2 5400 20 0 66 1 18.2 3.05 1 0 1 2 ESBL E.COLI 100000 1 AMOXICLAV 2
2 Not catheterised 5400 31 10 52 1 5.1 1.02 1 1 1 1 ESBL E.COLI 100000 1 AMOXICLAV 2
2 Not catheterised 10100 6 0 88 1 99.99 6.08 2 0 1 1 E coli 100000 1 AMOXICLAV 1
1 1 OLIGURIA, ALTE 5 2 9700 16 0 76 1 35.4 8.1 2 0 3 1 ESBL E.COLI 100000 1 AMOXICLAV 2
2 Not catheterised 12100 9 0 85 1 99.99 6.08 1 0 1 1 KLEBSIELLA 100000 1 AMOXICLAV 1
2 Not catheterised 19400 7 0 88 1 35.4 35.4 1 0 1 1
2 Not catheterised 43900 4 0 95 1 99.99 99.99 3 0 3 2 PSEUDOMONAS 100000 1 AMIKACIN 1
2 Not catheterised 14500 12 0 76 1 35.4 1.02 2 0 2 1
2 Not catheterised 18100 6 1 89 1 20.25 2.04 1 0 1 1 ESBL E.COLI 100000 1 AMOXICLAV 2
1 1 SHOCK 13 2 20900 20 4 73 1 99.99 16.18 2 0 2 1 YEAST 6000 2
2 Not catheterised 18400 9 0 80 1 99.99 10.15 3 0 1 1 ESBL E.COLI 100000 1 AMOXICLAV 2
1 2 SHOCK 3 2 11600 9 12 71 1 99.99 99.99 3 0 0 1 ENTEROCOCCI/ 100000 1 AMOXICLAV 2
1 2 SHOCK 3 2 16100 23 0 71 1 99.99 15.2 1 1 1 1 KLEBSIELLA/E C 100000 1 AMOXICLAV 2
1 1 CHANGE OF CA 14 2 13500 8 0 86 1 18.2 6.08 2 1 2 2 KLEBSIELLA/ESB 100000 1 MAGNEX 1
2 Not catheterised 16900 7 0 85 1 99.99 99.99 1 1 3 1 KLEBSIELLA 100000 1 AMOXICLAV 2
1 1 OLIGURIA,RENA 7 2 32800 3 0 91 1 99.99 10.12 3 0 1 1
1 1 CVA 19 2 17300 3 2 91 1 6.08 2.03 2 0 2 3 ESBL E.COLI 100000 1 AMOXICLAV 1
2 Not catheterised 9000 30 0 62 1 25.3 1.02 1 0 1 3 ESBL E.COLI 100000 1 AMOXICLAV 2
2 Not catheterised 12700 24 0 60 1 10.15 2.03 2 1 1 3 ESBL E.COLI 100000 1 AMOXICLAV 1
2 Not catheterised 21000 13 3 74 1 12.15 1.02 2 0 1 1 ESBL E.COLI 100000 1 AMOXICLAV 2
1 1 SHOCK 2 2 7300 10 0 86 1 20.25 10.12 3 1 2 1
1 1 NOT KNOWN 1 2 18800 6 0 90 1 99.99 15.2 3 1 3 1
2 Not catheterised 11100 6 0 85 1 1.02 1.02 0 1 1 1
1 1 OLIGURIA 3 2 12300 2 0 95 1 99.99 2.04 3 1 3 1 E COLI 100000 1 AMOXICLAV 1
2 Not catheterised 22200 13 0 77 1 6.08 20.25 0 0 5 1 KLEBSIELLA 20000 1 AMIKACIN 2
2 Not catheterised 18500 5 0 88 1 1.02 1.02 0 0 3 3 ESBL E.COLI 100000 1 AMOXICLAV 1
2 Not catheterised 11600 5 2 89 1 99.99 8.1 3 0 1 1 ESBL E.COLI 100000 1 AMOXICLAV 2
1 1 SHOCK 2 2 40800 3 0 94 1 99.99 8.1 3 1 3 NOT DONE
2 Not catheterised 15000 19 0 62 1 20.25 2.03 3 1 1 1
2 Not catheterised 12800 22 0 67 1 1.01 6.08 0 0 6 1
2 Not catheterised 9000 16 0 71 1 99.99 1.02 3 0 3 1 ESBL E.COLI 100000 1 AMOXICLAV 2
2 Not catheterised 17400 15 0 74 1 99.99 6.08 1 0 0 1 KLEBSIELLA/E C 100000 1 AMOXICLAV 1
1 1 CHANGE OF CA 270 2 5900 15 1 74 1 20.22 2.03 2 1 1 2 ESBL E.COLI 38000 1 AMOXICLAV 2
2 Not catheterised 11600 19 0 69 1 99.99 6.08 3 1 1 1 E COLI 100000 1 AMOXICLAV 1
1 1 OLGURIA 12 2 18800 2 2 90 1 10.15 99.99 3 1 1 1 ENTEROCOCCI/ 100000 1 AMOXICLAV 1
2 Not catheterised 2900 12 0 68 1 99.99 6.08 3 0 1 1
1 1 CHANGE OF CA 38 2 11700 7 0 82 1 99.99 8.1 3 1 0 2 ENTEROCOCI/E 100000 2
2 Not catheterised 13100 8 0 83 1 20.25 6.08 1 1 1 1 ESBL E.COLI 100000 1 AMOXICLAV 1
2 Not catheterised 13200 6 0 92 1 25.3 10.12 2 1 1 1 ENTEROCOCCI/ 100000 1 AMOXICLAV 2
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1 ESBL E.COLI TICARCLAV 2
1 ESBL E.COLI TICARCLAV 2
1 ESBL E.COLI TICARCLAV 2
2
AMIKACIN 1 MAGNEX 1 CARBOPENEM 1 NITROFURANTO 1 PIPTAZ 1 CEFPODOXIME 1 CIP 2 2
AMIKACIN 2 MAGNEX 2 CARBOPENEM 2 NETILMICIN 2 CEFTAZIDIME 2 COLISTIN 1 CIP 2 2
2
2
AMIKACIN 2 MAGNEX 2 CARBOPENEM 1 NETILMICIN 2 PIPTAZ 2 CEFPODOXIME 2 CIP 2 2
2
1 ESBL E.COLI TICARCLAV 2
1 ESBL E.COLI TICARCLAV 2
2
NALIDIXIC ACID 2 NITROFURANTO 1 CO TRIMOX 2 GENTAMICIN 2 CEFPODOXIME 2 1 ESBL E.COLI TICARCLAV 2
NITROFURANTO 1 NALIDIXIC ACID 2 COTRIMOX 2 GENTAMICIN 2 CEFPODOXIME 1 2
AMOXICLAV 1 MAGNEX 1 NITROFURANTO 1 CARBOPENEM 1 PIPTAZ 1 CEFPODOXIME 1 CIP 1 2
2
AMIKACIN 1 MAGNEX 1 CARBOPENEM 1 NITROFURANTO 1 PIPTAZ 2 CEFPODOXIME 2 CIP 2 1 ESBL E.COLI MAGNEX 1
COTRIMOX 2 NITROFURANTO 1 GENTAMICIN 2 CEFPODOXIME 2 CIPROFLOX 2 2
COTRIMOX 2 NITROFURANTO 1 GENTAMICIN 1 CEFPODOXIME 2 CIPROFLOX 1 2
1 E COLI MAGNEX 1
2
AMIKACIN 1 MAGNEX 1 NITROFURANTO 1 CARBOPENEM 1 PIPTAZ 2 CEFPODOXIME 2 CIP 2 2
COTRIMOX 2 NITROFURANTO 1 CEFPODOXIME 2 CIPROFLOX 2 1 ESBL ECOLI MAGNEX 1
COTRIMOX 2 NITROFURANTO 1 GENTAMICIN 2 CEFPODOXIME 2 CIPROFLOX 2 2
COTRIMOX 1 NITROFURANTO 1 GENTAMICIN 1 CEFPODOXIME 1 CIPROFLOX 1 2
NITROFURANTO 1 COTRIMOX 2 GENTAMICIN 1 CEFPODOXIME 2 CIPROFLOX 2 2
2
AMIKACIN 1 MAGNEX 1 CARBOPENEM 1 PIPTAZ 1 GENTAMICIN 1 CEFPODOXIME 1 CIP 2 2
COTRIMOX 1 NITROFURANTO 1 GENTAMICIN 2 CEFPODOXIME 1 2
1 E COLI TICARCLAV 1
2
COTRIMOX 2 NITROFUNATOI 1 GENTAMICIN 1 CEFPODOXIME 2 CIPROFLOX 1 1 ESBL E.COLI TICARCLAV 1
2
AMIKACIN 1 MAGNEX 1 CARBAPENEM 1 NETILMICIN 2 PIPTAZ 2 CEFPODOXIME 2 CIP 2 2
AMIKACIN 2 AMOXICLAV 2 NITROFURANTO 2 COTRIMOX 2 CEFTAZIDIME 1 CEFPODOX 2 CIP 2 2
AMIKACIN 1 MAGNEX 1 CARBOPENEM 1 NETILMICIN 2 PIPTAZ 2 CEFPODOXIME 2 CIP 2 2
COTRIMOX 1 NITROFURANTO 1 GENTAMICIN 2 CEFPODOXIME 2 CIPROFLOX 2 2
COTRIMOX 2 NITROFURANTO 2 GENTAMICIN 2 CEFPODOXIME 1 CIPROFLOX 2 1 ESBL E.COLI TICARCLAV 2
1 ESBL E.COLI TICARCLAV 2
2
COTRIMOX 2 NITROFURANTO 1 GENTAMICIN 1 CEFPODOXIME 2 CIPROFLOX 2 1 ESBL E.COLI TICARCLAV 2
AMIKACIN 1 MAGNEX 1 CARBOPENEM 1 NITROFURANTO 1 PIPTAZ 1 CEFPODOXIME 1 CIP 2 1 E COLI TICARCLAV 1
COTRIMOX 2 NITROFURANTO 1 GENTAMICIN 2 CEFPODOXIME 2 1 ESBL ECOLI TICARCLAV 2
COTRIMOX 2 NITROFURANTO 1 CARBOPENEM 1 NETILMICIN 1 PIPTAZ 2 CEFPODOXIME 2 CIP 2 2
AMIKACIN 1 MAGNEX 2 CARBOPENEM 1 NITROFURANTO 2 PIPTAZ 2 CEFPODOXIME 2 CIP 2 2
2
2
1 ESBL E.COLI TICARCLAV 1
GENTAMICIN 2 NITROFURANTO 1 2
COTRIMOX 2 NITROFURANTO 1 GENTAMICIN 1 CEFPODOXIME 2 CIPROFLOX 2 2
NITOFURANTOI 1 COTRIMOX 2 GENTAMICIN 2 CEFPODOXIME 2 CIPROFLOX 2 2
AMIKACIN 1 MAGNEX 2 CARBOPENEM 1 PIPTAZ 1 CEFPODOXIME 2 CIP 2 2
COTIRMOX 1 NITROFURANTO 1 GENTAMICIN 2 CEFPODOXIME 1 CIPROFLOX 2 1 E COLI TIGECYCLINE 2
AMIKACIN 1 MAGNEX 1 CARBOPENEM 1 COTRIMOX 1 PIPTAZ 2 CEFPODOXIME 2 CIP 2 2
AMIKACIN 1 MAGNEX 1 CARBOPENEM 1 NETILMICIN 1 PIPTAZ 1 CEFPODOXIME 2 CIP 2 2
AMIKACIN 1 MAGNEX 1 CARBOPENEM 1 COTRIMOX 2 PIPTAZ 2 CEFPODOXIME 2 CIP 2 2
COTRIMOX 2 NITROFURANTO 1 GENTAMICIN 2 CEFPODOXIME 2 CIPROFLOX 2 1 ESBL E.COLI TICARCLAV 2
2
COTRIMOX 1 NITROFURANTO 1 GENTAMICIN 1 CEFPODOXIME 1 2
GENTAMICIN 2 NITROFURANTO 1 TEICOPLANIN 1 VANCOMYCIN 1 LINEZOLID 1 CIPROFLOX 2 2
COTRIMOX 2 NITROFURANTO 1 GENTAMICIN 2 CEFPODOXIME 2 CIPROFLOX 2 1 ESBL E.COLI TICARCLAV 2
2
2
GENTAMICIN 1 NETILMICIN 1 CEFTAZIDIME 1 COLISITIN 1 CIPROFLOX 1 2
AMIKACIN 1 MAGNEX 1 CARBOPENEM 1 NETILMICIN 1 PIPTAZ 2 CEFPODOXIME 2 CIP 2 1 ESBL E.COLI TICARCLAV 2
AMIKACIN 1 MAGNEX 2 CARBOPENEM 1 NITROFURANTO 1 PIPTAZ 2 CEFPODOXIME 2 CIP 2 2
2
COTRIMOX 1 NITROFURANTO 1 GENTAMICIN 1 CEFPODOXIME 1 2
AMIKACIN 2 MAGNEX 2 CARBOPENEM 2 NITROFURANTO 1 PIPTAZ 2 CEFPODOXIME 2 CIP 2 2
AMIKACIN 1 MAGNEX 1 CARBOPENEM 1 NITROFURANTO 2 PIPTAZ 2 CEFPODOXIME 2 CIP 2 2
2
2
COTRIMOX 2 NITROFURANTO 1 GENTAMICIN 2 CEFPODOXIME 2 CIPROFLOX 2 2
2
2
AMIKACIN 1 MAGNEX 2 CARBOPENEM 1 NITROFURANTO 2 PIPTAZ 2 CEFPODOXIME 2 CIP 2 1 ESBL E.COLI AMOXICLAV 2
1 ESBL E.COLI TICARCLAV 2
AMIKACIN 1 MAGNEX 1 CARBOPENEM 1 NITROFURANTO 2 PIPTAZ 2 CEFPODOXIME 2 CIP 2 2
2
AMIKACIN 2 MAGNEX 2 CARBOPENEM 1 NETILMICIN 2 PIPTAZ 2 CEFPODOXIME 2 CIP 2 2
GENTAMICIN 2 NITROFURANTO 1 2
COTRIMOX 2 NITROFURANTO 1 GENTAMICIN 2 CEFPODOXIME 2 NALIDIXIC ACID 2 2
1 KLEBSIELLA TICARCLAV 2
COTRIMOX 2 NITROFURANTO 1 GENTAMICIN 2 CEFPODOXIME 2 2
AMIKACIN 1 MAGNEX 2 CARBOPENEM 1 NITROFURANTO 1 PIPTAZ 2 CEFPODOXIME 2 GEN 1 2
1 ESBL E.COLI COLISTIN 1
GENTAMICIN 1 NITROFURANTO 1 LINEZOLID 1 TEICOPLANIN 1 VANCOMYCIN 1 1 ESBL E.COLI TIGECYCLINE 1
COTRIMOX 1 NITROFURANTO 1 GENTAMICIN 1 CEFPODOXIME 1 CIPROFLOX 1 2
2
COTRIMOX 2 NITROFURANTO 1 GENTAMICIN 2 CEFPODOXIME 2 CIPROFLOX 2 2
COTRIMOX 2 NITROFURANTO 1 CARBOPENEM 1 CEFPODOXIME 2 CIPROFLOX 2 1 ESBL E.COLI TIGECYCLINE 1
1 E COLI MAGNEX 1
2
COTRIMOX 2 NITROFURANTO 1 GENTAMICIN 1 CEFPODOXIME 1 CIPROFLOX 2 2
COTRIMOX 2 NITROFURANTO 1 GENTAMICIN 2 CEFPODOXIME 2 2
GENTAMICIN 2 NITROFURANTO 1 1 ESBL E.COLI TICARCLAV 2
2
AMIKACIN 2 MAGNEX 2 CARBOPENEM 1 CEFTAZIDIME 2 PIPTAZ 2 CEFPODOXIME 2 CIP 2 2
2
22
COTRIMOX 2 NITROFURANTO 1 GENTAMICIN 2 CEFPODOXIME 1 1 E COLI TICARCLAV 1
COTRIMOX 1 NITROFURANTO 1 GENTAMICIN 2 CEFPODOXIME 1 2
1 STAPH AUREUSOXACILLIN 1
AMIKACIN 2 MAGNEX 1 CABOPENEM 1 NITROFURANTO 2 PIPTAZ 1 CEFPODOXIME 2 CIP 2 2
COTRIMOX 2 NITROFURANTO 1 GENTAMICIN 1 CEFPODOXIME 1 CIPROFLOX 1 1 E COLI TIGECYCLINE 1
COTRIMOX 1 NITROFURANTO 1 GENTAMICIN 1 CEFPODOXIME 2 CIPROFLOX 2 1 ESBL E.COLI TIGECYCLINE 1
COTRIMOX 2 NITROFURANTO 1 GENTAMICIN 2 CEFPODOXIME 2 CIPRFLOXACIN 2 2
2
1 ESBL E.COLI TIGECYCLINE 1
1 E COLI MAGNEX 1
2
1 ESBL E.COLI TIGECYCLINE 1
COTRIMOX 2 NITROFURANTO 1 GENTAMICIN 2 CEFPODOXIME 2 NALIDIXIC ACID 2 2
1 ESBL E.COLI COLISTIN 1
2
AMIKACIN 2 MAGNEX 2 CARBOPENEM 1 NITROFURANTO 1 PIPTAZ 2 CEFPODOXIME 2 CIP 2 2
AMIKACIN 2 CEFUROXIME 2 CARBOPENEM 1 PIPTAZ 2 NITROFURANTO 1 CEFOTAXIME 2 CIP 2 2
COTRIMOX 2 NITROFURANTO 1 GENTAMICIN 2 CEFUROXIME 2 1 ESBL E.COLI AMIKACIN 2
1 ESBL E.COLI AMIKACIN 2
CEFUROXIME 2 CEFOTAXIME 2 MAGNEX 1 NITROFURANTO 1 CARBOPENEM 1 PIPTAZ 1 CIP 2 2
AMIKACIN 1 CEFOTAXIME 2 CEFUROXIME 2 AMOXICLAV 2 CARBOPENEM 1 PIPTAZ 2 CIP 2 2
1 ESBL E.COLI TICARCLAV 2
AMIKACIN 2 MAGNEX 2 CARBOPENEM 1 NITROFURANTO 1 PIPTAZ 2 CEFPODOXIME 2 CIP 2 2
AMOXICLAV 1 MAGNEX 1 CARBOPENEM 1 NITROFURANTO 1 PIPTAZ 1 CEFPODOXIME 1 CIP 1 1 E COLI AMIKACIN 1
MAGNEX 1 AMIKACIN 1 NITROFURANTO 1 CARBOPENEM 1 PIPTAZ 2 CEFPODOXIME 1 CIP 2 2
AMIKACIN 2 MAGNEX 2 CARBOPENEM 1 PIPTAZ 2 NITROFURANTO 2 CEFPODOXIME 2 CIP 2 1 ESBL E.COLI TICARCLAV 2
TEICOPLANIN 1 LINEZOLID 1 AMPICILLIN 2 VANCOMYCIN 1 GENTAMICIN 2 CIPROFLOXACIN 2 2
NITROFURANTO 1 CO TRIMOX 2 CEFPODOXIME 2 GENTAMICIN 2 CIPROFLOX 2 2
AMIKACIN 1 NITROFURANTO 1 CARBOPENEM 1 PIPTAZ 2 CEFPODOXIME 2 CIPROFLOX 2 GEN 2 1 ESBL ECOLI MAGNEX 1
1 ESBL E.COLI MAGNEX 1
AMIKACIN 1 NITROFURANTO 1 CARBOPENEM 1 PIPTAZ 2 CEFPODOXIME 2 CIPROFLOX 2 2
NITROFURANTO 1 AMIKACIN 1 MAGNEX 1 COTRIMOX 1 CEFPODOXIME 1 CIPROFLOX 2 1 E COLI MAGNEX 1
2
1 ESBL E.COLI MAGNEX 2
AMIKACIN 1 MAGNEX 1 NITROFURANTO 2 CARBOPENEM 1 PIPTAZ 1 CEFPODOXIME 2 CIP 1 1 ESBL E.COLI MAGNEX 1
1 E COLI
AMIKACIN 1 MAGNEX 2 CARBOPENEM 1 COTRIMOX 2 PIPTAZ 2 CEFPODOXIME 2 CIP 2 2
1 KLEBSIELLA AMIKACIN 1
NITROFURANTO 2 COTRIMOX 1 GENTAMICIN 1 CEFPODOXIME 1 CIPROFLOX 1 2
2
AMIKACIN 1 MAGNEX 1 CARBOPENEM 1 NITROFURANTO 1 PIPTAZ 1 CEFPODOXIME 2 CIP 1 2
AMIKACIN 1 MAGNEX 1 CARBOPENEM 1 PIPTAZ 2 CEFPODOXIME 2 NITROFURANTO 2 CIP 2 2
NITROFURANTO 1 COTRIMOX 1 GENTAMICIN 1 CEFPODOXIME 1 NALIDIXIC ACID 2 1 E COLI AMIKACIN 1
AMIKACIN 1 MAGNEX 2 NITROFURANTO 1 CARBOPENEM 1 PIPTAZ 2 CEFPODOXIME 2 CIP 2 1 ESBL E.COLI AMIKACIN 1
NALIDIXIC ACID 1 NITROFURANTO 2 COTRIMOX 1 GENTAMICIN 1 CEFPODOXIME 1 2
2
MAGNEX 1 PIPTAZ 1 CEFTAZIDIME 1 CEFPODOXIME 1 LEVOFLOX 1 NITROFURANTO 2 GEN 1 1 KLEBSIELLA OXYAMIKACIN 1
2
CARBOPENEM 1 COTRIMOX 2 GENTAMICIN 2 NETILMICIN 1 PIPTAZ 2 CEFPODOXIME 2 CIP 2 1 ESBL E.COLI MAGNEX 1
1 ESBL E.COLI MAGNEX 1
AMIKACIN 1 MAGNEX 1 NITROFURANTO 1 CARBOPENEM 1 PIPTAZ 2 CEFPODOXIME 2 CIP 2 2
NITROFURANTO 1 COTRIMOX 2 GENTAMICIN 1 AMPICILLIN 1 CEFPODOXIME 2 CIPROFLOX 2 2
NITROFURANTO 2 COTRIMOX 1 GENTAMICIN 2 CEFPODOXIME 2 CIPROFLOX 2 2
AMIKACIN 1 CARBOPENEM 1 TIGECYCLINE 1 PIPTAZ 2 CEFPODOXIME 2 COLISTIN 1 CIP 2 2
NITROFURANTO 2 CARBOPENEM 1 COTRIMOX 2 GENTAMICIN 1 PIPTAZ 1 CEFPODOXIME 2 CIP 2 2
1 ESBL E.COLI MAGNEX 1
AMIKACIN 1 MAGNEX 1 NITROFURANTO 1 CARBOPENEM 1 PIPTAZ 1 CEFPODOXIME 2 CIP 2 1 ESBL E.COLI MAGNEX 1
AMIKACIN 1 MAGNEX 1 NITROFURANTO 1 CARBOPENEM 1 PIPTAZ 2 CEFPODOXIME 2 CIP 2 2
NITROFURANTO 1 CARBOPENEM 1 COTRIMOX 2 PIPTAZ 1 GENTAMICIN 2 CEFPODOXIME 2 CIP 2 2
NITROFURANTO 1 AMIKACIN 1 CARBOPENEM 1 MAGNEX 1 PIPTAZ 2 CEFPODOXIME 2 CIP 2 2
2
1 E COLI MAGNEX 1
2
NITROFURANTO 1 COTRIMOX 1 GENTAMICIN 1 CEFPODOXIME 1 CIPROFLOX 2 1 E COLI MAGNEX 1
MAGNEX 2 NITROFURANTO 2 CARBOPENEM 2 TIGECYCLINE 2 PIPTAZ 2 CEFPODOXIME 2 CIP 2 2
AMIKACIN 1 MAGNEX 1 NITROFURANTO 1 CARBOPENEM 1 PIPTAZ 1 CEFPODOXIME 2 CIP 2 2
NITROFURANTO 1 COTRIMOX 1 GENTAMICIN 1 CEFPODOXIME 2 CIPROFLOX 2 1 ESBL E.COLI MAGNEX 1
2
22
NITROFURANTO 1 COTRIMOX 2 GENTAMICIN 2 CEFPODOXIME 2 CIPROFLOX 2 2
NITROFURANTO 2 CEFPODOXIME 1 GENTAMICIN 1 CIPROFLOX 1 COTRIMOX 2 2
AMIKACIN 2 MAGNEX 2 NITROFURANTO 2 CARBOPENEM 1 PIPTAZ 2 CEFPODOXIME 2 CIP 2 2
NITROFURANTO 1 CARBOPENEM 1 COTRIMOX 1 PIPTAZ 1 GENTAMICIN 1 CEFPODOXIME 1 CIP 1 2
NITROFURTANT 1 COTRIMOX 2 GENTAMICIN 1 AMPICILLIN 1 CEFPODOXIME 1 CIPROFLOX 2 2
2
1 ESBL E.COLI MAGNEX 1
NITROFURANTO 1 COTRIMOX 2 GENTAMICIN 1 CEFPODOXIME 2 CIPROFLOX 2 2
NITROFURANTO 1 COTRIMOX 2 GENTAMICIN 2 AMPICILLIN 1 CEFPODOXIME 2 CIPROFLOX 2 1 ESBL E.COLI COLISTIN 1
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MAGNEX 2 AMIKACIN 1 CARBOPENEM 1 PIPTAZ 2 NETILMICIN 1 CEFPODOXIME 2 CIPROFLOX 2 2 2 2
MAGNEX 1 AMIKACIN 1 CARBOPENEM 1 NETILMICIN 2 PIPTAZ 2 CEFPODOXIME 2 CIPROFLOX 2 2 2 2








MAGNEX 1 AMIKACIN 1 CARBOPENEM 1 NETILMICIN 1 PIPTAZ 2 CEFPODOXIME 2 CIPROFLOX 2 2 2 2
MAGNEX 1 AMIKACIN 1 CARBOPENEM 1 PIPTAZ 2 CEFTAZIDIME 2 CEFOTAXIME 2 CIPROFLOX 2 2 2 2
1 1 1




AMIKACIN 1 CARBOPENEM 1 TIGECYCLINE 1 COLISTIN 1 PIPTAZ 2 CEFPODOXIME 2 CIPROFLOX 2 1 1 2
2 2 2
2 2 2
AMIKACIN 1 TIGECYCLINE 1 CARBOPENEM 1 COLISTIN 1 CEFPODOXIME 1 GENTAMICIN 1 CIPROFLOX 2 2 2 2
2 2 2
2 2 2







MAGNEX 1 AMIKACIN 1 CARBAPENEM 1 PIPTAZ 1 NETILMICIN 1 CEFPODOXIME 1 CIPROFLOX 2 1 1 2
2 2 2






MAGNEX 1 AMIKACIN 2 CARBOPENEM 1 PIPTAZ 1 NETILMICIN 1 CEFPODOXIME 2 CIPROFLOX 2 2 2 2
MAGNEX 1 AMIKACIN 1 CARBOPENEM 1 PIPTAZ 2 NETILMICIN 1 CEFPODOXIME 2 CIPROFLOX 2 2 2 2
2 2 2
MAGNEX 1 AMIKACIN 1 CARBOPENEM 1 PIPTAZ 1 NETILMICIN 1 CEFPODOXIME 2 CIPROFLOX 2 2 2 2
MAGNEX 1 AMIKACIN 1 CARBOPENEM 1 PIPTAZ 2 2 2 2

































MAGNEX 2 AMIKACIN 1 CARBOPENEM 1 PIPTAZ 2 NETILMICIN 1 CEFPODOXIME 2 CIPROFLOX 2 1 1 2






MAGNEX 2 AMIKACIN 2 CARBOPENEM 1 PIPTAZ 2 NETILMICIN 2 CEFPODOXIME 2 CIP 2 1 1 2
2 2 2
1 1 2
MAGNEX 1 AMIKACIN 1 CARBOPENEM 1 NETILMICIN 1 PIPTAZ 2 CEFPODOXIME 2 CIP 2 2 2 2




MAGNEX 1 AMIKACIN 1 CARBOPENEM 1 PIPTAZ 1 NETILMICIN 2 CEFPODOXIME 2 CIPROFLOX 2 2 2 2










MAGNEX 1 AMIKACIN 1 CARBOPENEM 1 PIPTAZ 1 NETILMICIN 1 CEFPODOXIME 1 CIPROFLOX 2 2 2 2
2 2 2
RIFAMPICIN 1 GENTAMICIN 1 LINEZOLID 1 VANCOMYCIN 1 CIPROFLOXCIN 1 2 2 2
2 2 2
MAGNEX 1 AMIKACIN 1 CARBOPENEM 1 PIPTAZ 2 NETILMICIN 1 CEFPODOXIME 1 CIPROFLOX 2 2 2 2
MAGNEX 1 AMIKACIN 1 CARBOPENEM 1 PIPTAZ 2 NETILMICIN 1 CEFPODOXIME 2 CIPROFLOX 2 2 2 2
2 2 2
2 2 2
MAGNEX 1 AMIKACIN 1 CARBOPENEM 1 PIPTAZ 1 COLISTIN 1 CEFPODOXIME 2 CIPROFLOX 2 1 1 2
AMIKACIN 1 CARBOPENEM 1 TIGICYCLIN 1 COLISTIN 1 PIPTAZ 1 CEFPODOXIME 1 CIPROFLOX 1 2 2 2
2 2 2
MAGNEX 2 AMIKACIN 1 CARBOPENEM 1 PIPTAZ 2 COLISTIN 1 CEFPODOXIME 2 CIP 2 2 2 2
2 2 2




CEFOTAXIME 2 CEFTAZIDIME 2 CIPROFLOX 2 PIPTAZ 2 TICARCLAV 2 CARBOPENEM 1 MAGNEX 2 2 2 2
CEFOTAXIME 2 CEFTAZIDIME 2 CIPROFLOX 2 CARBOPENEM 1 NETILMICIN 1 PIPTAZ 2 GENTAMICIN 2 2 2 2
2 2 2
2 2 2
MAGNEX 2 AMIKACIN 2 CARBOPENEM 1 PIPTAZ 2 NETILMICIN 1 CEFTAZIDIME 2 CIP 2 1 1 2
2 2 2
TICARCLAV 1 MAGNEX 1 CARBOPENEM 1 PIPTAZ 1 NETILMICIN 1 CEFPODOXIME 1 CIPROFLOX 1 2 2 2
1 1 2
MAGNEX 2 AMIKACIN 1 CARBOPENEM 1 PIPTAZ 1 CEFTAZIDIME 2 CIPROFLOX 2 NETILMICIN 1 2 2 2
2 2 2
2 2 2
AMIAKCIN 2 CARBOPENEM 1 NETILMICIN 2 TIGICYCLIN 1 COLISTIN 1 PIPTAZ 2 CEFPODOXIME 2 2 2 2
AMIKACIN 1 CARBOPENEM 1 TIGECYCLINE 1 COLISTIN 1 PIPTAZ 2 CEFPODOXIME 2 GENTAMICIN 2 2 2 2
1 1 2
AMIKACIN 1 CARBOPENEM 1 TIGECYCLINE 1 COLISTIN 1 CEFPODOXIME 1 PIPTAZ 2 CIPROFLOX 2 2 2 2
2 2 2
AMIKACIN 1 CARBOPENEM 1 TIGECYCLINE 1 COLISTIN 1 PIPTAZ 2 CEFPODOXIME 2 NETILMICIN 2 2 2 2
AMIKACIN 1 GENTAMICIN 1 CARBOPENEM 1 TIGECYCLINE 1 PIPTAZ 1 CEFPODOXIME 2 COLISTIN 1 2 2 2
2 2 2
2 2 2





TICARCLAV 2 MAGNEX 1 CARBOPENEM 1 PIPTAZ 1 CEFPODOXIME 1 GENTAMICIN 1 CIPROFLOX 1 1 1 2
TICARCLAV 2 MAGNEX 2 CARBOPENEM 1 NETILMICIN 2 PIPTAZ 2 CEFPODOXIME 2 CIPROFLOX 2 2 2 2
2 2 2
1 1 2
MAGNEX 1 CARBOPENEM 1 TIGECYCLINE 1 COLISTIN 1 PIPTAZ 1 CEFPODOXIME 1 CIPROFLOX 1 2 2 2
2 2 2
AMIKACIN 1 CARBOPENEM 1 GENTMICIN 2 CEFPODOXIME 2 CIPROFLOX 2 COLISTIN 1 TIGECYCLINE 1 1 1 2






AMIKACIN 1 CARBOPENEM 1 GENTAMICIN 2 TIGECYCLINE 1 PIPTAZ 2 CEFPODOXIME 2 CIPROFLOX 2 2 2 2





AMIKACIN 1 CARBOPENEM 1 TIGECYCLINE 1 COLISTIN 1 PIPTAZ 1 CEFPODOXIME 1 CIPROFLOX 2 2 2 2
2 2 2
AMIKACIN 1 TIGECYCLINE 1 CARBOPENEM 1 COLISTIN 1 PIPTAZ 1 CEFPODOXIME 1 CIPROFLOX 2 2 2 2
2 2 2
1 1 2










AMIKACIN 1 CARBOPENEM 1 TIGECYCLINE 1 COLISTIN 1 PIPTAZ 1 CEFPODOXIME 1 CIP 2 2 2 2
1 1 2
CARBOPENEM 1 AMIKACIN 1 MAGNEX 1 CEFPODOXIME 2 PIPTAZ 2 CIPROFLOX 2 ` 2 2 2
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2 ERTAPENEM 1 2 10 based on culture sensitivity
2 PIPTAZ 9 2 10 based on culture sensitivity
2 PIPTAZ 6.75 2 3 Clinical worsen MEROPENEM 3 2 2 Based on culturPIPTAZ 13.5 2
2 PIPTAZ 9 2 10 based on culture sensitivity
2 PIPTAZ 2.25 2 1 based on culturERTAPENEM 1 2 10
2 ERTAPENEM 1 2 14 based on culture sensitivity
2 MEROPENEM 2 2 10 based on culture sensitivity
2 PIPTAZ 13.5 2 3 Clinical worsen MEROPENEM 3 2 7
2 PIPTAZ 13.5 2 14
2 NORFLOX 0.8 2 5 Based on clinical suspicion
1 PIPTAZ 9 2 10 Based on clinical suspicion
2 ERTAPENEM 1 2 10 Based on clinical suspicion
2 ERTAPENEM 1 2 10 based on culture sensitivity
2 PIPTAZ 9 2 5 clinical recoveryAUGMENTIN 19.75 1 10 Based on culture sensitivity
2 ERTAPENEM 1 2 14 based on culture sensitivity
2 PIPTAZ 4.5 2 1 based on culturERTAPENEM 0.5 2 4
2 PIPTAZ 13.5 2 7 Cutlure negative
1 PIPTAZ 9 2 3 Based on clinicaERTAPENEM 1 2 14 Based on culture sensitivity
2 PIPTAZ 9 2 3 Based on clinicaPIPTAZ 13.5 2 2 Based on culture sensitivity
2 PIPTAZ 13.5 2 7 based on culturAUGMENTIN 2.4 1 3 Plan at discharge
2 PIPTAZ 13.5 2 5 Based on clinical suspicion
2 ERTAPENEM 1 2 14 based on culture sensitivity
1 ERTAPENEM 1 2 10 based on culture sensitivity
1 COTRIMOX 1.92 1 10 Based on clinical suspicion
2 MEROPENEM 2 2 4 untimely discharge
2 PIPTAZ 13.5 2 10 Cutlure negative
2 ERTAPENEM 1 2 14 untimely discharge
2 MEROPENEM 3 2 10 based on culture sensitivity
2 ERTAPENEM 1 2 14 based on culture sensitivity
2 MEROPENEM 3 2 3 Based on clinicaAMAKACIN 0.75 2 9 Based on culture sensitivity
2 ERTAPENEM 1 2 10 based on culture sensitivity
2 MEROPENEM 2 2 5 Clinical worsening
2 MEROPENEM 1 2 10 based on culture sensitivity
1 CIPROFLOX 1 1 4 based on culturAMPICILLIN 2 1 14
2 PIPTAZ 9 2 14 based on culture sensitivity
2 AMIKACIN 0.5 2 7 Based on clinical suspicion
2 PIPTAZ 6.75 2 2 Clinical worsen MEROPENEM 2 2 7 Plan at discharge
2 PIPTAZ 13.5 2 1 untimely discharge
2 ERTAPENEM 1 2 14 Based on clinical suspicion
2 PIPTAZ 13.5 2 14 Based on clinical suspicion
2 MEROPENEM 3 2 14 based on culture sensitivity
2 PIPTAZ 9 2 2 based on culturERTAPENEM 0.5 2 5 Plan at discharge
2 ERTAPENEM 1 2 12 untimely discharge
2 MEROPENEM 0.5 2 4 untimely discharge
2 PIPTAZ 9 2 1 untimely discharge
2 MEROPENEM 2 2 14 based on culture sensitivity
2 MEROPENEM 3 2 14 based on culture sensitivity
2 PIPTAZ 6.75 2 1 based on culture sensitivity
2 PIPTAZ 13.5 2 2 Clinical worsen MEROPENEM 3 2 7 Based on culture sensitivity
2 MEROPENEM 3 2 7 Cutlure negative
2 ERTAPENEM 1 2 7 Cutlure negative
2 MEROPENEM 3 2 21 Based on clinicaTECOPLANIN 0.4 2 14 Doctor's discretCEFPODOXIME 0.4 1
1 ERTAPENEM 1 2 14 completed treatment 
1 MEROPENEM 2 2 5 based on culturLINEZOLID 1.2 1 28 completed treatment 
2 ERTAPENEM 1 2 10 based on culture sensitivity completed treatment 
2 ERTAPENEM 1 2 7 based on culture sensitivity completed treatment 
2 MEROPENEM 3 2 5 untimely discharge completed treatment 
2 PIPTAZ 4.5 2 1 based on culturMEROPENEM 1 2 1 Plan at discharge
2 PIPTAZ 9 2 2 based on culturMEROPENEM 3 2 10 completed treatment 
1 ERTAPENEM 1 2 5 untimely dischaAUGMENTIN 2.4 1 10 Plan at discharge
2 ERTAPENEM 1 2 14 completed treatment 
2 PIPTAZ 13.5 2 1 based on culturERTAPENEM 0.5 2 14 completed treatment 
2 CEFTRIAXONE 2 2 1 Clinical worsen PIIPTAZ 13.5 2 7 completed treatment 
2 AUGMENTIN 12.5 1 14 based on culture sensitivity completed treatment 
2 PIPTAZ 13.5 2 7 based on culture sensitivity completed treatment 
2 ERTAPENEM 1 2 14 based on culture sensitivity completed treatment 
2 PIPTAZ 13.5 2 14 Clinical worsen MEROPENEM 3 2 10 clinical worsening
2 ERTAPENEM 1 2 2 Clinical worsening completed treatment 
2 C.PENICILLIN 20.4 2 3 Clinical worsen PIPTAZ 13.5 2 2 clinical worseni MEROPENEM 3 2
2 ERTAPENEM 0.5 2 10 completed treatment 
2 ERTAPENEM 0.5 2 10 completed treatment 
2 CEFUROXIME 0.5 1 14 completed treatment 
2 COTRIMOX 19.2 1 10 based on culture sensitivity completed treatment 
2 PIPTAZ 13.5 2 7 Based on clinical suspicion completed treatment 
2 ERTAPENEM 1 2 10 completed treatment 
2 AMIKACIN 0.75 2 7 Based on clinical suspicion completed treatment 
2 ERTAPENEM 1 2 14 completed treatment 
2 CEFTRIAXONE 2 2 4 Clinical worsen NITROFURANTO 0.2 1 7 Based on culture sensitivity
2 ERTAPENEM 0.5 2 14 completed treatment 
2 PIPTAZ 9 2 1 clinical recoveryCIPROFLOXACIN 1 1 7 completed treatment 
2 PIPTAZ 4.5 2 1 based on culturMEROPENEM 2 2 14 completed treatment 
1 CEFTRIAXONE 2 2 2 Based on clinicaERTAPENEM 1 2 14 Based on culture sensitivity
2 PIPTAZ 9 2 14 clinical recovery completed treatment 
2 PIPTAZ 9 2 14 Based on clinical suspicion completed treatment 
2 AMIKACIN 0.75 2 2 based on culturMEROPENEM 2 2 5 completed treatment 
2 AMIKACIN 0.75 2 7 based on culturAMPICILLIN 2 1 7 Based on culture sensitivity
2 PIPTAZ 6.75 2 3 Clinical worsening completed treatment 
2 MEROPENEM 3 2 14 based on culture sensitivity completed treatment 
2 CEFTRIAXONE 4 2 1 Based on clinicaDOXY 0.4 1 2 Doctor's discretPIPTAZ 9 2
2 ERTAPENEM 1 2 14 based on culture sensitivity completed treatment 
2 PIPTAZ 4.5 2 1 based on culturMEROPENEM 3 2 14 completed treatment 
2 MEROPENEM 3 2 14 based on culturATT completed treatment 
2 ERTAPENEM 1 2 7 based on culture sensitivity completed treatment 
1 MAGNEX 6 2 1 Cutlure negativ MEROPENEM 3 2 14 Based on culture sensitivity
2 PIPTAZ 13.5 2 3 Clinical worsen ERTAPENEM 1 2 14 Plan at discharge
2 MEROPENEM 3 2 10 based on culture sensitivity completed treatment 
2 ERTAPENEM 1 2 2 based on culturPIPTAZ 13.5 2 2 Plan at dischargCEFPODOXIME 0.4 1
2 PIPTAZ 13.5 2 14 Based on clinical suspicion completed treatment 
2 CIPROFLOX 0.4 2 2 Clinical worsening completed treatment 
2 AMIKACIN 0.75 2 2 based on culturERTAPENEM 1 2 14 completed treatment 
2 ERTAPENEM 1 2 14 based on culture sensitivity completed treatment 
2 CIPROFLOX 0.4 2 7 Cutlure negative completed treatment 
2 PIPTAZ 4.5 2 1 AMIAKCIN 0.5 2 5 clinical worseni MEROPENEM 2 2
2 CIPROFLOX 1 1 5 Cutlure negative completed treatment 
2 PIPTAZ 6.75 2 3 Based on clinical suspicion completed treatment 
2 PIPTAZ 13.5 2 1 Based on clinical suspicion completed treatment 
2 AUGMENTIN 12.5 1 5 Clinical worsen CIPROFLOX 1 1 10 clinical worseni MEROPENEM 1 2
2 PIPTAZ 13.5 2 10 based on culture sensitivity completed treatment 
1 PIPTAZ 9 2 5 MEROPENEM 2 2 2 clinical worsening
2 ERTAPENEM 0.5 2 14 based on culture sensitivity completed treatment 
2 PIPTAZ 13.5 2 1 Based on clinicaERTAPENEM 1 2 14 Based on culture sensitivity
2 PIPTAZ 13.5 2 1 Clinical worsening completed treatment 
1 PIPTAZ 9 2 1 Based on clinicaERTAPENEM 1 2 14 Based on culture sensitivity
1 PIPTAZ 13.5 2 1 Based on clinicaERTAPENEM 1 2 14 Plan at discharge
2 PIPTAZ 4.5 2 1 Based on clinicaERTAPENEM 1 2 14 Based on culturFLUCONAZOLE 0.2 2
2 PIPTAZ 9 2 2 Based on clinicaPIPTAZ 13.5 2 7 Based on culturDOXY 0.2 1
2 PIPTAZ 0.9 2 1 Based on clinicaAUGMENTIN 2 1 14 Plan at discharge
1 ERTAPENEM 1 2 14 based on culture sensitivity completed treatment 
2 PIPTAZ 13.5 2 4 Clinical worsen MEROPENEM 2 2 10 Plan at discharge
2 PIPTAZ 6.75 2 2 Based on clinicaDOXY 2 1 2 Doctor's discretAZITHROMYCIN 0.5 2
1 CEFTAZIDIME 3 2 5 Based on clinicaAMPICILLIN 2 2 3 Based on culture sensitivity
2 PIPTAZ 9 2 3 Based on clinicaERTAPENEM 1 2 14 Based on culture sensitivity
1 MAGNEX 6 2 9 based on cultur IMIPENEM 0.75 2 1 Plan at discharge
2 CEFOTAXIME 3 2 2 Based on clinicaIMIPENEM 0.75 2 14 Based on culture sensitivity
2 CEFOTAXIME 2 2 1 Based on clinicaMEROPENEM 1.5 2 14 Based on culture sensitivity
2 MAGNEX 4 2 14 based on culture sensitivity completed treatment 
1 AMIKACIN 0.75 2 10 based on culture sensitivity completed treatment 
2 PIPTAZ 13.5 2 2 Based on clinicaERTAPENEM 1 2 10 Based on culture sensitivity
2 IMIPENEM 2 2 14 based on culture sensitivity completed treatment 
2 PIPTAZ 13.5 2 14 based on culture sensitivity completed treatment 
2 AMPICILLIN 4 2 3 Cutlure negativ CEFPODOXIME 0.4 1 7 Based on culture sensitivity
1 MEROPENEM 2 2 14 based on culturCLOXACILLIN 4 2 7 clinical worsening
2 PIPTAZ 13.5 2 14 Based on clinicaDOXY 0.2 1 7 Doctor's discretLINEZOLID 1.2 2
2 MEROPENEM 3 2 10 based on culture sensitivity completed treatment 
2 ERTAPENEM 1 2 14 based on culture sensitivity completed treatment 
1 PIPTAZ 13.5 2 1 Based on clinicaAMIKACIN 0.75 2 14 Based on culture sensitivity
2 PIPTAZ 13.5 2 10 Based on clinicaNITROFURANTO 0.2 1 30 completed treatment 
1 MEROPENEM 1 2 6 Based on clinicaERTAPENEM 1 2 6 Based on culture sensitivity
2 CIPROFLOX 1 1 7 Based on clinical suspicion completed treatment 
2 PIPTAZ 13.5 2 2 Based on clinicaMEROPENEM 3 2 3 clinical worseni ERTAPENEM 1 2
1 PIPTAZ 13.5 2 2 Based on clinicaMEROPENEM 3 2 3 Based on culturERTAPENEM 1 1
2 PIPTAZ 13.5 2 1 Based on clinical suspicion completed treatment 
2 MEROPENEM 3 2 10 based on culture sensitivity completed treatment 
2 PIPTAZ 13.5 2 5 based on culturCIPROFLOX 1 1 10 Plan at discharge
2 AMIKACIN 0.75 2 10 based on culture sensitivity completed treatment 
2 PIPTAZ 9 2 6 Based on clinical suspicion completed treatment 
2 PIPTAZ 6.75 2 7 based on culture sensitivity completed treatment 
2 MAGNEX 4 2 14 based on culture sensitivity completed treatment 
1 ERTAPENEM 1 2 7 Based on clinicaPIPTAZ 13.5 2 7 Based on culture sensitivity
2 PIPTAZ 6.75 2 2 Based on clinicaMEROPENEM 0.5 2 1 Based on culturERTAPENEM 0.5 2
2 AMIKACIN 0.75 2 5 based on culturCEFIXIME 0.5 1 5 Plan at discharge
2 MEROPENEM 3 2 14 based on culturCO TRIMOX 1.92 1 14 clinical worsening
2 MEROPENEM 3 2 4 based on culture sensitivity completed treatment 
1 ERTAPENEM 1 2 14 based on culture sensitivity completed treatment 
2 PIPTAZ 13.5 2 3 Based on clinicaMEROPENEM 3 2 14 Based on culture sensitivity
1 MEROPENEM 2 2 14 Based on clinical suspicion completed treatment 
2 ERTAPENEM 1 2 1 Based on clinicaMEROPENEM 2 2 10 Based on culture sensitivity
2 PIPTAZ 13.5 2 2 Based on clinicaMEROPENEM 3 2 3 completed treatment 
2 PIPTAZ 9 2 3 Based on clinicaMEROPENEM 3 2 3 clinical worsening
2 PIPTAZ 13.5 2 10 Based on clinical suspicion completed treatment 
2 ERTAPENEM 1 2 9 Based on clinicaMEROPENEM 3 2 6 Plan at discharge
1 PIPTAZ 4.5 2 1 Based on clinicaERTAPENEM 1 2 1 Doctor's discretMEROPENEM 1 2
1 PIPTAZ 13.5 2 14 based on culture sensitivity completed treatment 
2 PIPTAZ 13.5 2 3 Based on clinicaERTAPENEM 1 2 10 Based on culture sensitivity
2 PIPTAZ 13.5 2 3 Based on clinicaERTAPENEM 1 2 10 Based on culture sensitivity
2 PIPTAZ 13.5 2 2 Based on clinicaERTAPENEM 1 2 10 Based on culture sensitivity
2 PIPTAZ 13.5 2 2 Based on clinical suspicion completed treatment 
1 PIPTAZ 13.5 2 3 Based on clinicaAMIKACIN 0.75 2 10 Based on culture sensitivity
2 PIPTAZ 9 2 10 Cutlure negative completed treatment 
1 MEROPENEM 1 2 2 Based on clinicaPIPTAZ 6.75 2 14 Based on culture sensitivity
2 MEROPENEM 2 2 14 Based on clinicaCLOXACILLIN 2 1 42 clinical worsening
1 MEROPENEM 2 2 14 based on culture sensitivity completed treatment 
2 MEROPENEM 3 2 14 based on culture sensitivity completed treatment 
2 MEROPENEM 2 2 2 Based on clinical suspicion completed treatment 
1 ERTAPENEM 1 2 5 Based on clinicaAMOXICLAV 2 2 3 Based on culture sensitivity
2 PIPTAZ 13.5 2 2 Based on clinicaMEROPENEM 3 2 1 Plan at discharge
2 ERTAPENEM 1 2 10 based on culture sensitivity completed treatment 
2 PIPTAZ 9 2 10 based on culture sensitivity completed treatment 
2 PIPTAZ 13.5 2 3 Based on clinicaMEROPENEM 3 2 12 Based on culture sensitivity
2 PIPTAZ 13.5 2 4 Based on clinicaAMIKACIN 0.75 2 10 Based on culture sensitivity
2 PIPTAZ 3.5 2 10 based on culture sensitivity completed treatment 
2 ERTAPENEM 1 2 4 based on culturMEROPENEM 0.5 2 10 Doctor's discretion
2 PIPTAZ 13.5 2 2 Based on clinicaERTAPENEM 1 2 7 Based on culture sensitivity
2 ERTAPENEM 0.5 2 3 Based on clinicaPIPTAZ 6.75 2 10 Based on culture sensitivity
2 PIPTAZ 13.5 2 7 Based on clinicaMEROPENEM 3 2 7 Based on culture sensitivity
N0f3DurationdaN0f3Rchange N0f4Antibiotic N0f4Dose N0f4Route N0f4DurationdaN0f4Rchange N0g1CureaClini N0g1bBacteriol N0gb2ndUrineCN10g1b3Organ N0g2DeathYesNN0g2IfyesCauseN0g3durationof
Completed treatment Completed trea 1 1 2 2 8
Completed treatment Completed trea 1 1 2 2 7
10 based on culture sensitivity Completed trea 1 2 1 E.COLI 2 8
Completed treatment Completed trea 1 1 2 2 2
Completed treatment Completed trea 1 2 2 2 8
Completed treatment Completed trea 2 2 2 2 9
Completed treatment Completed trea 1 1 1 NO GROWTH 2 5
Completed treatment Completed trea 1 1 1 NO GROWTH 2 10
Completed treatment Completed trea 1 1 1 NO GROWTH 2 29
Completed treatment Completed trea 1 2 1 PSEUDOMONAS 2 15
Completed treatment Completed trea 1 1 1 NO GROWTH 2 12
Completed treatment Completed trea 1 1 1 NO GROWTH 2 4
Completed treatment Completed trea 1 2 2 2 8
Completed treatment Completed trea 1 1 1 NO GROWTH 2 7
Completed treatment Completed trea 1 1 1 NO GROWTH 2 23
Completed treatment Completed trea 1 2 2 2 7
Completed treatment Completed trea 1 1 1 NO GROWTH 2 8
Completed treatment Completed trea 1 1 2 2 6
Completed treatment Completed trea 1 1 1 CONTAMINANT 2 7
Completed treatment Completed trea 1 1 1 CONTAMINANT 2 8
Completed treatment Completed trea 1 2 2 2 5
Completed treatment Completed trea 1 2 1 ESBL ECOLI > 10 2 14
Completed treatment Completed trea 1 1 1 INSIGNIFICANT 2 12
Completed treatment Completed trea 1 1 1 CONTAMINANT 2 5
Completed treatment Completed trea 2 2 2 2 4
Completed treatment Completed trea 1 2 2 2 5
Completed treatment Completed trea 2 2 2 2 8
Completed treatment Completed trea 1 2 1 NFGNB 32000 2 12
Completed treatment Completed trea 1 1 1 CONTAMINANT 2 4
Completed treatment Completed trea 1 2 2 2 5
Completed treatment Completed trea 1 1 1 NO GROWTH 2 9
Completed treatment Completed trea 2 2 2 2 5
Completed treatment Completed trea 2 2 1 CANDIDA/ENTE 1 SEPTIC SHOCK 17
Completed treatment Completed trea 1 1 1 NO GROWTH 2 3
Completed treatment Completed trea 1 1 1 NO GROWTH 2 14
Completed treatment Completed trea 1 2 2 2 6
Completed treatment Completed trea 1 2 2 2 7
Completed treatment Completed trea 2 2 2 2 1
Completed treatment Completed trea 1 2 2 2 21
Completed treatment Completed trea 1 2 2 2 14
Completed treatment Completed trea 1 2 2 2 14
Completed treatment Completed trea 1 1 1 NO GROWTH 2 5
Completed treatment Completed trea 1 1 1 NO GROWTH 2 12
Completed treatment Completed trea 2 2 2 2 4
Completed treatment Completed trea 2 2 2 2 1
Completed treatment Completed trea 1 1 1 NO GROWTH 2 14
Completed treatment Completed trea 1 1 1 NO GROWTH 2 41
Completed treatment Completed trea 2 2 2 1 SEPTIC SHOCK 1
Completed treatment Completed trea 2 2 2 2 8
Completed treatment Completed trea 1 1 1 NO GROWTH 2 16
Completed treatment Completed trea 1 2 2 2 7
4 Plan at dischargMETROGYL 1.5 1 5 Plan at discharg 1 1 1 PROTEUS 2 26
Completed treatment Completed trea 1 1 1 NO GROWTH 2 20
Completed treatment Completed trea 1 1 1 NO GROWTH 2 16
Completed treatment Completed trea 1 1 1 NO GROWTH 2 15
Completed treatment Completed trea 1 2 2 2 7
Completed treatment Completed trea 1 1 1 NO GROWTH 2 5
Completed treatment Completed trea 2 2 2 2 1
Completed treatment Completed trea 1 1 2 NO GROWTH 2 12
Completed treatment Completed trea 1 1 1 2 10
Completed treatment Completed trea 1 2 1 ECOLI 6000 2 8
Completed treatment Completed trea 1 1 1 NO GROWTH 2 17
Completed treatment Completed trea 1 1 1 NO GRWTH 2 5
Completed treatment Completed trea 1 2 1 KLEBSIELLA 2 4
Completed treatment Completed trea 1 1 1 NO GROWTH 2 9
Completed treatment Completed trea 1 1 1 NO GROWTH 2 10
Completed treatment Completed trea 1 2 2 2 29
Completed treatment Completed trea 2 2 1 DNI / DNR ‐ SHO 2
10 based on culture sensitivity Completed trea 1 1 1 NO GROWTH 2 20
Completed treatment Completed trea 1 2 1 ECOLI 500 2 7
Completed treatment Completed trea 1 1 1 NO GROWTH 2 9
Completed treatment Completed trea 1 1 1 NO GROWTH 2 7
Completed treatment Completed trea 1 2 2 2 4
Completed treatment Completed trea 1 2 2 2 15
Completed treatment Completed trea 1 1 1 NO GROWTH 2 13
Completed treatment Completed trea 1 2 1 YEAST 2 4
Completed treatment Completed trea 1 1 1 CONTAMINANT 2 7
Completed treatment Completed trea 2 2 2 2 7
Completed treatment Completed trea 1 1 1 NO GROWTH 2 6
Completed treatment Completed trea 1 1 2 2 3
Completed treatment Completed trea 1 2 2 2 14
Completed treatment Completed trea 1 2 1 ENTEROCOCCI 2 2 11
Completed treatment Completed trea 1 1 1 NO GROWTH 2 17
Completed treatment Completed trea 1 1 1 NO GROWTH 2 11
Completed treatment Completed trea 2 2 2 2 10
Completed treatment Completed trea 1 2 2 2 7
Completed treatment Completed trea 2 2 2 2 3
Completed treatment Completed trea 1 2 1 CANDIDA 2 14
1 Plan at discharge Completed trea 2 2 2 2 1
Completed treatment Completed trea 1 1 1 NO GROWTH 2 14
Completed treatment Completed trea 1 1 1 NO GROWTH 2 15
Completed treatment Completed trea 1 1 1 NO GROWTH 2 16
Completed treatment Completed trea 1 1 1 NO GROWTH 2 17
Completed treatment Completed trea 1 2 2 2 14
Completed treatment Completed trea 1 2 2 2 4
Completed treatment Completed trea 1 2 2 2 10
10 Completed treatment Completed trea 1 1 1 NO GROWTH 2 4
Completed treatment Completed trea 1 2 2 2 3
Completed treatment Completed trea 2 2 2 1 MALIGNANT M 2
Completed treatment Completed trea 1 1 1 NO GROWTH 2 5
Completed treatment Completed trea 1 1 1 NO GROWTH 2 23
Completed treatment Completed trea 1 1 1 NO GROWTH 2 9
7 based on culturVANCOMYCIN 2 2 10 Basedon culture 1 2 1 ENTEROCOCCI , 2 21
Completed treatment Completed trea 1 1 1 NO GROWTH 2 3
Completed treatment Completed trea 2 2 2 1 REFRACTORY SH 4
Completed treatment Completed trea 2 2 2 1 ARF , SHOCK 1
3 Clinical worsening Completed trea 2 2 2 1 SEPTIC SHOCK 30
Completed treatment Completed trea 1 1 2 2 8
Completed treatment Completed trea 1 1 2 1 UROSEPSIS 14
Completed treatment Completed trea 1 1 1 NO GROWTH 2 6
Completed treatment Completed trea 1 2 2 2 15
Completed treatment Completed trea 2 2 2 1 SEPTIC SHOCK 1
Completed treatment Completed trea 1 2 1 YEAST , 600 2 18
Completed treatment Completed trea 1 1 1 INSIGNIFICANT 2 8
14 based on culture sensitivity Completed trea 1 1 1 NO GROWTH 2 18
7 Doctor's discretAUGMENTIN 2 1 7 Plan at discharg 1 2 2 2 8
Completed treatment Completed trea 2 2 2 2 1
Completed treatment Completed trea 1 2 2 2 14
Completed treatment Completed trea 2 2 2 2 13
1 Doctor's discretMEROPENEM 1 2 7 Basedon culture 1 1 1 NO GROWTH 2 0 10
Completed treatment Completed trea 1 2 1 ENTEROCOCI 40 2 8
Completed treatment Completed trea 1 2 1 ESBL ECOLI>100 2 14
Completed treatment Completed trea 1 2 2 2 9
Completed treatment Completed trea 1 2 2 2 3
Completed treatment Completed trea 1 2 2 2 16
Completed treatment Completed trea 1 2 2 2 8
Completed treatment Completed trea 1 2 2 2 4
Completed treatment Completed trea 1 2 2 2 9
Completed treatment Completed trea 1 2 1 ESBL ECOLI,200 2 8
Completed treatment Completed trea 1 2 1 YEAST,40000 2 17
Completed treatment Completed trea 1 2 2 2 10
Completed treatment Completed trea 1 2 2 2 26
7 based on culture sensitivity Completed trea 1 1 1 NO GROWTH 2 37
Completed treatment Completed trea 1 1 1 NO GROWTH 2 15
Completed treatment Completed trea 1 2 1 PROTEUS  / ECO 2 17
Completed treatment Completed trea 1 1 1 NO GROWTH 2 17
Completed treatment Completed trea 1 1 1 INSIGNIFICANT 2 9
Completed treatment Completed trea 1 2 2 2 6
Completed treatment Completed trea 1 2 2 2 7
10 based on culture sensitivity Completed trea 1 2 2 2 17
1 based on culturCIPROFLOX 1.5 1 7 Plan at discharg 1 2 2 2 7
Completed treatment Completed trea 2 2 2 2 1
Completed treatment 3 Completed trea 1 2 1 YEAST > 100000 2 12
Completed treatment Completed trea 1 2 2 2 10
Completed treatment Completed trea 1 1 1 NO GROWTH 2 7
Completed treatment Completed trea 2 2 2 1 SEPSIS‐DNI / DN 6
Completed treatment Completed trea 1 2 2 2 7
Completed treatment Completed trea 1 2 2 2 14
Completed treatment Completed trea 1 2 1 YEAST 2600 2 18
14 based on culture sensitivity Completed trea 1 2 2 2 10
Completed treatment Completed trea 1 2 2 2 5
Completed treatment Completed trea 1 1 1 MIXTURE OF OR 2 19
Completed treatment Completed trea 2 2 2 1 SEPTIC SHOCK,D 5
Completed treatment Completed trea 1 2 2 2 4
Completed treatment Completed trea 1 1 1 NO GROWTH 2 21
Completed treatment Completed trea 1 1 1 CONTAMINANT 2 20
Completed treatment Completed trea 1 2 2 2 11
Completed treatment Completed trea 2 2 2 1 REFRACTORY SE 5
Completed treatment Completed trea 2 2 2 1 SEPTIC SHOCK 6
Completed treatment Completed trea 1 2 1 ENTROCOCCI, 3 2 12
Completed treatment Completed trea 1 1 1 CONTAMINANT 2 6
14 based on culture sensitivity Completed trea 1 2 2 2 14
Completed treatment Completed trea 1 2 2 2 19
Completed treatment Completed trea 1 2 2 2 5
Completed treatment Completed trea 1 1 1 NO GROWTH 2 6
Completed treatment Completed trea 1 2 2 2 7
Completed treatment Completed trea 2 2 2 1 SEPTIC SHOCK , 2
Completed treatment Completed trea 1 1 1 NO GROWTH 2 7
Completed treatment Completed trea 1 1 1 NO GROWTH 2 15
Completed treatment Completed trea 1 1 1 NO GROWTH 2 15
Completed treatment Completed trea 1 1 1 NO GROWTH 2 18
Completed treatment Completed trea 1 1 1 NO GROWTH 2 15
Completed treatment Completed trea 1 2 1 ENTEROCOCCU 2 21
Completed treatment Completed trea 2 2 2 1 SEPTIC SHOCK 2
Completed treatment Completed trea 1 2 2 2 5
Completed treatment Completed trea 1 2 2 2 3
Completed treatment Completed trea 1 1 1 NO GROWTH 2 12
Completed treatment Completed trea 1 1 1 NO GROWTH 2 14
Completed treatment Completed trea 1 2 1 CANDIDA , 7000 2 14
Completed treatment Completed trea 1 2 1 ENTEROCOCCI 1 2 14
Completed treatment Completed trea 1 1 1 NO GROWTH 2 11
Completed treatment Completed trea 1 1 1 NO GROWTH 2 14
Completed treatment Completed trea 1 2 2 2 8
Completed treatment Completed trea 1 2 2 2 7
Completed treatment Completed trea 1 1 1 NO GROWTH 2 17
N0g3ICUorHDU N0g3aDischargeN0g3aReason N0g4InitiatedonN0g4Reason N0g5Procedure N10g5IfYes N0g6TotalIPBill N0g6PaidYesNoN0g6WrittenoffN0g6WrittenofVaN10g7Follow Numberofepiso timetofirstepiso
2 2 Completed Trea 2 2 20147 1 1 9140 1 1 120
2 2 Completed Trea 2 2 14768 1 2 0 2
2 2 Completed Trea 2 2 16393 1 2 0 1 1 180
2 2 Completed Trea 2 2 580 1 2 0 2
2 2 Completed Trea 2 2 11419 1 1 4021 1 3 30
1 1 NOT KNOWN 2 2 32184 1 2 0 2
2 2 Completed Trea 2 2 6973 1 2 0 1 0
2 2 Completed Trea 2 2 65657 1 2 0 1 0
2 2 Completed Trea 1 PCN INSITU 1 LEFT PCN 162308 1 2 0 1 0
2 1 Patient's reque 2 1 PRESSURE FLOW 56673 1 2 0 1 1 15
2 2 Completed Trea 2 2 23877 1 2 0 2 0
2 2 Completed Trea 2 2 5941 1 2 0 2 0
2 2 Completed Trea 2 2 21360 1 2 0 2
2 2 Completed Trea 2 2 13252 1 2 0 1 0
1 2 Completed Trea 2 2 110324 1 2 0 1 1 30
2 1 For continuatio 2 2 7813 1 2 0 1 1 30
2 2 Completed Trea 2 1 MCU 11488 1 1 1570 1 3 1
2 2 Completed Trea 2 2 8880 1 1 0 1 2
2 2 Completed Trea 2 2 34747 1 2 0 2 0
2 2 Completed Trea 2 2 12377 1 2 0 1 0
2 1 Financial constr 2 2 9191 1 2 0 2 0
2 2 Completed Trea 1 PERSISTENT CU 2 24320 1 1 20674 1 1 42
2 2 Completed Trea 2 2 19303 1 2 0 1 0
2 2 Completed Trea 1 IMMUNOSUPPR 2 8876 1 1 6440 1 0
2 1 NOT KNOWN 2 2 28590 1 1 6529 2 0
2 1 For continuatio 2 2 21862 1 2 0 2 0
2 2 Completed Trea 2 2 17391 1 2 0 2 0
2 2 Completed Trea 1 RECURENT UTI  2 49193 1 1 15953 1 1 150
2 1 For continuatio 1 AT REVIEW 2 6456 1 2 0 1 1 42
2 1 Patient's reque 2 2 21713 1 1 8975 2 0
2 2 Completed Trea 1 2 67687 1 1 27535 2 0
2 1 Patient's reque 2 2 18812 1 2 0 2 0
2 2 Death 2 1 DIALYSIS 92527 1 2 0 2 0
2 1 Patient's reque 2 2 92950 2 1 92950 1 3 90
1 2 Completed Trea 2 2 24115 1 2 24115 1 0
2 2 Completed Trea 2 2 12100 1 1 5755 2 0
2 1 Patient's reque 2 2 19501 1 2 0 1 2 90
2 1 For continuatio 2 2 7575 1 2 0 2 0
2 2 Completed Trea 2 2 42759 1 2 0 1 1 60
2 2 Completed Trea 2 2 31158 1 2 0 1 1 60
2 2 Completed Trea 2 1 RIGHT PCN 17329 1 2 0 1 1 120
2 2 Completed Trea 2 2 6884 1 1 5420 2 0
2 1 Clinical Detriora 2 2 85474 1 2 0 2 0
2 1 Financial constr 2 2 25177 1 2 0 2 0
2 1 Financial constr 2 2 7249 1 2 0 2 0
2 2 Completed Trea 2 2 26222 1 2 0 2 0
2 2 Completed Trea 2 2 261270 1 2 0 1 0
1 2 Death 2 2 17159 2 1 17159 2 0
1 Financial constr 2 2 45860 1 1 10669 2 0
2 2 Completed Trea 2 2 33564 1 2 0 1 2
2 2 Completed Trea 1 2 12553 1 1 5605 1 0
2 2 Completed Trea 2 2 148350 1 2 0 1 0
2 2 Completed Trea 2 2 38260 1 1 12479 1 0
2 2 Completed Trea 1 RECURRENCE 2 33894 1 2 0 2 0
2 2 Completed Trea 2 2 27705 1 2 0 2 0
2 1 NOT KNOWN 1 2 13466 2 1 13466 2 0
2 2 Completed Trea 2 1 IVU 9295 1 2 0 2
2 1 Financial constr 2 1 DIALYSIS 8018 1 1 4720 2 0
2 2 Completed Trea 2 2 19769 1 2 0 2 0
2 1 Financial constr 1 IMMUNOSUPPR 2 26821 1 1 19529 1 0
2 2 Completed Trea 1 OPD 2 17602 1 1 4270 1 0
1 2 Completed Trea 2 2 40828 1 1 12970 1 1 210
2 2 Completed Trea 2 2 17172 1 2 0 1 0
2 2 Completed Trea 2 2 5860 1 2 0 1 0
2 2 Completed Trea 2 2 13553 1 2 0 1 0
2 2 Completed Trea 2 2 23591 1 2 0 2 0
1 2 Completed Trea 2 2 238837 1 2 0 2 0
2 2 Death 2 2 12257 1 2 0 2
2 2 Completed Trea 2 1 CBD IN SITU 76145 1 2 0 1 1 60
2 2 Completed Trea 2 2 13629 1 2 0 2 0
2 2 Completed Trea 2 2 16728 1 2 0 2
2 2 Completed Trea 2 2 68075 1 2 0 2
2 2 Completed Trea 2 2 10841 1 2 0 2
2 2 Completed Trea 2 2 33600 1 2 0 2
2 2 Completed Trea 2 2 61584 1 2 0 2
2 2 Completed Trea 2 2 6591 1 1 3254 1 0
2 2 Completed Trea 2 2 11605 1 2 0 2 0
2 1 Financial constr 2 2 13108 1 2 0 2
2 2 Completed Trea 2 2 15304 1 1 7470 1 0
2 2 Completed Trea 2 2 5331 1 2 0 2 0
1 2 Completed Trea 2 1 LEFT PCN 78941 1 1 56960 1 4 30
2 2 Completed Trea 2 2 80419 1 2 0 2 0
2 1 Financial constr 2 2 24824 2 1 20664 2 0
1 2 Completed Trea 2 2 27649 1 2 0 1 1 21
2 2 Completed Trea 2 2 18318 1 2 0 2 0
2 2 Completed Trea 2 2 10395 1 2 0 1 0
2 1 NO FAMILY SUP 2 2 12220 1 2 0 2
2 2 Completed Trea 2 2 162251 1 2 0 1 2 30
2 1 Financial constr 2 2 3461 1 2 0 2 0
2 2 Completed Trea 2 2 23029 1 2 0 1 1 180
2 1 Patient's reque 2 2 44619 1 2 0 1 1 240
2 2 Completed Trea 2 2 29346 1 1 2249 1 0
2 2 Completed Trea 2 2 51421 1 1 7365 1 0
2 2 Completed Trea 2 2 28649 1 2 0 1 1 150
2 1 Financial constr 2 2 6958 1 2 0 2 0
2 2 Completed Trea 2 2 13234 1 2 0 1 0
2 2 Completed Trea 2 2 6896 1 1 3860 1 0
2 1 For continuatio 2 2 7719 1 1 3129 1 0
2 2 Death 2 2 5994 1 2 0 2 0
2 2 Completed Trea 1 RECURRENT UT 2 10044 1 2 0 1 0
2 2 Completed Trea 2 2 56169 1 2 0 1 0
2 2 Completed Trea 2 2 13693 1 2 0 1 0
2 2 Completed Trea 2 2 30440 1 2 0 1 0
2 2 Completed Trea 2 2 5715 1 2 0 1 0
2 2 Death 2 2 23546 1 1 9916 2
2 2 Death 2 2 3576 1 2 0 2 0
1 2 Death 2 2 109855 1 2 0 2 0
2 2 Completed Trea 2 2 19100 1 2 0 1 0
2 2 Death 2 2 112118 1 2 0 2 0
2 2 Completed Trea 2 2 11971 1 2 0 2 0
1 2 Completed Trea 2 2 119662 1 2 0 1 1 90
2 2 Death 2 2 5454 1 1 3779 2 0
1 2 Completed Trea 2 2 109482 1 1 19999 1 1 90
2 2 Completed Trea 2 2 28120 1 2 0 2 0
2 2 Completed Trea 2 2 56506 1 1 3539 2 0
1 1 Financial constr 2 2 30875 2 1 30875 2 0
2 1 NOT KNOWN 2 2 2909 1 1 1815 1 1 30
2 1 Financial constr 2 2 60790 1 1 34745 2 0
2 1 Clinical Detriora 2 2 29044 1 1 16278 2 0
2 1 Financial constr 2 2 54142 1 1 25160 2 0
2 1 Financial constr 2 1 TPI 38672 1 1 10844 2 0
2 2 Completed Trea 1 PERSITENT CUL 2 18483 1 2 0 2 0
2 2 Completed Trea 2 1 RIGHT PCN 11920 1 1 11768 2 0
2 1 Financial constr 2 2 7008 1 1 3001 2 0
2 2 Completed Trea 2 2 17525 1 1 8862 1 1 90
2 1 Financial constr 2 1 CBD INSITU 10517 1 1 5109 2 0
2 1 Financial constr 2 2 4185 1 2 0 1 0
2 2 Completed Trea 2 2 13195 1 2 0 2 0
2 2 Completed Trea 2 2 115357 1 2 0 2 0
2 1 NOT KNOWN 2 1 CBD INSITU 158118 1 2 0 1 0
2 2 Completed Trea 2 1 CBD INSITU 23886 1 2 0 1 2 210
2 1 NOT KNOWN 2 2 90086 1 2 0 2 0
1 2 Completed Trea 2 2 89097 1 1 21385 2 0
2 2 Completed Trea 2 2 51327 1 2 0 2 0
2 2 Completed Trea 2 2 24261 1 1 5650 1 1 42
2 2 Completed Trea 2 2 28667 1 1 6025 2 0
2 2 Completed Trea 1 2 13763 1 1 5110 1 0
2 1 For continuatio 2 2 14057 1 1 5694 2 0
2 2 Completed Trea 2 2 31839 1 2 0 2 0
2 2 Completed Trea 2 2 25366 1 1 14754 2 0
2 1 Financial constr 2 2 21145 1 1 1015 2 0
2 1 Clinical Detriora 2 2 6285 1 1 5560 2 0
2 2 Completed Trea 1 CBD INSITU, RE 2 19912 1 1 4634 2 0
2 2 Completed Trea 2 2 21896 1 1 13324 1 1 60
2 1 For continuatio 2 2 14460 2 1 14460 2 0
2 2 Death 2 2 15455 1 2 0 2 0
1 2 Completed Trea 2 2 20926 1 2 0 2 0
2 2 Completed Trea 2 2 33848 1 1 5636 1 0
2 2 Completed Trea 2 2 126911 1 2 0 1 1 150
2 2 Completed Trea 2 2 16295 1 1 1239 1 1 30
2 2 Completed Trea 2 2 8208 1 1 869 2 0
1 2 Completed Trea 2 2 54828 1 2 0 1 1 14
1 2 Death 2 2 44782 1 2 0 2 0
2 2 Completed Trea 2 2 10134 1 2 0 1 1 30
2 2 Completed Trea 1 NEUROPATHIC  2 40761 1 2 0 2 0
1 2 Completed Trea 2 2 123977 1 1 79295 1 0
2 2 Completed Trea 2 2 30835 1 1 7714 1 0
2 2 Death 2 2 35916 1 2 0 2 0
1 2 Death 2 2 51306 1 2 0 2 0
2 2 Completed Trea 2 2 41470 1 1 36010 1 0
2 1 For continuatio 2 2 18437 1 1 3615 1 0
2 2 Completed Trea 2 2 50882 1 1 31774 1 0
2 1 Clinical Detriora 2 2 72441 1 1 55712 2 0
2 1 Financial constr 2 2 10908 1 1 4159 1 0
2 1 Patient's reque 2 2 17102 1 2 0 1 1 30
2 1 Patient's reque 2 2 20880 1 2 0 2 0
2 2 Death 2 2 5486 1 2 0 2 0
2 1 Patient's reque 2 2 18780 1 2 0 1 1 30
2 2 Completed Trea 2 1 RENAL BIOPSY 49655 1 2 0 1 0
2 2 Completed Trea 2 1 LEFT PCN 53973 1 2 0 1 0
2 2 Completed Trea 2 1 USG GUIDED AB 44137 1 2 0 1 0
2 2 Completed Trea 1 RECURRENT UT 2 25948 1 2 0 1 0
2 2 Completed Trea 2 2 42564 1 1 20470 1 0
2 2 Death 2 2 3144 1 2 0 2 0
2 2 Completed Trea 1 RECURRENT UT 2 13157 1 1 11200 2 0
2 1 NOT KNOWN 2 2 8219 1 2 0 2
2 Completed Trea 1 UTI ON IMMUN 2 29371 1 1 4204 2 0
2 2 Completed Trea 2 2 34768 1 1 26699 1 1 30
2 2 Completed Trea 2 2 31578 1 1 3424 1 0
2 2 Completed Trea 1 NEPHROLITHIAS 1 CYSTOSCOPY 24320 1 1 9135 1 0
2 2 Completed Trea 2 1 CBD INSITU 52291 1 2 0 1 0
2 1 NOT KNOWN 2 1 DIALYSIS 53958 1 2 0 2 0
2 1 For continuatio 2 2 18722 1 2 0 2 0
2 2 Completed Trea 2 2 20457 1 2 0 1 1 14
2 2 Completed Trea 2 2 112615 1 2 0 2 0
N10g7A1Organ N10g7A1remar timetosecondepN10g7A2Organ N10g7A2Remartimetothirdepis N10g7A3Organ N10g7A3RemarUniqueKey RECSTATUS N10e6Urine
E Coli TREATED AS OP 1 1 2
No follow up  2 1 2
E Coli Same Anitbiogram,Hospitalised,Piptazx14d 3 1 2
No follow up  4 1 2
ESBL E coli MAGNEX 14 DA 365 ESBL E.COLI TREATED OP 730 ENTERCOCCI NOT TREATED 5 1 1
No follow up  6 1 1
No UTI episodes 13 1 2
No UTI episodes 14 1 1
No UTI episodes 15 1 1
Pseudomonas sIP TREATED COLISTIN 16 1 1
No follow up  17 1 2
No follow up  18 1 2
No follow up  7 1 1
No UTI episodes 8 1 2
ESBL E coli IP MEROPENEM 14 DAYS 9 1 1
ESBL E coli IP ERTAPENEM 14 DAYS 10 1 1
ESBL E coli TREATED IP 12 1 2
details unavailable 119 1 1
No follow up  120 1 1
No UTI episodes 121 1 1
No follow up  122 1 1
ESBL E coli ERTAPENEM OPD* 7 DAYS 123 1 1
No UTI episodes 124 1 1
No UTI episodes 125 1 1
No follow up  126 1
No follow up  127 1
No follow up  128 1 1
E Coli NOT TREATED 129 1 1
ESBL E coli NOT TREATED 130 1 1
No follow up  131 1 1
No follow up  132 1 1
No follow up  133 1 1
No follow up  134 1 1
E Coli TREATED IP 19 1 1
No UTI episodes 20 1 2
No follow up  21 1 1
ESBL E coli IP TREATED ME 300 ESBL E COLI ERTAPENEM 14 DAYS,NO PROPHYLAXIS 22 1 1
No follow up  23 1 2
ESBL E coli SAME ORG,IP RX WITH MEROPENEM 24 1 1
ESBL E coli TREATED AS OP 25 1 1
ESBL E coli RX WITH MAGNEX,PROPHYLAXIS STARTED 26 1 1
No follow up  27 1 1
No follow up  28 1 1
No follow up  29 1 2
No follow up  30 1 2
No follow up  31 1 1
No UTI episodes 32 1 1
No follow up  33 1 1
No follow up  34 1 1
details unavailable 35 1 1
No UTI episodes 36 1 2
No UTI episodes 37 1 2
No UTI episodes 38 1 2
No follow up  39 1 1
No follow up  40 1 1
No follow up  41 1 1
No follow up  42 1 1
No follow up  43 1 1
No follow up  44 1 1
No UTI episodes 45 1 1
No UTI episodes 46 1 1
ESBL E coli OPD TREATMENT 47 1 1
No UTI episodes 48 1 2
No UTI episodes 49 1 1
No UTI episodes 50 1 1
No follow up  51 1 1
No follow up  52 1 1
No follow up  53 1 2
ESBL E coli TCC OF BLADDER 54 1 1
No follow up  55 1 1
No follow up  56 1 1
No follow up  57 1 2
No follow up  58 1 1
No follow up  59 1 1
No follow up  60 1 1
No UTI episodes 61 1 1
No follow up  62 1 2
No follow up  63 1 1
No UTI episodes 64 1 2
No follow up  65 1 1
ESBL E coli ICU ADMISSION 66 1 1
No follow up  67 1 1
No follow up  68 1 1
E Coli PAN RESISTANT 69 1 1
No follow up  70 1 1
No UTI episodes 71 1 1
No follow up  72 1 1
Klebsiella  TREATED IP 120 CANDIDA DJ STENTING 73 1 1
No follow up  74 1 1
E Coli TREATED OP 75 1 1
not known ADMITTED NOW 76 1 1
No UTI episodes 77 1 1
No UTI episodes 78 1 1
ESBL E coli TREAT COLISTIN 79 1 1
No follow up  80 1 1
No UTI episodes 81 1 1
No UTI episodes 82 1 1
No UTI episodes 83 1 2
No follow up  84 1 1
No UTI episodes 85 1 1
No UTI episodes 86 1 1
No UTI episodes 87 1 1
No UTI episodes 88 1 1
No UTI episodes 89 1 2
No follow up  90 1 2
No follow up  91 1 2
No follow up  92 1 1
No UTI episodes 93 1 1
No follow up  94 1 1
No follow up  95 1 1
E Coli NOT TREATED 96 1 1
No follow up  97 1 1
ESBL E coli TREATED OP 98 1 1
No follow up  99 1 1
No follow up  100 1 2
No follow up  101 1 2
Culture NegativPROPYLAXIS INITIIATED 102 1 2
No follow up  103 1 2
No follow up  104 1 1
No follow up  105 1 2
No follow up  106 1 1
No follow up  107 1 1
No follow up  108 1 1
No follow up  109 1 1
E Coli PCN,MAGNEX,PROPHYLAXIS 110 1 1
No follow up  111 1 1
No UTI episodes 112 1 1
No follow up  113 1 1
No follow up  114 1 1
No UTI episodes 115 1 1
Enterococci  TREATED OP,PR 480 ESBL E COLI NOT TREATED 116 1 1
No follow up  117 1 1
No follow up  118 1 1
No follow up  135 1 1
ESBL E coli TREATED OP / PROPHYLAXIS 136 1 1
No follow up  137 1 1
No UTI episodes 138 1 1
No follow up  139 1 1
No follow up  140 1 1
No follow up  141 1 1
No follow up  142 1 1
No follow up  143 1
No follow up  144 1 1
Enterococci  NOT TREATED 145 1 1
No follow up  146 1 1
No follow up  147 1 2
No follow up  148 1 1
No UTI episodes 149 1 1
ESBL E coli IV AMIKACIN 14 DAYS 150 1 1
ESBL E coli SPC , NOT TREATED 151 1 1
No follow up  152 1 1
NFGNB > 10000NOT TREATED 153 1 2
No follow up  154 1 1
Culture NegativTREATED WITH MEROPENEM, 155 1 2
No follow up  156 1 1
No UTI episodes 157 1 1
No UTI episodes 158 1 1
No follow up  159 1 1
No follow up  160 1 1
No UTI episodes 161 1 1
No UTI episodes 162 1 1
No UTI episodes 163 1 2
No follow up  164 1 1
No UTI episodes 165 1 1
Klebsiella  NOT TREATED YET 166 1 1
No follow up  167 1 1
No follow up  168 1 2
E Coli TREATED OPD,ORAL AUGMENTIN 169 1 2
No UTI episodes 170 1 2
No UTI episodes 171 1 1
No UTI episodes 172 1 1
No UTI episodes 173 1 1
No UTI episodes 174 1 1
No follow up  175 1
No follow up  176 1 2
No follow up  177 1 2
No follow up  178 1 1
not known CURRENTLY ADMITTED 179 1 1
No UTI episodes 180 1 1
No UTI episodes 181 1 1
No UTI episodes 182 1 1
No follow up  183 1 2
No follow up  184 1 1
ESBL E coli TREATED OP,PROPHYLAXIS INITIATED 185 1 1
No follow up  186 1 1
